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RED PANDA: A NOVEL METHOD FOR DETECTING VARIATION IN
SINGLE-CELL RNA SEQUENCING
Adam Cornish, Ph.D.
University of Nebraska, 2018
Supervisor: Chittibabu Guda, Ph.D.
Single-cell sequencing enables the rapid acquisition of genomic and transcriptomic data
from individual cells to better understand genetic diseases, such as cancer or
autoimmune disorders, which are often affected by changes in rare cells. Currently, no
existing software is aimed at identifying single nucleotide variations or micro (1-50bp)
insertions and deletions in single-cell RNA sequencing (scRNA-seq) data. However,
generating high quality data is vital to the study of the aforementioned diseases, among
others. Our goal is to create such a tool and use in-house sequencing to validate its
effectiveness. Our software, Red Panda, employs the unique information found in
scRNA-seq data to more accurately identify variants in ways not possible with software
designed for bulk sequencing. We intentionally isolate variants based on three different
classes: homozygous-looking, heterozygous, and bimodally-distributed heterozygous,
the last of which can only be identified in scRNA-seq. To properly validate the results
from this method, variants were called on: scRNA-seq and exome sequencing jointly
performed on human articular chondrocytes, scRNA-seq from mouse embryonic
fibroblasts (MEFs), and simulated data stemming from the MEF alignments. The
chondrocyte exome sequencing was used to validate the chondrocyte scRNA-seq results.
For Red Panda, on average, 913 variants were shared with the exome and had a Positive
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Predictive Value (PPV) of 45.0%. Other tools—FreeBayes, GATK HaplotypeCaller,
GATK UnifiedGenotyper, and Platypus—ranged from 65-705 variants and 5.8%-31.7%
PPV. Sanger sequencing was performed on a subset of the variants identified in the
MEFs, and simulated data was generated to assess the sensitivity of each tools. From the
latter, Red Panda had the highest sensitivity at 72.44%. The other tools ranged from
18.22% to 39.09%. We show that our method provides a novel and improved mechanism
to identify variants in scRNA-seq as compared to currently-existing software.
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INTRODUCTION

Single-cell sequencing
Single-cell sequencing (SCS) is a relatively new technique that saw its first use in
20111. Since its introduction, it has been used to investigate the heterogeneity of different
cancers2–4, determine copy number variation in enhanced detail5,6, and better characterize
circulating tumor cells using differential expression analysis7–10. Multiple recent studies
using SCS have also shown that tumors are genetically diverse and produce subclones
that contribute to the pathogenicity of the disease by conferring chemotherapy resistance
and metastatic capabilities to the tumor11–13. Application of this new technology is not
limited to cancer research; it has proven very useful in areas such as characterizing
somatic mutations in neurons14, identifying rare intestinal cell types15, and
discriminating cell types in healthy tissues15–17.
Regarding the exact methodology, SCS itself is composed of three steps: 1.) cell
capture, 2.) RNA or DNA library preparation, and 3.) sequencing of those libraries. The
different technologies used at each step can greatly influence the type and quality of
data generated. Our study captured cells with the C1 Fluidigm System, which uses a
microfluidic circuit design (Integrated Fluidics Circuit, or IFC) to accurately capture
single cells into 96 or 800 different reaction chambers18. These cells were then lysed and
had their mRNA isolated, converted into cDNA, amplified, and prepared for sequencing
using the Smart-seq2 protocol19. This library preparation method is unique in that it
amplifies the entire transcript, as opposed to just the 3’ end. Following this, the cDNA is
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sequenced using standard Illumina protocol on the NextSeq500 or a similar instrument
to generate short reads that can be used in downstream analyses.

Variant detection in SCS
Single Nucleotide Variants (SNVs) and micro (1-50bp) insertions and deletions
(indels) can have a large impact on human disease20–22 and are typically identified using
exome sequencing or whole genome sequencing (WGS)23. In these datasets where of
millions of cells are sequenced—otherwise referred to as bulk sequencing—, reads are
aligned to a reference genome, and variations are identified by one of a number of
different tools, such as FreeBayes24, GATK-HaplotypeCaller25, GATKUnifiedGenotyper26, or Platypus27.
The ability to accurately assess the presence of SNVs and indels in an individual
without having to perform both exome sequencing and RNA sequencing would be a
great boon to researchers. Further, as some studies rely on obtaining data from rare cell
types, it is important that it be possible to identify mutations and characterize gene
expression in the same cell. While it is possible to sequence both DNA and RNA from
the same cell as described by Macaulay et al.28, this technique is one that the typical lab
or core facility will not be able to perform due to the custom procedures and chemistry
involved. Further, the method developed by Macaulay et al. makes it impossible to
accurately identify variants28–30. Instead investigators are limited to using standard
reagent kits, such as the extant SMARTer Ultra Low RNA Kit by Clontech for Illumina
Sequencing, to obtain material of high enough quality to identify variants.
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In addition to the aforementioned types of studies performed in SCS (copy
number variation detection, differential expression analysis, rare cell identification, etc.),
effort has been made to apply standard bulk sequencing bioinformatic methods to
identify variants in SCS datasets14,31, and while this is feasible, it does not take advantage
of the unique nature of the data produced by the SCS platform. Further, it has been
necessary to rely on tools that were designed for Next Generation Sequencing (NGS)
data derived from genomic DNA instead of data generated from mRNA.
This study introduces a novel method, Red Panda, that is designed to identify
variants in single-cell RNA sequencing (scRNA-seq) and tests how it compares to
currently-available variant callers. These tools are those that have previously been
determined by our group to be the most accurate32. They are FreeBayes24,
HaplotypeCaller found in the Genome Analysis Toolkit (GATK) package 25, Platypus27,
and UnifiedGenotyper as found in the GATK package26. FreeBayes is a Bayesian
statistical framework capable of modeling multiallelic loci regardless of copy number.
GATK HaplotypeCaller (GATK-HC) uses a De Bruijn-like graph to reassemble regions
of the genome that show evidence of significant variation. GATK UnifiedGenotyper uses
a Bayesian genotype likelihood model to estimate the most likely genotypes and allele
frequency. Platypus uses local realignment of reads and local reassembly to accurately
identify variants in a genome. All four tools infer information about changes in
sequencing data when compared to a reference genome.
These tools were originally developed for calling variants using bulk DNA
sequencing data, but can also identify variants in bulk mRNA-seq data (e.g., The Broad
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Institute has put together a Best Practices guide using GATK HaplotypeCaller33);
however, ultimately this is software that was not designed for the unique case of
scRNA-seq data . Ideally variant calling would be performed on data derived from
genomic DNA from single cells as these would suit such software better as well as
provide more comprehensive results, but there exist too many problems with these data
to make this approach viable, namely: amplifying genomic DNA by any method leads to
allelic dropout; coverage nonuniformity reduces the probability of identifying variants
in useful areas of the genome, such as exons; and False Positive (FP) amplification errors
are very common34. While it is certainly possible to utilize these programs on data
derived from single-cell genomic sequencing, the aforementioned problems ultimately
make variant calling untenable. For this reason developing a method that can utilize the
higher quality scRNA-seq data to perform variant calling is necessary, as it does not
suffer the same shortcomings. Once such a strategy has been implemented, it will also
have the benefit of allowing us to investigate allele-specific expression, which play a role
in understanding different cell processes and how it correlates with diseases35,36.
Currently all bioinformatic tools used for variant identification in mRNA-seq
data treat variants within a transcript as independent events because they assume the
sample is composed of source material from millions of cells. This approach works well
for bulk sequencing but loses its power when used in scRNA-seq. To address this, our
method, Red Panda, employs the unique information found in scRNA-seq data to more
accurately identify variants in ways not possible with software designed for bulk
sequencing. The fact that transcripts represented by scRNA-seq reads necessarily only
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originate from the chromosomes present in a single cell is important. Where applicable,
this fact is used to decide what is and is not a heterozygous variant. For example, if 20%
of the transcripts in a cell originate from the maternal chromosome and 80% originate
from the paternal, then every heterozygous variant in the expressed transcript will be
represented by reads in the scRNA-seq data at a reference allele to alternate allele ratio
of either 1:4 or 4:1. This is because the expressed transcripts must have been derived
from either the maternal or maternal chromosomes in one cell. These types of
heterozygous variants are termed bimodally-distributed heterozygous. As part of the
process of identifying this class of variant, Red Panda creates three different classes:
homozygous-looking, bimodally-distributed heterozygous, and non-bimodallydistributed heterozygous. This partitioning strategy, as well as treating bimodallydistributed variants differently, grants an advantage compared to currently available
tools.

Datasets
In order to properly test Red Panda, a number of datasets were used and/or
generated. To be useful in a testing environment, test data needed to satisfy the
following criteria:
1. Bulk genomic sequencing data must pair with scRNA-seq data generated from
Smart-seq libraries.
2. The tissue used to generate these libraries must be isogenic.
3. The sequencing data must be of high quality.
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4. The data must be from a well-annotated genome, specifically either human or
mouse.
5. The data must be from healthy tissue to ensure as few variables as possible be
introduced to the software testing environment.
The first criterion was especially important because the bulk sequencing data
will be used to corroborate the findings from the scRNA-seq data.
To ensure high quality data was available for algorithm development, the
Genomics Core Facility at UNMC performed sequencing using the Smart-seq2 protocol
for single cells on human articular chondrocytes. In addition to RNA from 30 cells being
sequenced, exome sequencing data were also generated from these chondrocytes using
traditional exome sequencing. Ultimately, data from 22 cells were used after eliminating
poor quality data from eight of the cells. Additionally, 55 normal mouse embryonic
fibroblasts (MEFs) have been sequenced for additional validation using the Smart-seq2
protocol.

Validation
To confirm the existence or nonexistence of variants identified by Red Panda as
well as the four bulk sequencing variant callers (FreeBayes, GATK HaplotypeCaller,
GATK UnifiedGenotyper, and Platypus), Sanger sequencing was used attempt to verify
the existence of 40 randomly identified variants: 20 unique to Red Panda and 20
identified by all five variant callers. Simulated data was also generated from the MEF
sequencing to accurately predict the sensitivity of each variant caller.
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Statistics
Sensitivity and specificity are the metrics most often used to determine how
accurate data collection is or how accurate bioinformatic tools are. Sensitivity measures
the proportion of True Positives present in the measured dataset from the total that
should exist, and specificity measures the proportion of True Negatives that are
correctly measured as such. In this dataset:
●

A True Positive (TP) is a variant that truly exists as compared to the reference
genome and is identified as such.

●

A True Negative (TN) is a position on the genome that is correctly identified as
not differing from the reference genome.

●

A False Positive (FP) is a position on the genome that is incorrectly identified as a
variant when compared to the reference.

●

A False Negative (FN) is a variant that truly exists but is incorrectly identified as
not differing from the reference genome.
For our purposes, specificity (TN/(TN+FP)) and its derivatives such as False

Positive Rate (1-specificity), were not calculated for the exome and single-cell RNA
sequencing results due to how many True Negatives exist in the dataset as compared to
the number of False Positives: often the number of True Negatives in these datasets are
in the millions as opposed to the hundreds or thousands of False Positives. Instead, True
Positive Rate (TPR) and Positive Predictive Value (PPV) are focused on in these
analyses, as those numbers are more meaningful when using the results from the
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scRNA-seq and exome sequencing. However, sensitivity is calculated using the
simulated results from the MEF sequencing.

Software distribution
To ensure ease of access to and adoption of this tool, it shall be published via
GitHub as a stand-alone package where the source code will also be made available. The
stand-alone package will be a binary that any Linux-based system can run in
conjunction with the Genome Analysis Toolkit.

Hypothesis
Modern variant calling software, designed for bulk sequencing, cannot take
advantage of the information found only in scRNA-seq. Our method, Red Panda,
efficiently utilizes this unique information resulting in greater accuracy, opening up
more ways to analyze scRNA-seq data as it was previously not possible to use SNVs and
micro indels to investigate diseases at the cellular level.
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CHAPTER 1: ALGORITHM DEVELOPMENT OF RED PANDA

Introduction
Proper development of the software required a dataset that satisfied a number of
criteria for testing purposes. The sequencing data needed to:
1. Be isogenic for both a bulk genomic sequencing sample and also a
scRNA-seq sample.
2. Be high quality
3. Belong to an organism with a well-annotated genome
4. Come from a healthy sample individual
The data obtained from Borel et al. 2015 was the testing dataset employed to
assess the algorithm because, upon first inspection, it fit all four criteria. There are 163
cells from the UCF1014 cell line and 40 cells from the TN2A cell line on which variant
calling was performed, and there is WGS from both cell lines.
The largest challenge when identifying SNVs in any NGS data is reducing the
number of False Positives while maximizing the number of True Positives. The novel
method outlined here utilizes the uniqueness of the scRNA-seq data to classify variants:
all heterozygous variants in a given isoform can be pooled together into an expected
bimodally-distributed pattern to determine which variants in the isoform are real. This
strategy results in sorting variants into three different classes: homozygous-looking,
heterozygous and not bimodally-distributed, and bimodally-distributed heterozygous.
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This partitioning strategy and treatment of bimodally-distributed variants grants an
advantage compared to currently available tools.
Normally, by necessity, variant callers look at each SNV or indel as independent
events: they scan the alignment files for discrepancies between the reference genome
and the reads aligned to the reference genome. If there is a difference between the two,
then multiple statistical measures are calculated for that location. The particular method
depends on the tool, e.g., GATK HaplotypeCaller performs a de novo assembly of the
reads at the location in question and then uses Hidden Markov Models to determine the
haplotype of the variant at that position. If the results of those statistical tests meet
certain cutoff criteria, then that location, whether it is an SNV or an indel, is reported as
a potential variant and the variant caller moves on to the next position. While this works
very well for bulk sequencing datasets, improvements are possible through utilizing the
extra information specifically obtained from SCS data.
Red Panda utilizes the unique information found in scRNA-seq data to more
accurately identify variants. We capitalize on the fact that, because data come from a
single cell, transcripts represented by the scRNA-seq reads necessarily only come from
the two chromosomes present (or more, if there is aneuploidy), and we factor that into
our decision-making process when establishing what is and is not a variant. In a diploid
cell, one would expect transcripts to originate from two chromosomes, and thus, any
heterozygous variant present in a transcript as seen in the sequencing data will be
represented in a fraction consistent with the fraction of transcripts coming from a
specific chromosome. For instance Figure 1 shows that if 30% of the transcripts in a cell
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originate from the maternal chromosome and 70% from the paternal chromosome, then
reads in the scRNA-seq data will represent every heterozygous variant present in that
transcript at either a 7:3 ratio (reference:alternate allele) or a 3:7 ratio. This type of
variant is considered to be bimodally-distributed heterozygous. Using this concept of
read distributions, Red Panda can accurately remove False Positives—often artefacts
from the library preparation, sequencing, or alignment—that modern variant callers
would not remove, as well as pick up variants supported by a low fraction of reads.
With this concept, we were able to provide a novel and improved method for
identifying variants in datasets generated in a rapidly-evolving technology. However, to
accurately develop this algorithm, an appropriate dataset is needed for testing.

Primary fibroblast data analysis
To properly evaluate the development of our algorithm, an appropriate dataset is
needed for testing. Ideally, this is NGS data generated from a single sample but by two
different methods: bulk sequencing of genomic DNA and scRNA-seq of many
individual cells. Such a dataset has been acquired through the European Genome
Archive and is described below.
In 2015, Borel et al. performed a study to test the differential allelic distribution in
human primary fibroblasts31. Their interest lay in whether alleles were expressed
uniformly or preferentially. To determine the pattern of allelic expression, the
researchers sequenced 203 cells using scRNA-seq from two human primary fibroblast
cell lines, TN2A and UCF1014. Figure 2 shows a schematic detailing the full sequencing
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Figure 1. Finding a bimodal distribution. Any variant (green box) that fits into the expected
distribution of reads stays. Any that do not are removed: here the variant existing at a fraction of
0.5 (red box) would be removed.
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Figure 2. UCF1014 and TN2A sequencing strategy. Bulk WGS is paired with scRNA-seq for the
two primary fibroblast cell lines. The library prep for the single cells was performed using the
original Smart-seq protocol.
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strategy for sample preparation. The amplification kit used to generate the cDNAs of the
transcripts was the SMARTer Ultra Low RNA Kit for Illumina Sequencing (Clontech).
This is crucial because, while many other kits create transcripts of only the 3’ ends, this
kit generates cDNAs of the full transcripts, and for our study the ability to look at the
entire transcript for variants—not just the 3’ end—is necessary. This amplified cDNA
was turned into a proper mRNA-seq library using the Nextera XT DNA Kit, following
which the cells were multiplexed with 12 or 16 samples per lane and sequenced on a
HiSeq 2000.
In addition to the above, bulk WGS was performed for both the TN2A and
UCF1014 cell lines. Genomic DNA was harvested the same day as the single cells using
the QIAGEN kit, followed by library prep using the Illumina TruSeq DNA Kit. Two
lanes on the HiSeq 2000 were allotted for genomic DNA of the UCF1014 cell line and
three lanes were used for the TN2A cell line.
Validation requires both genomic DNA and scRNA-seq data from the same
source. Variant calling of genomic NGS data, especially whole genome (as opposed to
whole exome), is a very well-established practice and can determine True Positives,
False Positives, True Negatives, and False Negatives when identifying putative SNVs in
the scRNA-seq dataset. Also, while Borel et al. did perform variant calling on this data, it
was determined that the methods used to perform these analyses were outdated and we
opted to generate our own list using modern methods. Specifically, the Best Practices
outlined by the Broad Institute to identify variants in RNA-seq data37 was followed, and
the bcbio-nextgen pipeline, which implements the Best Practices outlined by the Broad
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Institute, was used to identify genomic variants38. We are uniquely qualified to assess
the quality of the type of bioinformatic analysis used due to previous work we have
published on assessing the quality of various variant calling pipelines32. It is important
to perform variant identification correctly, since these are the data used during software
development. The goal of this experiment was to compare any variants identified in the
scRNA-seq data by Red Panda and the other four variant callers to those found in the
dataset derived from the WGS results. Any SNVs that are present in both datasets are
True Positives; SNVs found in the genomic dataset and not the scRNA-seq dataset
(assuming appropriate read coverage in the scRNA-seq dataset) will be considered False
Negatives; SNVs found in the scRNA-seq dataset and not the genomic dataset will be
considered False Positives; and SNVs not found in either dataset will be classified as
True Negatives.
The bcbio-nextgen version (v.) 1.0.3 pipeline was used for variant calling to align
reads and identify variants in the bulk genome data. Reads were aligned to the human
genome v. 38 (hg38) using BWA MEM v. 0.7.15. Following this, three variant callers
were used to identify SNVs and indels: FreeBayes (v. 1.1.0)24, GATK HaplotypeCaller (v.
3.7.0)25, and Platypus (v. 0.8.1)27. Only variants identified by at least two out of the three
algorithms were kept as this has been shown to work well39. Following this, MultiQC v.
1.0.dev040 was run to aggregate QC statistics from bcbio-nextgen, samtools v. 1.441,
bcftools v. 1.4, and FastQC v. 0.11.542. Table 1 displays the number of reads, coverage,
mapping rates, number of SNVs identified, and the average number of SNVs per gene
for the genomic DNA. Of particular note are the mean number of heterozygous variants
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Sample

Reads

Coverage

Map
Rate

hetVariants
found in genes

Mean hetVariants
found per gene

UCF1014

8,460,80,874

27.9x

98.9%

105,779

5.32

TN2A

14,40,893,964

47.5x

99.0%

110,412

5.56

Table 1. Genomic sequencing statistics for UCF1014 and TN2A. Sequencing and analysis
statistics of the WGS from the two cell lines, UCF1014 and TN2A, to show that the quality is
appropriate as well as that there are enough hetVariants per gene to evaluate the concept unique
to Red Panda.
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(hetVariants) found per gene. For Red Panda to work, it was necessary that there be
enough heterozygous variants available in a gene to establish a bimodal distribution in
the first place. With ~5-6 hetVariants per gene—this number naturally increases or
decreases with the length of the gene—it was determined that there were enough to
continue with development of our software.
Once the genomic data had been analyzed, testing began on the scRNA-seq data,
specifically the TN2A cells, for quality. Testing the number of reads aligning outside of
exons found that the number was unexpectedly high: 41.70%. To determine if this was a
normal number, ten samples from each of six other datasets were investigated43–48. Three
datasets using cancer samples and three datasets using non-cancer samples (i.e., normal)
were chosen. Additionally, because the human fibroblast samples used version 1 of the
Smart-seq protocol, we checked the alignment rates of reads outside exons in Smartseq249 to check its performance. As can be seen in Figure 3, Smart-seq2 did perform
better. This matches expectations, as Picelli et al. proved that the newer protocol
produces longer and more complete transcripts49.
Due to the degree to which Smart-seq2 outperforms Smart-seq, it was
determined that it would not be appropriate to develop software using the fibroblast
data since it was generated using the inferior capture kit. Instead, data were generated
in-house using the Smart-seq2 protocol.
Articular chondrocyte sequencing
Since it was determined that Smart-seq2 produced higher quality data, in-house
sequencing was performed in collaboration with Dr. Andrew Dudley and his graduate
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Figure 3. Average fraction of reads aligned outside exons using two versions of Smart-seq
protocols. Here, v1 refers to version 1 of the Smart-seq protocol and v2 refers to Smart-seq2. Both
samples using the Smart-seq2 protocol contain a lower fraction of reads outside exons than the
other samples.
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student Krishna Sarma. This dataset met all of the four previously-mentioned criteria for
testing the software. The sequencing strategy employed for this sample can be seen in
Figure 4.
Krishna Sarma processed the articular chondrocytes harvested from a female
patient of Caucasian origin undergoing total knee replacement, who provided informed
consent prior to the study. Beau S. Konigsberg (orthopedic surgeon), Dillon R. Ellis
(Clinical research associate), and Dana M. Schwarz (Research nurse coordinator) (IRB
#691-13-EP) at UNMC approved this tissue for use. Human articular chondrocytes were
specifically chosen because they are the only cell type present in the cartilage of the
human knee and because they are locked in G050. This means that during software
development aberrations in isoform expression would be minimized due to the absence
of different cell types and cells in different phases of their cell cycle.
Cells were extracted from shavings of articular cartilage through sequential
digestion in .2% Pronase (Roche) for 2 hours followed by overnight digestion in .2%
collagenase (Gibco), all while shaking at 37°C. Cell suspensions were passed through
70μM cell strainers (BD Falcon) and centrifuged at 500xG for 10 minutes to recover
chondrocytes. The cells were subsequently embedded in three-dimensional alginate
bead cultures at a final concentration of about 75 million cells per mL. The cultures were
maintained in DMEM/F12 (1:1) media supplemented with 1% penicillin-streptomycinglutamine (Invitrogen, 10378-016), Amphotericin B (Gibco, 15290026), insulintransferrin-sodium selenite (Sigma, I2771), 50μg/mL Vitamin C, 10ng/mL FGF2, and
10ng/mL TGF-bb3 (PeproTech®, 100-36E) and maintained at 37°C in a 5% CO2
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Figure 4. Human articular chondrocyte sequencing strategy. Exome sequencing was paired with
scRNA-seq from the primary tissue culture of human articular chondrocytes. The library prep for
the single cells was performed using the updated Smart-seq2 protocol.
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atmosphere for 14 days. The day before single-cell capture, cells were lysed using
Trizol® reagent (Life Technologies) according to the manufacturer’s protocol. These cells
were split into two groups for DNA and RNA extraction.

Exome sequencing
Krishna Sarma performed the cell prep and DNA extraction on cells harvested
the same day as the single-cell capture. Genomic DNA was extracted using the QIAGEN
DNA extraction kit using the manufacturer's instructions. The UNMC Sequencing Core
Facility performed DNA prep. Due to the low amount of DNA (80ng) captured by the
QIAGEN kit, instead of the normal 10 PCR amplification cycles, 12 were performed
prior to library preparation to obtain enough DNA. Therefter, the Agilent SureSelect
Clinical Research Exome V2 kit was used to capture coding regions on the genome and
generate a library. Notably, the Clinical Research Exome V2 kit used does not include 5’UTR and 3’-UTR regions which limits what can be compared between the exome and
the scRNA-seq data, the latter of which will naturally have coverage in those regions.
The exome library was sequenced on two lanes of the NextSeq500 using 75 base pair
paired-end sequencing.
The bcbio-nextgen v. 1.0.3 pipeline was used for germline variant calling to align
reads and identify variants in the bulk exome data. For this analysis, the pipeline was
run on human genome v. 38 (hg38). The aligner BWA MEM v. 0.7.15 was used to align
reads to the human genome. Results of this can be found in Table 2. Following this,
three variant callers were used to identify SNVs and indels: FreeBayes (v. 1.1.0), GATK
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Total
Reads

Paired
Reads

182M

111M (61%)

PCR
Duplicate Alignment
38.3%

98.7%

Coverage

On-target rate

74.67x

55%

Table 2. Human articular chondrocyte exome sequencing statistics. Sequencing and
analysis statistics of the exome data from the human articular chondrocytes.
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HaplotypeCaller (v. 3.7.0), and Platypus (v. 0.8.1). After variant calling, only those
identified by at least two out of the three algorithms were kept. MultiQC v. 1.0.dev0 was
run to aggregate QC statistics from bcbio-nextgen, samtools v. 1.4, bcftools v. 1.4, and
FastQC v. 0.11.5.
The output of the exome sequencing resulted in good coverage of the coding
exons, however the percentage of reads that were PCR duplicates was particularly high,
likely due to the low amount of starting DNA. Normally 200ng of DNA is used during
library preparation, but only 80ng could be extracted which required two extra cycles of
PCR amplification. The ratio of homozygous to heterozygous variants is in line with
what one would expect from this type of sequencing32,51,52, however the numbers were
high since, originally, variants within 100bp of the coding exon boundary were
included. This means that variants were identified in the intronic regions as well as the
exonic region, but since this dataset is being used to compare against scRNA-seq, only
variants found within exons were included. This led to numbers more in line with what
is expected from exome sequencing as seen in the second row in Table 332.

Single-cell RNA sequencing
The UNMC Sequencing Core Facility performed capture and sequencing. For
single-cell capture, 735 cells were loaded on to a 10-17 μm Fluidigm C1 Single-Cell Auto
Prep IFC (with 96 wells), and the cell-loading script was performed using the
manufacturer's instructions. Each of the 96 capture sites were inspected under a confocal
microscope to remove sites containing dead cells as identified by the LIVE/DEAD Cell
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Bed file
contains 100bp
Total
Homozygous Heterozygous
± coding exons Variants
Variants
Variants

Ratio

SNVs

indels

Yes

85,128

33,856

45,769

0.74

79,627

5,504

No

20,315

7,777

12,538

0.62

20,057

258

Table 3. Human articular chondrocyte exome variant calling statistics. Variant analysis statistics
of the exome data from the human articular chondrocytes using the ensemble approach where
2/3 variant caller tools had to agree to call a variant.
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Viability Assay and to remove capture sites containing more than one cell. Cells that
were not identified as either alive or dead by the LIVE/DEAD assay were retained for
RNA sequencing.
Following capture, reverse transcription and cDNA amplification were
performed in the C1 system using the Clontech SMARTer Ultra Low Input RNA Kit for
Sequencing v3 which was done according to the manufacturer's instructions. Only 27
Single-cell cDNA libraries were obtained at a concentration of 0.09 to 0.55 ng/μl. Three
libraries were below a concentration of 0.08 ng/μl which may have been dying cells and
did not have a LIVE/DEAD staining. They have ‚NC‛ attached to their sample name
signifying ‚No Color‛. The majority of failed cells on the capture plate were either a
single dead cell (37) or a combination of live and dead cells (17) as seen in Table 4 and
Figure 5. Amplification was performed using the Nextera XT DNA Sample Preparation
Kit and the Nextera XT DNA Sample Preparation Index Kit (Illumina) was used for
indexing. After quantification using an Agilent Bioanalyzer, sequencing was performed
on two lanes of the NextSeq500 using 150 base pair paired-end sequencing.
The bcbio-nextgen v. 1.0.3 pipeline was used for RNA-seq to align reads and
perform transcript quantification for each of the cells. For this analysis, the pipeline was
run twice, once on human genome v. 19 (hg19) and once on human genome v. 38 (hg38).
For hg19 STAR v. 2.5.3a was used to align reads to the human genome; however, hisat2
v. 2.0.5 was used to align reads to hg38 due to its ability to correctly handle the alt alleles
present in that version of the human genome. Following this, MultiQC v. 1.0.dev0 was
run to aggregate QC statistics from bcbio-nextgen, samtools v. 1.4, QualiMap v. 2.2.2a53,
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Live
Cells

Dead
Cells

No Color
(NC)

Live and
Dead

>1 Live

>1 Dead

Empty

27

37

3

17

2

3

7

Table 4. Summary of the cells captured on the C1.
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a

b

c

d

Figure 5. Four capture sites on the C1 chip. Here we see (a) one cell stained as LIVE, (b) one
cell stained as DEAD, (c) three cells: two stained as LIVE, and one as DEAD, (d) cell debris, one
cell stained as LIVE and one stained as DEAD. The latter three illustrate the type of difficulties
present when trying to capture the articular chondrocytes.
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and FastQCv. 0.11.5. In addition to performing this type of analysis on each cell
individually, it was also performed on two bulk samples: one in which all 30 cells were
pooled together, and also a smaller pool of 26 cells where four (A3-C1NC, C10-C64, D12C72, and H7-C46) were removed for quality reasons. Full alignment statistics can be
found in Table 5. Once alignments had been performed, the genomic origin of the reads
in each cell was assessed. Any cells that had more than 30% of their reads originating
from outside exons are considered poor quality and will not be considered for further
analysis. This results in excluding the cells A3-C1NC, C10-C64, D12-C72, and H7-C46 as
seen in Figure 6. Since this is paired-end sequencing, the insert size of each fragment
was also calculated to see if there were any outliers. As seen in Figure 7, the cells A3C1NC, C10-C64, D12-C72, and G2-C38NC all have significantly smaller insert sizes than
the rest of the cells. Interestingly, three of these are the same as those cells that have
reads whose origin is largely intronic or intergenic.
To further assess the quality of the cells that were sequenced, the expression of
the transcripts needed to be assessed. As these cells are all of the same type and in the
same stage of the cell cycle, their expression profiles should be highly correlative. To
generate raw counts of genes expressed in each cell, htseq v. 0.6.154 was run using
default parameters. Normalized quantification was then performed using sailfish v.
0.10.155. Following this, custom scripts were used to generate a matrix containing the
expression counts generated by htseq for each gene in each cell and the two pooled
sample groups. In total there were 33 columns, one for the gene name, 30 for each cell,
one for the high quality data of cells (pooled26), and one for the total batch
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Sample Name

Reads

% Dup

rRNA pct

5'-3' bias

% GC

A3-C1NC

9.80 M

24.8%

3.8%

4.24

49%

A7-C6

11.04 M

25.3%

0.6%

1.18

47%

A8-C5

9.69 M

16.9%

0.7%

1.12

46%

B1-C9

9.50 M

16.9%

0.6%

1.15

47%

B12-C60

7.24 M

22.5%

0.9%

1.32

47%

B3-C7

14.80 M

15.4%

0.4%

1.21

46%

B6-C57

11.47 M

24.0%

0.6%

1.20

46%

B7-C12

11.62 M

19.4%

0.5%

1.14

45%

B8-C11

8.10 M

24.3%

1.7%

1.28

47%

C10-C64

11.76 M

17.2%

2.8%

2.66

46%

C11-C65

7.80 M

19.8%

0.4%

1.20

47%

C12-C66

0.08 M

1.5%

0.7%

1.32

53%

C5-C62

10.55 M

19.4%

0.3%

1.22

46%

C8-C17

16.34 M

25.7%

0.5%

1.14

46%

D11-C71

10.37 M

22.3%

0.4%

1.14

47%

D12-C72

6.79 M

20.6%

5.4%

3.24

47%

E1-C25

9.89 M

23.1%

0.5%

1.13

46%

E11-C77

9.59 M

26.7%

0.6%

1.14

46%

E2-C26

7.84 M

19.7%

0.6%

1.13

45%

E4-C75

7.06 M

18.3%

3.0%

1.38

48%

E5-C74

5.86 M

17.1%

0.4%

1.13

47%

F2-C32

9.33 M

18.9%

0.3%

1.18

46%

F3-C33

9.96 M

16.7%

0.5%

1.10

46%

G1-C37

10.75 M

17.7%

0.3%

1.19

45%

G2-C38NC

7.65 M

27.2%

0.7%

7.60

50%

G5-C86

7.65 M

17.2%

0.4%

1.20

46%

G8-C41

13.05 M

21.0%

0.6%

1.10

46%

H4-C93NC

8.57 M

19.2%

0.3%

1.12

47%

H6-C91

7.12 M

17.1%

0.5%

1.14

46%

H7-C46

5.43 M

17.8%

15.1%

1.76

52%

Table 5. Alignment statistics for the 30 cells captured on the C1.
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Figure 6. The genomic origin of reads found in each cell. Here one can see what percentage of
reads originate from exons (blue), introns (black) or intergenic space (green). The cells A3-C1NC,
C10-C64, D12-C72, and H7-C46 have significantly more reads originating outside the exonic
region than other samples.

31

Figure 7. The average insert size for each paired read for each cell. The average insert size of the
pair-end fragment is calculated from the alignment. The cells A3-C1NC, C10-C64, D12-C72, and
G2-C38NC have significantly smaller average insert sizes than other samples.
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of cells (pooled30) as seen in Figure 8. Here, pooled26 contains all cells excluding the
four that have been previously identified as low quality due to genomic origin of the
reads present: A3-C1NC, C10-C64, D12-C72, and H7-C46. Using this matrix as input,
cormat56 was used in R to generate a Pearson's correlation coefficient for all pairwise
comparisons between the cells as well the two pooled samples. Following this, ggplot257
was used generate a heat map of these comparisons.
From the correlation data, one can clearly see the four poor quality cells not
correlating to the rest of the batch as well as identify three other cells that do not
correlate well based on their expression patterns: H4-C93NC, G2-C38NC, and E4-C75.
All three (0.31, 0.39, and 0.35) are well below the median of 0.785 for all 30 cells. Because
these three do not correlate well with the rest of the samples, they will not be used for
further analysis. Unsurprisingly, all three cells that did not have a LIVE/DEAD stain,
labeled as NC, have now been removed for quality reasons.
Scatter plots were generated for all five of the samples that did not correlate with
the rest of the cells and one sample that did correlate well with the rest of the cells, and
they can be seen in Figure 9. From these it is clear that the expression profile of the cell
that has a high correlation coefficient, E2-C26, is much more tightly clustered along the
diagonal than the other samples.
The last method for removing low quality samples was to check the total read
count. Confidence Intervals (CI) were originally used to determine if there were enough
reads in a sample for it to be kept, and those intervals can be seen in Table 6. Instead of
arbitrarily removing sample C12-C66 because it had too few reads (80k vs. millions for
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Figure 8. Expression correlation between articular chondrocytes. Pearson Correlation
Coefficient calculated for every possible comparison of cells to each other and the two batches of
cells. The darker the color red, the higher the correlation between each cell. One can clearly see
the four poor quality cells not correlating to the rest of the batch as well as identify three other
cells that do not correlate well based on their expression patterns: H4-C93NC, G2-C38NC, and
E4-C75.
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a

b

c

d

e

f

Figure 9. Scatter plots generated based on expression. Five cells with low correlation and one
cell with high correlation as compared to the total batch. (a) A3-C1NC, R = 0.31 (b) C10-C64,
R=0.19 (c) D12-C72, R=0.34 (d) E4-C75, R=0.35 (e) H7.C46, R=0.13 (f) E2-C26, R=0.88
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n

Mean

Std
Dev.

Confidence

CI

Samples
outside CI

# above
upper-bound

Confidence intervals for reads generated per sample.
95% CI

30

9.22

3.01

2.41

9.22 (7.26–
11.19)

12

5

99% CI

30

9.22

3.01

3.17

9.22 (6.64–
11.81)

5

3

Confidence intervals for reads mapped per sample.
95% CI

30

7.37

3.25

3.17

7.37 (4.96–
9.78)

11

5

99% CI

30

7.37

3.25

2.41

7.37 (4.20–
10.54)

8

3

Table 6. Confidence intervals for number of reads. Confidence intervals for reads generated per
sample and reads mapped per sample. This data was used to determine if a statistical cutoff
based on confidence intervals could be calculated.
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the other samples), confidence intervals were used for the total number of reads
generated per sample and total number of reads mapped per sample.
Unfortunately it does not make a lot of sense to use confidence intervals here
since they imply that a sample falling outside the CI is an aberration in the population of
data and should be discarded; however that is inappropriate logic since more
sequencing data per sample is good thing even though those samples fall outside the CI.
Given that, it makes sense to use 500k reads as a lower-bound cutoff since that is what
one aims for in experiments using the Smart-Seq2 protocol58. This cutoff only removes
sample C12-C66 as it is the only one that has fewer than 500k reads. All of the above
filtering and QC steps have removed eight cells as seen in Table 7, leaving us with 22
cells of high quality data.
After establishing which samples to remove due to quality reasons, it became
necessary to prove that there exist transcripts that support the model that spawned our
algorithm. Such a proof of concept exists in Figure 10 where four variants were found in
the scRNA-seq data, but only three in the exome data. In cell A7-C6, gene CWC22, there
are two heterozygous variants and one homozygous variant. In the scRNA-seq two of
the heterozygous variants support each other when you add their fraction of reads
together (0.2 and 0.8 together add up to 1 as one would expect). However, there is
another putative heterozygous variant where 53% of the reads contribute to its existence,
but since this doesn’t fit what is expected (i.e., either 20% or 80%), it would be discarded.
Corroborating this is the fact that no such variant exists in the exome data. Also seen is
the homozygous variant in both the scRNA-seq data and the exome.
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Sample Name

Reason for removal

A3-C1NC

Too many reads outside exon; Poor correlation coefficient

C10-C64

Too many reads outside exon; Poor correlation coefficient

C12-C66

Number of reads < 500k

D12-C72

Too many reads outside exon; Poor correlation coefficient

E4-C75

Poor correlation coefficient

G2-C38NC

Poor correlation coefficient

H4-C93NC

Poor correlation coefficient

H7-C46

Too many reads outside exon; Poor correlation coefficient

Table 7. Reasons for removing eight samples from further analysis.
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a

b

Figure 10. Proof of concept data in articular chondrocytes. An example of the variations, from
gene CWC22, that we find in the scRNA-seq data as compared to the exome. The main area of
interest is the coverage track (the gray histograms). Red corresponds to T and blue corresponds
to a C. When there are two colors, the top color corresponds to the alternate allele. (a) Two
hetSNVs found in the cell A7-C6 have reads supporting them at percentages of 80% (left) and
20% (right). The same hetSNVs are found in the exome data at 50%. There is also a homozygous
variant (middle) seen in both. (b) One hetSNV found in the same gene at 53% in the cell A7-C6 is
absent in the exome sequencing. This is expected as it does not fit the existing biomodal
distribution at 80% or 20%.
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Algorithm Development

Logic
With an established dataset in hand, algorithm development commenced. The
basic workflow can be found in Figure 11. For each cell, it is first determined which
transcripts are expressed. This is done using the quantification numbers provided by
running sailfish v. 0.10.1 to filter out transcripts with a Transcripts Per Million (TPM)
value < 1. Once a list of expressed transcripts is established, samtools mpileup v1.4 is
used to generate a list of every possible variant contained within the provided alignment
file for this cell.
This list is then broken down into two lists containing variants that are likely
heterozygous or likely homozygous. Heterozygous variants are first filtered to exclude
those where, proportionally, few reads support their existence:
1. Remove variants where the fraction of reads supporting them is <20% and
read depth is <20x.
2. Remove variants where the fraction of reads supporting them is <10% and
read depth is <40x.
3. Remove variants where the fraction of reads supporting them is <5%.
Then, the remaining are checked to see if a potential bimodal distribution exists where
the fraction assigned to each mode adds up to 1, and if such a distribution does exist,
remove all heterozygous variants that do not fit, assuming a tolerance of 5%. For
example, if heterozygous variants are expected to be either 30% or 70%, anything falling
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Figure 11. A simple schematic of the logic used in Red Panda. For every cell, every expressed
isoform is identified with sailfish. All putative variants are then identified in each isoform and
split into a homozygous-looking VCF file and a heterozygous VCF file. The latter is then filtered
using Red Panda if the variants are bimodally-distributed or GATK-HC if they are not.
Homozygous-looking variants are filtered by Red Panda using quality cutoffs. These three sets of
variants are then combined into a single VCF file.
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in the range of 25%-35% and 65%-75% would be allowed. If a bimodal distribution does
not exist, then all heterozygous variants that have sufficient read support are written to
a file that will later be evaluated by GATK HaplotypeCaller. Similarly, all variants that
look to be homozygous are added to this sample’s file that will later be assessed. This
software is used because, as was established in our previous work, it is the best variant
caller available32 and it makes sense to use it in scenarios where the unique information
afforded to us by single-cell sequencing was no longer available. Specifically, in scRNAseq those scenarios are heterozygous variants that do not have enough supporting
variants to determine an appropriate bimodal distribution.
The final list of variants that is presented to the user contains those that: are
heterozygous and fit a bimodal distribution, are heterozygous and did not fit a bimodal
distribution but were supported by GATK HaplotypeCaller, and those that appeared to
be homozygous and had a read depth of at least 10x.
It should be noted that this method of taking advantage of the fraction of reads
supporting a heterozygous allele is also used to identify insertions and deletions. This is
especially important because indels are frequently disruptive while also being
notoriously difficult to accurately identify in sequencing data due to the length of the
typical next generation sequencing read as well as problems with short read aligners
being consistent in their alignment of reads to the reference genome59–64.
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Results
All putative variants were generated for each of the 22 samples using samtools
mpileup and the number of variants per sample ranged from 415,888 for B8-C11 to
1,398,345 for B3-C7 as seen in Figure 12a. To get more realistic numbers in line with
what is used in other methods, a minimum depth cutoff of 10x was used as can be seen
in Figure 12b. The number of variants per sample now ranges from 6,239 for E5-C74 to
15,737 for C8-C17. As expected, the largest bin is the 10x-14x bin due to the relatively
low amount of sequencing performed for each sample.
After the total putative variants are identified and filtered by depth, in the
instance of a bimodal distribution, variants are removed or kept based on whether they
fit said distribution. Figure 13 shows that when a bimodal distribution existed for a
transcript, on average 7.96%, or ~215, of the total putative variants heterozygous variants
in that transcript were kept. However, in the instance where there was not a bimodal
distribution present for a transcript and there was sufficient read support, variants were
filtered using HaplotypeCaller. On average, 34.89% of the variants checked at this stage
were kept after being evaluated as seen in Figure 14.
After all heterozygous variants were identified, both those identified by Red
Panda and those filtered by GATK HaplotypeCaller, they were combined with the
homozygous-looking variants into a final VCF file. Table 8 shows that, on average, there
were 1,369 variants per cell, of which 69.78% were homozygous-looking and
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a

b

Figure 12. Putative variants per Sample. (a) Total Putative Variants per Sample. There is a
very large number of putative variants per sample generated by samtools mpileup. These
numbers are before any filtering has taken place. (b) Number of Putative Variants per Sample
at Differing Depths. This is to see what proportion of putative variants exist at different depths.
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Figure 13. Variants fitting or failing a bimodal distribution. On average 7.96% of variants were
kept per cell. That’s an average of 215 variants. It is unclear why B8-C11 has so few variants
compared to other cells despite having a high read count.
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Figure 14. Variants not fitting a bimodal distribution. These variants were found in isoforms
that did not contain an obvious bimodal distribution and need to be filtered with GATK
HaplotypeCaller (HC). On average 34.89% of variants were kept after being evaluated. It is
unclear why B8-C11 has so few variants compared to other cells despite having a high read
count.
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Total
Percent of total variants that are homozygous

69.78%

Percent of total variants that are heterozygous

30.22%

Percent of heterozygous variants that are not bimodally-distributed

77.17%

Percent of heterozygous variants that are bimodally-distributed

22.83%

Total Variants

1369.5

Table 8. Summary table of variants identified by Red Panda. Percent of variants that are
homozygous-looking, heterozygous, heterozygous and not bimodally-distributed, heterozygous
and bimodally-distributed are calculated. Average total number of variants in the final VCF file is
also shown.
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30.22% were heterozygous. Of the latter group, 22.83% on average were bimodallydistributed variants.
After initial algorithm development, it was determined that a more deliberate
approach should be taken to determine whether a variant is being correctly classified as
heterozygous or homozygous. In the first iteration, variants were considered
heterozygous if one of the following criteria held true where AF = allele frequency, DP =
depth of the sequencing at this location, and C = the cutoff fraction at which this variant
is no longer considered heterozygous:
1. DP < 20 and AF < C where C = 0.85
2. 21 <= DP < 40 and AF < C where C = 0.90
3. DP >= 40 and AF < C where C = 0.95
To ensure that this Method, termed Method A, was the most accurate, ten total
strategies—Methods A-J—were created and compared: for each cell, all variants that
were identified by a certain method as heterozygous in the cell were cross-referenced
with that location in the exome. Assuming there was proper coverage in the exome to
come to an accurate conclusion, that method was then scored for that location.
Methods A-J largely follow the same logic where different bins, composed of two
cutoffs are used. The cutoffs are for depth and allele frequency at that location. The
general idea is that, as the depth at a location increases, it is more certain that the variant
at this spot is either homozygous or heterozygous. The methods are as follows:
Method A: three bins
1. DP < 20 and AF < C where C = 0.85
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2. 21 <= DP < 40 and AF < C where C = 0.90
3. DP >= 40 and AF < C where C = 0.95
Method B: three bins, with the cutoff fractions reversed
1. DP < 20 and AF < C where C = 0.95
2. 21 <= DP < 40 and AF < C where C = 0.90
3. DP >= 40 and AF < C where C = 0.85
Method C: three bins with laxer cutoffs for C
1. DP < 20 and AF < C where C = 0.90
2. 21 <= DP < 40 and AF < C where C = 0.933
3. DP >= 40 and AF < C where C = 0.967
Method D: three bins with laxer cutoffs for C, and the fractions reversed
1. DP < 20 and AF < C where C = 0.967
2. 21 <= DP < 40 and AF < C where C = 0.933
3. DP >= 40 and AF < C where C = 0.90
Method E: six bins
1. DP < 20 and AF < C where C = 0.8
2. 21 <= DP < 40 and AF < C where C = 0.84
3. 41 <= DP < 60 and AF < C where C = 0.88
4. 61 <= DP < 80 and AF < C where C = 0.92
5. 81 <= DP < 100 and AF < C where C = 0.94
6. DP > 100 and AF < C where C = 0.96
Method F: six bins; reversed fractions
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1. DP < 20 and AF < C where C = 0.96
2. 21 <= DP < 40 and AF < C where C = 0.94
3. 41 <= DP < 60 and AF < C where C = 0.92
4. 61 <= DP < 80 and AF < C where C = 0.88
5. 81 <= DP < 100 and AF < C where C = 0.84
6. DP > 100 and AF < C where C = 0.80
Method G: six bins with laxer cutoffs
1. DP < 20 and AF < C where C = 0.900
2. 21 <= DP < 40 and AF < C where C = 0.915
3. 41 <= DP < 60 and AF < C where C = 0.930
4. 61 <= DP < 80 and AF < C where C = 0.945
5. 81 <= DP < 100 and AF < C where C = 0.960
6. DP > 100 and AF < C where C = 0.975
Method H: six bins with laxer cutoffs; reversed fractions
1. DP < 20 and AF < C where C = 0.975
2. 21 <= DP < 40 and AF < C where C = 0.960
3. 41 <= DP < 60 and AF < C where C = 0.945
4. 61 <= DP < 80 and AF < C where C = 0.930
5. 81 <= DP < 100 and AF < C where C = 0.915
6. DP > 100 and AF < C where C = 0.900
Method I: 10 bins
1. DP < 10 and AF < C where C = 0.80
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2. 11 <= DP < 20 and AF < C where C = 0.82
3. 21 <= DP < 30 and AF < C where C = 0.84
4. 31 <= DP < 40 and AF < C where C = 0.86
5. 41 <= DP < 50 and AF < C where C = 0.88
6. 51 <= DP < 60 and AF < C where C = 0.90
7. 61 <= DP < 70 and AF < C where C = 0.92
8. 71 <= DP < 80 and AF < C where C = 0.94
9. 81 <= DP < 90 and AF < C where C = 0.96
10. DP > 90 and AF < C where C = 0.98
Method J: 10 bins
1. DP < 10 and AF < C where C = 0.80
2. 11 <= DP < 20 and AF < C where C = 0.82
3. 21 <= DP < 30 and AF < C where C = 0.84
4. 31 <= DP < 40 and AF < C where C = 0.86
5. 41 <= DP < 50 and AF < C where C = 0.88
6. 51 <= DP < 60 and AF < C where C = 0.90
7. 61 <= DP < 70 and AF < C where C = 0.92
8. 71 <= DP < 80 and AF < C where C = 0.94
9. 81 <= DP < 90 and AF < C where C = 0.96
10. DP > 90 and AF < C where C = 0.98
Figure 15 shows that Method C identifies the highest number of variants
correctly identified as heterozygous, but it has one of the lowest total percent of variants
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Figure 15. Different methods for determining if a variant is heterozygous. Ten different
methods were written to determine if a variant is considered heterozygous by only looking at the
scRNA-seq data. This graph is an average across all 22 cells of the percentage and counts of
correctly identified heterozygous variants by each method.
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identified correctly. Interestingly the original method used, Method A, is among the best
performers, but Method E will be used as it slightly outperformed everything else.
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CHAPTER 2: VALIDATION USING SIMULATED AND EXPERIMENTAL
DATA

Introduction
To determine the effectiveness of Red Panda, we tested the method using both
simulated and experimentally-generated datasets. Our results are compared to those
from four currently available variant calling tools: FreeBayes, Genome Analysis Toolkit
HaplotypeCaller, Genome Analysis Toolkit UnifiedGenotyper, and Platypus. It is
important to compare these tools because, in addition to being popular in the
bioinformatics community, their performance has been assessed in bulk sequencing
settings32,65,66, but not in single-cell sequencing.
The first dataset used is the human articular chondrocyte single-cell RNA
sequencing described previously. To ensure consistency of comparisons, all tools are
given identical inputs: alignment files which are uniformly generated using the scRNAseq data from the articular chondrocytes. All variant calling software is then run using
their recommended settings. These variant calling data from each cell are compared to
the results from the human articular chondrocyte exome sequencing to determine its
veracity. To abrogate any False Negatives, the variant calls are restricted to those
locations that have sufficient supporting alignments from the scRNA-seq datasets as
well as the exome sequencing data. Once these regions have been identified, all variants
are compared to the exome sequencing variant calling results to assess the Positive
Predictive Value (PPV) of Red Panda as well as the other variant calling tools.
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The second dataset is generated from MEFs. These cells are isolated using the C1
Fluidigm 96-well chip and have libraries generated using version three of the SMARTer
Ultra Low RNA Kit for Illumina Sequencing in the same manner as the articular
chondrocytes. Alignment and variant calling is performed the same as with the first
dataset; however validation is performed differently as this data will not be paired with
exomic bulk sequencing. Sanger sequencing was used to verify the existence of 40
randomly identified variants: 20 unique to Red Panda and 20 identified by all five
variant callers. Simulated data was also generated from the MEF sequencing to
accurately predict the sensitivity of each variant caller.

Comparing variant callers using human articular chondrocyte data
Alignment file preparation
For four of the five variant calling pipelines, alignments are prepared by running
hisat2 version 2.1.0 using human genome version hg38 as the reference. The exception to
this is Platypus which used BWA MEM v. 07.1767 due to its requirements for alignment
files. Hisat2 is specifically designed for aligning RNA-seq reads and will split reads
across exons to ensure the highest-quality alignments. Unfortunately this results in very
large fragments that Platypus cannot process. Instead, BWA MEM, another high quality
alignment tool, was used in a manner that generated alignments that Platypus could
process.
Alignment is followed by running the Genome Analysis Toolkit version 3.8.0
module, SplitNTrim + ReassignMappingQuality. This method of alignment preparation
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ensures that the highest quality alignment files are generated when trying to identify
variants, and thus, that the only deficiencies identified are due to the variant caller itself
instead of other processing steps. Specifically, reads spanning exon-intron junctions
have overhanging regions clipped to remove any intronic sequence if they have been
incorrectly aligned. Lastly, for every tool, a bed file containing the regions of probes
pulled down by the SureSelect Clinical Research Kit V2 was used to limit the location of
where variants could be identified to ensure proper overlap of the single-cell data and
the exome data.

FreeBayes
FreeBayes is Bayesian statistical framework capable of identifying, in a reference
genome, small variations including SNVs, indels, multi-nucleotide variants (MNVs), and
composite insertion and substitution events so long as these events are shorter than the
length of the sequencing read belonging to the alignment. Version 1.1.0.46 was used to
generate Variant Call Format (VCF) files containing all variants present in the alignment
file for each cell. FreeBayes was run using the following arguments in addition to default
parameters:
●

--min-alternate-fraction 0.01

●

--targets SureSelect_Clinical_Research_Exome_v2.bed

●

--no-partial-observations
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GATK HaplotypeCaller
GATK HaplotypeCaller uses a De Bruijn-like graph to perform local de novo
assembly of regions of the genome that show evidence of significant variation, including
SNVs, MNVs, and indels. This has the advantage of more accurately identifying more
complex variation in a sample such as indels, and, importantly for our study, splice
junctions. However these benefits come at the expense of increased computation time 68.
Version 3.8-0-ge9d806836 was used to generate VCF files containing all variants present
in the alignment file for each cell. GATK HaplotypeCaller was run using the following
arguments in addition to default parameters:
●

--filter_reads_with_N_cigar

●

--standard_min_confidence_threshold_for_calling 4.0

●

--dbsnp dbsnp-150.vcf.gz

●

-L SureSelect_Clinical_Research_Exome_v2.bed

GATK UnifiedGenotyper
GATK UnifiedGenotyper uses a Bayesian genotype likelihood model to estimate
the most likely genotypes (SNVs, MNVs, and indels) and allele frequency. GATK
UnifiedGenotyper also benefits from not assuming ploidy for the organism being
analyzed which is not the case for GATK HaplotypeCaller68. Version 3.8-0-ge9d806836
was used to generate VCF files containing all variants present in the alignment file for

57

each cell. GATK UnifiedGenotyper was run using the following arguments in addition
to default parameters:
●

--filter_reads_with_N_cigar

●

--standard_min_confidence_threshold_for_calling 4.0

●

--dbsnp dbsnp-150.vcf.gz

●

-L SureSelect_Clinical_Research_Exome_v2.bed

●

--geontype_likelihoods_model BOTH

Platypus
Platypus uses local realignment of reads and local reassembly to accurately
identify variants--SNVs, MNVs, indels, and long-range insertions and deletions--in a
genome. Version 0.8.1.1 was used to generate VCF files containing all variants present in
the alignment file for each cell. Platypus was run using the following arguments in
addition to default parameters:
●

--regions=SureSelect_Clinical_Research_Exome_v2.bed

●

--filterDuplicates=0

Comparison of all tools’ results with the exome data
Comparisons are performed by looking at the data produced by each tool for
each cell; one VCF file is created per cell per tool, totaling 110 files (22 cells×5 tools).
Statistical metrics are then calculated to evaluate each tool using the exome variant
analysis results as the reference against which these 110 files are compared. This process

58

involves calculating the intersection of regions in the genome that are common between
the SureSelect Clinical Research Exome V2 library preparation kit and only the
transcripts that are expressed in the cell being analyzed. This is needed because the
scRNA-seq is a subset of the exome data, and not limiting the search space to those
regions corresponding to genes expressed in this cell leads to the erroneous
identification of thousands of False Negatives. All of these regions of interest are
contained in a bed file in a format that can be seen in Table 9. The intersection of the
exome bed file and the expression bed file for that cell is created using bedtools69 and
results in a file that only contains regions common to both files as seen in Figure 16.
As an example, a new bed file that is the intersection between the exome bed file
and the transcripts expressed in cell G1-C37 (named here: exome_G1-C37.bed, or the
bounded exome bed file) is created. Following this, five new VCF files are generated,
one per tool (these are bounded VCF files as they are restricted by the boundaries of the
exome + transcripts bed file):
1. Variants identified by FreeBayes (FreeBayes_G1-C37.vcf) that fall into the regions
contained in exome_G1-C37.bed produce a file containing variants found only in
the intersected regions: FreeBayes_exome_G1-C37.vcf.
2. Variants identified by GATK HaplotypeCaller (GATK_HaplotypeCaller_G1C37.vcf) that fall into the regions contained in exome_G1-C37.bed produce a file
containing variants found only in the intersected regions:
GATK_HaplotypeCaller_exome_G1-C37.vcf
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Chromosome

Chromosome start location

Chromosome end location

chr1

14211

15031

chr1

61724

62229

...

...

56874614

56876385

...
chrY

Table 9. The bed file format. These files contain the regions that will be analyzed for variants in
each cell.
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Figure 16. Intersection example of exome and expression bed files. The resulting file containing
the purple regions is what is used to determine concordance of variants found exome and those
found in the cell.
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3. Variants identified by GATK_UnifiedGenotyper (GATK_UnifiedGenotyper_G1C37.vcf) that fall into the regions contained in exome_G1-C37.bed produce a file
containing variants found only in the intersected regions:
GATK_UnifiedGenotyper_exome_G1-C37.vcf
4. Variants identified by Platypus (Platypus_G1-C37.vcf) that fall into the regions
contained in exome_G1-C37.bed produce a file containing variants found only in
the intersected regions > Platypus_exome_G1-C37.vcf
5. Variants identified by Red Panda (Red_Panda_G1-C37.vcf) that fall into the
regions contained in exome_G1-C37.bed produce a file containing variants found
only in the intersected regions: Red_Panda_exome_G1-C37.vcf
Once these files are created, PPV (specificity and False Positive Rate are not
calculated as the number of True Negatives is so large that it results in values so close
together that they cannot be meaningfully distinguished) can be calculated for each tool:
●

Positive Predictive Value: (TP)/(TP + FP) where:
a. TP = number variants in both the tool’s bounded VCF file (e.g.,
Red_Pand_exome_G1-C-37.vcf) AND the exome VCF file that only
contains variants found in the intersected bed file (e.g., exome_G1C37.bed)
b. FP = number of variants in the tool’s bounded VCF file that are not also in
the bounded exome VCF file.
In addition to the PPV statistics, the total number of variants—SNVs and

indels—produced by each tool in each cell was intersected with the variants found in the
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exome as can be found in Figure 17. Specifically, only those regions that were supported
by read data in both the exome and the single-cell data were compared.
It is immediately apparent that Red Panda finds more variants than every other
tool. On average, Red Panda identifies 913 variants per cell that are in accordance with
the exome whereas FreeBayes identifies 65, GATK HaplotypeCaller identifies 705,
GATK UnifiedGenotyper identifies 222, and Platypus identifies 386.
The overlap between the tools was also assessed by creating UpSet70 plots (a
method of showing intersection between datasets) between each tool for each cell as
seen in Figure 18. There is consistent overlap between the tools, even for FreeBayes and
GATK UnifiedGenotyper which typically did not identify as many variants as the other
tools. Of note is the fact that while Red Panda shares significant overlap with the other
tools, it also identifies a large number of unique variants. This is expected given that Red
Panda consistently identified more variants than every other tool.
To assess the effectiveness of these software with regards to heterozygous
variant identification, the same analysis was performed using just the heterozygous
SNVs and indels in each sample. This posed a new problem as it is difficult to determine
what is heterozygous and what is homozygous in scRNA-seq data. This is because
transcription does not always occur from both chromosomes at the same time, but rather
can happen in a burst fashion resulting in only monoallelic expression being seen71,72.
Given this, it is possible that what might look like a homozygous variant in the
sequencing data, might actually be heterozygous. To handle this, the method created for
Red Panda—Method E from the Algorithm section of Chapter 1—was utilized to
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Figure 17. Total variants in concordance with the exome. The total number of variants in
concordance with the exome for every cell as identified by each tool. Each cell had variants
identified by FreeBayes, Red Panda, GATK HaplotypeCaller, Platypus, and GATK
UnifiedGenotyper, after which they were compared to the exome sequencing data to determine
their veracity. Red Panda is characterized by three box plots: 1, 2, and all. Red Panda_1 contains
variants exclusive to Red Panda logic: homozygous-looking variants and bimodally-distributed
heterozygous variants. Red Panda_2 contains non-bimodally-distributed heterozygous variants
that are called by GATK-HaplotypeCaller. Red Panda_all is a superset of the two. Comparisons
were performed using T-tests: ns = not significant, * is p < 0.05, ** is p < 0.01, *** is p < 0.001, and
**** is p < 0.0001.
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Intersection of Variants for each tool in cell G1-C37

Figure 18. UpSet plots of the overlap between each tool. The overlap of the variants identified
by each tool can be seen for the cell G1-C37. Red Panda identifies the most variants as well as the
most unique variants in concordance with the exome. Each column of the X-axis shows the
overlap between each tool represented by a filled-in dot. For example, the first column indicates
that GATK-HC and Red Panda shared 552 variants, the second shows that there were 213
variants unique to Red Panda, the third column indicates that there were 120 variants shared
between Platypus, GATK-HC, and Red Panda, and so on.
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determine whether something was homozygous-looking or heterozygous. This variant
is then cross-referenced with the exome sequencing data to confirm that it is, in fact,
heterozygous. Method E utilizes metadata found in the VCF files to identify AF (Allele
Frequency = # alt alleles/(# alt alleles + # ref alleles)) and DP (depth of the sequencing at
this location). In this method, C = cutoff fraction at which this variant is no longer
considered heterozygous (i.e., if AF > C, it is considered homozygous). If a variant fits
one of these six criteria then it is considered heterozygous for our comparisons:
1. DP < 20 and AF < C where C = 0.8
2. 21 <= DP < 40 and AF < C where C = 0.84
3. 41 <= DP < 60 and AF < C where C = 0.88
4. 61 <= DP < 80 and AF < C where C = 0.92
5. 81 <= DP < 100 and AF < C where C = 0.94
6. DP > 100 and AF < C where C = 0.96
The five tools had their variants filtered so that heterozygous variants were split
out into separate files for further analysis. Method E was used to determine whether
something was heterozygous for Platypus and Red Panda as they contained appropriate
metadata to calculate DP and AF. For FreeBayes, GATK UnifiedGenotyper, and GATK
HaplotypeCaller, there is no metadata available in the VCF file for how many reads
supported the alternate allele vs. the reference allele. Instead for FreeBayes and GATK
UnifiedGenotyper, the AF field provided in the variant’s metadata (not to be confused
with the AF value used in Method E) was used to determine the fraction of reads that
support the alternate allele. Unfortunately, this is not a perfect comparison since this
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value is calculated after reads are filtered out by the variant caller from the alignment
(typically reads that are low quality or have poor mapping scores are removed), whereas
the fractions calculated by Method E are performed before reads are filtered. For GATK
HaplotypeCaller, the MLEAF (Maximum Likelihood Expectation for the Allele
Frequency) value was used which attempts to approximate the original proportion of
the allele in the context of a diploid organism73. For this data, MLEAF is either 0.5
(heterozygous variant) or 1.0 (homozygous); the former is used to filter variants into the
file containing heterozygous-looking variants.
Once an accurate method has been developed for identifying how to determine
what a heterozygous variant is, the effectiveness of these software with regards to
heterozygous variant identification was performed. Figure 19 shows the total number of
heterozygous SNVs and indels in concordance with the exome for each tool and each
cell. While the improvement is not as drastic as compared the total number of variants in
agreement with the exome data, Red Panda still improves on the other methods. On
average Red Panda identifies 154 variants in agreement with the exome, 31 for
FreeBayes, 136 for GATK HaplotypeCaller, 118 for GATK UnifiedGenotyper, and 36 for
Platypus.
After identifying the total number of variants found per cell per tool that agreed
with the exome, PPV and False Discovery Rate (FDR) are calculated. As seen in Table 10
and Figure 20, Red Panda has the highest average PPV of any of the other tools. This
shows that, compared to the variant calling software traditionally used for bulk
sequencing, Red Panda correctly identifies a variant more consistently. Despite
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Figure 19. Total heterozygous variants in concordance with the exome. The total number of
heterozygous variants in concordance with the exome for every cell as identified by each tool.
Each cell had variants identified by FreeBayes, Red Panda, GATK HaplotypeCaller, Platypus,
and GATK UnifiedGenotyper, after which they were compared to the exome sequencing data to
determine their veracity and then selected for comparison if they were heterozygous-looking.
Red Panda consistently identifies more variants in concordance with the exome than every other
tool. Red Panda is characterized by three box plots: 1, 2, and all. Red Panda_1 contains
bimodally-distributed heterozygous variants. Red Panda_2 contains non-bimodally-distributed
heterozygous variants. Red Panda_all is a superset of the two. Comparisons were performed
using T-tests: ns = not significant, * is p < 0.05, ** is p < 0.01, *** is p < 0.001, and **** is p < 0.0001.
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Algorithm

Average PPV (%)

Average FDR (%)

FreeBayes

8.69% ± 0.35%

91.31% ± 0.35%

GATK- HaplotypeCaller

31.67% ± 2.08%

68.33% ± 2.08%

GATK-UnifiedGenotyper

5.84% ± 0.45%

94.16% ± 0.45%

Platypus

6.95% ± 0.49%

93.05% ± 0.49%

Red Panda

44.96% ± 3.15%

55.04% ± 3.15%

Table 10. PPV and FDR for each tool. The average PPV and FDR with standard deviations for
each tool using the exome as reference.
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this, PPV is still low compared to traditional datasets32,74. For all of the comparisons in
Figures 17, 19 and 20, with the exception of Red Panda and GATK-HC heterozygous
variant calls, the differences between the results for Red Panda and the other software
was statistically significant when assessed with T-tests.
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Figure 20. The average PPV calculated for each tool. Red Panda has the highest average PPV
than other tools indicating that it has far fewer False Positives. Comparisons were performed
using T-tests: ns = not significant, * is p < 0.05, ** is p < 0.01, *** is p < 0.001, and **** is p < 0.0001.
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Mouse Embryonic Fibroblasts sequencing
After the development of Red Panda was finished, further testing needed to be
performed on other datasets to ensure that this software works as a generalized tool and
is not specifically tailored to the conditions found in human articular chondrocytes. The
data that is being used to perform additional tests on Red Panda is generated from
single-cell RNA sequencing on Mouse Embryonic Fibroblasts (MEFs).
The MEFs used for sequencing are generated in collaboration with Dr. Kishor
Bhakat and his graduate student Shrabasti Roychoudhury, the full sequencing strategy
of which can be seen in Figure 21. Their study involves investigating the effect the gene
Ape1—also known as Apex1—has at the cellular level when it is mutated in a specific
way. Ape1’s function is to repair apurinic/apyrimidinic (AP) sites—DNA lesions—in
mammalian cells75. Two MEF samples have been generated: one normal/wild-type and
one mutated. The mutated sample has had two amino acids altered in the gene Ape1.
Lysine 6 and Lysine 7 are both converted to Alanine to remove its ability to be acetylated
at those sites76,77. The mutated sample—also designated ‚Ape1K6A,K7A‛ and the normal
sample, designated ‚Ape1K/K‛—was modified using the Easi-CRISPR78 system to induce
these mutations. Both of these samples, Ape1K,K and Ape1K6A,K7A, had single cells isolated
on the Fluidigm C1 system and had RNA sequenced on a NextSeq500.
Following sequencing, variant calling is performed on both sets of samples using
the same tools used with the articular chondrocytes—FreeBayes, GATK Haplotype
Caller, GATK Unified Genotyper, Platypus, and Red Panda—but for the purposes of this
study, focus is placed solely on the normal Ape1K,K sample. This is because it is the only
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Figure 21. The sequencing strategy for the MEFs. Two groups of MEFs are sequenced, one WT
and one mutated. The WT cells have variant calling performed on them with five variant callers
as with the articular chondrocytes. Validation is performed by Sanger sequencing on 40 variants.
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sample that will have Sanger sequencing79 and simulation used to confirm the existence
of variants identified. The Ape1K6A/K7A mutation will likely lead to an accumulation of
spurious mutations throughout the genome but only at the single-cell level, hence these
results are not appropriate for validation studies. That is, the increase in mutations
would not necessarily lead to an increase in mutations shared across all of the cells, but
rather only mutations found in single cells. If this hypothesis is correct, then it would not
be possible to identify cell-specific mutations via Sanger sequencing.
Results from variant calling by the five different software packages are compared
in a number of ways: total number of variants identified by each tool, total number of
homozygous-looking variants identified, and total number of heterozygous variants
identified. The distinction between heterozygous variants and homozygous-looking
variants is an important one in this analysis as has been mentioned previously. Variants
will either have a fraction of reads that supports an unambiguously heterozygous
variant, or they will have a fraction of reads that, in a single cell, appears to be a
homozygous variant, but could potentially be heterozygous. This is due to the stochastic
nature of RNA transcription leading to allele-specific expression80–82. This pattern of
expressing RNA from a single chromosome—otherwise known as monoallelic
expression—can lead to a heterozygous variant looking like a homozygous variant71,83.
Due to this ambiguity, variation in the genome that has full read coverage supporting an
alternate allele is hereafter termed ‚homozygous-looking‛ rather than ‚homozygous‛.
In addition to the total number of variants identified, variant overlap between
cells is assessed. As these cells are isogenic, each cell should share a large portion of their
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variants with the other cells sequenced. This overlap is evaluated with the assumption
that a high overlap identified by a variant caller is an indicator of that software
performed well.
The final way these five tools are compared is using the results of Sanger
sequencing validation as well as simulated variants inserted into the normal MEF
alignment files. Sanger validation is performed on a set of 20 random variants identified
by all variant callers, and on a set of 20 random variants identified exclusively by Red
Panda. The first group is meant to assess the accuracy of all the tools taken as a whole.
The second is to address whether the Red Panda-specific variants are reliable. One
requirement of the variants being checked is that they are identified in at least two cells.

Single-cell RNA sequencing
Shrabasti Roychoudhury performed cell prep and DNA extraction for these
samples. This data came from MEFs that were harvested from embryos at E13.5. Cells
were extracted using previously standardized methods84. After isolation, cells were
cultured in Dulbecco’s modified Eagle medium (DMEM) medium containing 10% FBS
and 1% Penicillin and Streptomycin at 37°C in a 5% CO2 atmosphere for 2 days. On the
day of single-cell capture, cells were trypsinized (0.05% Trypsin-EDTA solution),
counted and resuspended in media at 105 cells/mL concentration.
The UNMC Sequencing Core Facility performed cell capture and sequencing.
Cells were loaded on to a 17-25 μm Fluidigm C1 Single-Cell Auto Prep IFC (with 96
wells), and the cell-loading script was performed using the manufacturer's instructions.
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Each of the 96 capture sites were inspected under a confocal microscope to remove sites
containing dead cells as identified by the LIVE/DEAD Cell Viability Assay and also to
remove capture sites containing more than one cell. Only cells that were labeled as LIVE
were kept for sequencing. Total DNA was isolated from the remaining MEF cells for
Sanger validation purposes.
Following capture, reverse transcription and cDNA amplification were
performed in the C1 system using the Clontech SMARTer Ultra Low Input RNA Kit for
Sequencing v3 which was done according to the manufacturer's instructions. Only 56
Ape1K6,K7 and 55 Ape1K6A,K7A single-cell cDNA libraries were obtained at a concentration
of 0.09 to 0.55 ng/μl. The majority of failed cells on the capture plate were dead cells.
Amplification was performed using the Nextera XT DNA Sample Preparation Kit, and
the Nextera XT DNA Sample Preparation Index Kit (Illumina) was used for indexing.
After quantification using an Agilent Bioanalyzer, sequencing was performed on two
lanes each of the NextSeq500 for the 56 normal cells and 55 mutated cells. Paired-end
reads totaling 150 base pairs were generated.

scRNA-seq processing and QC
As mentioned above, only the normal MEFs are used for software testing
purposes. Given this, all following QC metrics and processing steps will be exclusive to
that dataset.
The bcbio-nextgen v. 1.0.3 pipeline85 was used to process the RNA-seq data by
way of generating Quality Control (QC) checks, alignments to a reference genome, and
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expression values for genes in each cell. For this analysis, the pipeline was run on the
mouse genome v. 10 (mm10) and its annotation was acquired from Ensembl, release 93.
MultiQC v. 1.0.dev0 was run to aggregate QC statistics from bcbio-nextgen, samtools v.
1.4, QualiMap v. 2.2.2a53, and FastQCv. 0.11.5. The aligner hisat2 v. 2.1.0 was used to
align reads to the reference genome, and sailfish v. 0.10.1 was used generate expression
values.
The QC metrics aggregated by MultiQC were used to determine if it was
immediately apparent that any of the cells had failed sequencing. Quality scores along
the length of the read are a good way of determining if there was a systematic problem
with the library prep or sequence generation. As seen in Figure 22, the quality scores for
every sample appeared to be high with the exception of a slight dip at the end of the
reads. This dip is expected with Illumina sequencing and it was trimmed off using
fqtrim v. 0.9.7—this software was also used to trim adapter sequences common to RNAseq—using default parameters. This trimming resulted in an average length of 139bp for
the normal samples.
Sequencing metrics looked good for all cells with each producing around 5
million reads on average as seen in Table 11. One exception to this is Cell 07 which only
produced 70,000 reads. This cell was removed from the final analysis due to the low
number of reads attributed to it.
To further assess the quality of the cells that were sequenced, the origin of the
reads was checked to assess whether the reads are from exonic regions. As this is RNAseq, the majority of reads should be derived from these regions, and if they are not, then
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Figure 22. Mean quality scores for reads sequenced from each MEF. The quality score graph
generated by FastQC shows the mean quality scores for each normal MEF were generated across
the length of the sequenced read.
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Sample
Normal MEFs

Reads

% Dup

rRNA pct

5'-3' bias

% GC

5.35 M

40%

1.13%

1.09

46%

Table 11. Average alignment statistics for the MEFs. Average alignment statistics for the 56
normal cells captured on the C1.
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there was likely something wrong with the cell upon capture (most likely that the cell
was in the process of dying). Any cell that had < 60% of the reads coming from exons
were removed. Using this filter, as can be seen in Figure 23, only one cell was removed:
cell C47.
The last quality control metric employed was checking the Pearson correlation
coefficient calculated by comparing the expression profile of all of the cells. To generate
these coefficients, a matrix was created where each column to a cell and its expression
values for every possible isoform found in the mouse Ensemble 93 database. The value
in each cell of the matrix is the expression of the isoform measured by TPM as calculated
by sailfish for that particular cell. As these MEFs are from the same population of cells, it
is expected that they all contain similar expression patterns. Any cells that are largely
deviating from entire the group are likely to be in an altered state that may affect the
downstream analyses. As seen in Figures 24, only one cell of the 56 sequenced falls into
this category and is already being removed due to having a low read count: cell C07.
There does exist a block of cells seen at the bottom of the heat map that clusters together,
but as they still show significant similarity with a large number of cells, they are
retained.

Comparing variant callers using MEF data
Alignment file preparation
For four of the five variant calling pipelines, alignments are prepared by running
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Qualimap RNAseq: Genomic Origin

Figure 23. The genomic origin of reads found in each MEF. Here one can see what percentage
of reads originate from exons (blue), introns (black) or intergenic space (green). The cell C47 in
the normal group is the only cell to have significantly more reads originating outside the exonic
region than other samples.
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Figure 24. Expression correlation between MEF. Pearson Correlation Coefficient calculated for
every possible comparison of cells to each other for the normal MEFs. The darker the color red,
the higher the correlation between each cell. Only one cell fails to correlate will with any of the
other cells: C07. The bottom block of cells significantly correlates with a high number of cells and
they are therefore retained.
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hisat2 version 2.1.0 using mouse genome version mm10 as the reference. The exception
to this is for the variant caller Platypus which used BWA MEM v. 07.1767. Hisat2 is
specifically designed for aligning RNA-seq reads and will split reads across exons to
ensure the highest-quality alignments. Unfortunately this results in very large fragments
that Platypus cannot process. Instead, BWA MEM, another high quality alignment tool,
was used in a manner that generated alignments that Platypus could process.
Alignment is followed by running the Genome Analysis Toolkit version 3.8.0
module, SplitNTrim + ReassignMappingQuality. This method of alignment preparation
ensures that the highest quality alignment files are generated when trying to identify
variants, and thus, that the only deficiencies identified are due to the variant caller itself
instead of other processing steps. Specifically, reads aligned around exon junctions have
overhanging regions clipped to remove any intronic sequence if that intronic sequence is
spurious. Lastly, for every tool, a bed file containing the regions of coding exons in the
Ensembl 93 mouse database was used to limit the location of where variants could be
identified. The file ref-transcripts.bed contains all of those locations.

FreeBayes
FreeBayes is Bayesian statistical framework capable of identifying, in a reference
genome, small variations including SNVs, indels, MNVs, and composite insertion and
substitution events so long as these events are shorter than the length of the sequencing
read belonging to the alignment. Version 1.1.0.46 was used to generate VCF files
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containing all variants present in the alignment file for each cell. FreeBayes was run
using the following arguments in addition to default parameters:
●

--min-alternate-fraction 0.01

●

--targets ref-transcripts.bed

●

--no-partial-observations

GATK HaplotypeCaller
GATK HaplotypeCaller uses a De Bruijn-like graph to perform local de-novo
assembly of regions of the genome that show evidence of significant variation, including
SNVs, MNVs, and indels. This has the advantage of more accurately identifying more
complex variation in a sample such as indels, and, importantly for our study, splice
junctions. However these benefits come at the expense of increased computation time68.
Version 4.0.7.0 was used to generate VCF files containing all variants present in the
alignment file for each cell. GATK HaplotypeCaller was run using the following
arguments in addition to default parameters:
●

--filter_reads_with_N_cigar

●

--standard_min_confidence_threshold_for_calling 4.0

●

--dbsnp dbsnp-20130912.vcf.gz

●

-L ref-transcripts.bed
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GATK UnifiedGenotyper
GATK Unified Genotyper uses a Bayesian genotype likelihood model to
estimate the most likely genotypes (SNVs, MNVs, and indels) and allele frequency.
GATK UnifiedGenotyper also benefits from not assuming ploidy for the organism being
analyzed which is not the case for GATK HaplotypeCaller68. Version 3.8-0-ge9d806836
was used to generate VCF files containing all variants present in the alignment file for
each cell. This version is different from the GATK HaplotypeCaller version as GATK
version 4 does not contain GATK UnifiedGenotyper. GATK UnifiedGenotyper was run
using the following arguments in addition to default parameters:
●

--filter_reads_with_N_cigar

●

--standard_min_confidence_threshold_for_calling 4.0

●

--dbsnp dbsnp-20130912.vcf.gz

●

-L ref-transcripts.bed

●

--geontype_likelihoods_model BOTH

Platypus
Platypus uses local realignment of reads and local reassembly to accurately
identify variants--SNVs, MNVs, indels, and long-range insertions and deletions--in a
genome. Version 0.8.1.1 was used to generate VCF files containing all variants present in
the alignment file for each cell. Platypus was run using the following arguments in
addition to default parameters:
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●

--regions=ref-transcripts.modified.bed

●

--filterDuplicates=0

Also, because Platypus does not work on large read fragments and is using the
BWA MEM-aligned files, the ref-transcripts.bed file had to be modified to include entire
gene regions as well as modifying other functional elements such as lncRNA
annotations.

Comparison of all tools using raw counts and cell-to-cell comparisons
After VCF files were generated for each cell by all five tools, they were then
compared by looking at the total number of variants identified as well as the percentage
of variants identified by each tool that are shared between each of the cells.
The average number of variants identified can be seen in Table 12. FreeBayes
identifies the highest average number of variants per cell followed Red Panda, then
GATK HaplotypeCaller, GATK UnifiedGenotyper, and Platypus. This is unexpected
based on the results from the human articular chondrocyte data where FreeBayes had
the fewest number of variants shared between the scRNA-seq results and the exome.
One explanation from this is that FreeBayes may identify a high number of variants, but
the majority of those are False Positives. This idea is supported by the PPV numbers as
seen in Figure 20.
After the total variant numbers were calculated, comparisons between cells were
performed. To test the initial hypothesis that any two cells should share a high number
of variants, only data produced by Red Panda from cells C02 (353 total variants) and C06
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GATK
GATK

Unified

Red

FreeBayes

HaplotypeCaller

Genotyper

Platypus

Panda

Average # of
variants

567.22

423.93

387.82

315.42

510.02

Standard
deviation

161.16

124.44

106.80

107.16

143.26

Table 12. Average variant count and standard deviation for each tool. For this analysis, the total
number of variants identified by each tool after filtering steps is reported.
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(593 total variants) were compared. This measurement was performed by taking the list
of variants in cell C02 and checking to see if there was sufficient sequencing coverage
(20x coverage) and variant match at the corresponding location for each variant in cell
C06. Variants satisfying both criteria were then added to the list of common variants
between the two cells; however, if it is not found in C06’s VCF file it is added to a list
containing variants that are present in C02 but not C06. Using these two lists it is
possible to calculate the percentage of overlap between the two cells.
The resulting percentage of overlap between C02 and C06 was 20.1%. This makes
sense as it is difficult to do a one-to-one comparison of locations between the two cells,
even after we’ve guaranteed there are sufficient reads covering that location. As
mentioned previously, monoallelic expression makes it impossible to say for sure that a
variant is not shared based on scRNA-seq data. One way to help combat this hurdle is
by only looking at homozygous-looking variants. Heterozygous variants have the
disadvantage of having increased ambiguity, but homozygous-looking ones are more
likely to show up in both cells even when factoring in the idea that the list of
homozygous-looking variants will contain heterozygous variants that are the result of
monoallelic expression.
To test this, variants that are homozygous-looking in both C02 and C06 are
compared. This results in a much higher percentage of overlap than identified
previously: 80.3% were found to be shared which is what is expected from cells that
should be isogenic. Additionally, the fact that it’s not 100% is also expected: variants that
look homozygous may actually be heterozygous.
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After doing this initial analysis, the comparison was expanded to analyzing the
percentage of pairwise overlap between six cells for all five tools: C02 vs. [C04, C06, C08,
C14, and C40]. This was done for all variants in those cells as well as those that are only
homozygous-looking. As seen in Figure 25, Platypus and Red Panda perform well in the
latter category, and Red Panda fared well over Platypus in four out of five comparisons.
But barring one comparison for Platypus (C02 vs C04), all of the tools performed poorly
(under 25%) when looking at all variants.
This minimal comparison of variant overlap resulted in more questions than
answers which prompted a full reassessment of the variants identified by each tool. To
ensure as close of a one-to-one comparison between the human articular chondrocyte
data and the MEF data as possible, the MEF variant calling was originally restricted to
coding exons, which resulted in poor overlap of variants across cells. However, this
restriction precludes a large portion of the genome that contains functionally important
elements such as the untranslated regions (UTR) of genes. With this in mind, variant
reporting and pairwise comparisons were re-run without the restriction of only keeping
those in coding exons.
This led to new results for the average number of variants reported by each tool
as seen in Table 13. Red Panda identifies the highest number of variants of all the tools.
Assuming we can extrapolate from the PPV results from the articular chondrocyte data,
this also means that Red Panda is identifying the highest number of True Positives as
well. One thing to note is that the numbers for Platypus did not change as its pipeline
had already been modified include these regions. This was necessary because Platypus
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Figure 25. Comparison of variants between Cell C02 and five other cells [C04, C06, C08, C14,
and C40]. Pairwise comparisons between C02 and five other cells was performed for every
variant caller after filtering was performed on the variants. Here we can see Platypus and Red
Panda performing well for homozygous-looking variants and every other tool performing poorly
when looking at all variants.
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Average # of
variants
Standard
deviation

FreeBayes

GATK-HC

GATK-UG

Platypus

Red Panda

865.87

611.15

574.73

315.42

1071.83

235.36

195.17

170.59

107.16

372.67

Table 13. Average variant count and standard deviation for each tool after filtering steps were
removed. For this analysis, the total number of variants identified by each tool now includes all
areas of the genome.
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will not run if it has to process reads spanning large regions such as exon-intron
junctions. This restriction meant that the original analysis could not be limited to just
coding exons for Platypus.
After removing the restriction on where in the genome variant calling can occur,
the same pairwise comparison as described previously was performed for all 3,025 (55
cells * 55 cells) possible comparisons. Additionally, three groups of variants were
assessed instead of two: percentage of overlap for heterozygous variants was also added
to assess how each software handles these types of variants. Custom scripts and the R
package ggplot2 were used to generate these comparisons.
To visualize this analysis, a heat map was generated showing the fraction of
overlap between each cell. A hypothetical scenario is illustrated in Figure 26. Higher
overlap leads to a redder color and low overlap leads to a bluish-green color. As we can
see in Figure 27 and Figure 28, each tool, especially Red Panda and FreeBayes, performs
well when only the homozygous-looking variants are being compared, but they all
suffer when assessing purely heterozygous variants.
Interesting to note is the fact that while GATK HaplotypeCaller and GATK
UnifiedGenotyper both have a good fraction of overlap among the homozygous-looking
variants, it does not appear to affect the overall fraction of variants identified by these
tools because the heat maps look almost identical for both the ‚Heterozygous‛ and ‚All
Variants‛ maps. This is because homozygous-looking variants do not contribute much
to the total list as seen in Table 14. Also important is that Red Panda performs extremely
well for homozygous-looking variants, but is average for heterozygous variants. This is
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Figure 26. Example of comparisons made between cells. In this example heat map, three cells
are being compared. There is one variant in common between cells A→B and B→C but none in
common between A→C.
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Figure 27. The fraction of overlap in variants for every cell using FreeBayes, GATK HC, and
GATK UG. The fraction of overlap for (a-c) FreeBayes, (d-f) GATK-HaplotypeCaller, and (g-i)
GATK-UnifiedGenotyper when comparing (a, d, g) all variants, (b, e, h) homozygous-looking
variants, and (c, f, i) heterozygous variants. Each box in the matrix is a comparison between two
cells.
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Figure 28. The fraction of overlap in variants for every cell using Platypus and Red Panda. The
fraction of overlap for (a-c) Platypus and (d-f) Red Panda when comparing (a, d) all variants, (b,
e) homozygous-looking variants, and (c, f) heterozygous variants. Each box in the matrix is a
comparison between two cells.
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Tool

All variants

Homozygous variants Heterozygous variants

FreeBayes

85.70

35.22

50.48

GATK-HC

72.06

6.66

65.40

GATK-UG

58.72

11.35

47.37

Platypus

28.83

19.90

8.93

Red Panda

171.34

115.39

55.95

Table 14. Average number of variants overlapping for pairwise comparisons between cells.
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due to the fact that, while Red Panda confers an advantage to identifying heterozygous
variants, the majority of those identified are not bimodally-distributed and are thus
actually picked up by GATK HaplotypeCaller as seen in Figure 19.
To better visualize the distribution of the fraction of overlap of variants as well as
the total variants overlapping in the pairwise comparison, violin plots were created for
all three classes of variants (Figure 29), and all comparisons between Red Panda and the
other tools were statistically significant. These show that there tends to be a tight
distribution of values for every tool in each class with the exception of Red Panda and its
ability to identify homozygous-looking variants. The total number of homozygouslooking variants has a wide distribution, but the distribution of the fraction of variants
in this class is tight and very close to 1. It follows that the same trend can be seen in total
variants shared in these comparisons since homozygous-looking variants make up the
largest proportion of those identified by Red Panda to be overlapping between two cells
as can be seen in Table 14.
In Figure 29 it is clear that Red Panda performs the best both at identifying raw
numbers of variants shared between cells as well as fractions of variants shared. This is
an important distinction because, as can be seen with FreeBayes, it’s possible to have a
large number of variants shared while also having a small fraction of the total variants
possible be shared. As a hypothetical example, there may be 200 variants out of 1000
possible shared between two cells. This results in a large number of variants shared
(200), but a small fraction (0.2) of total possible variants shared. This pattern indicates
that there are a lot of potential False Positives in the FreeBayes results which fits with
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Figure 29. Violin plots for variants shared between cells. Violin plots showing the fraction (left)
and quantitative (right) overlap for (a, b) all variants, (c, d) homozygous-looking variants, and (e,
f) heterozygous variants shared in every pairwise cell comparison. Comparisons were performed
using T-tests: ns = not significant, * is p < 0.05, ** is p < 0.01, *** is p < 0.001, and **** is p < 0.0001.
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what was seen in the articular chondrocyte sequencing.
As we saw in the heat maps, it is clear that the highest fraction of variants shared
pairwise between two cells comes from the homozygous-looking class. This is made
very evident where, again, Red Panda has the highest number of variants and the
highest fraction of variants shared. However, it is clear that it is the homozygouslooking class that is contributing most to the total shared between cells for Red Panda.
This is significant as it was originally thought that Red Panda would perform the best
among the heterozygous variants, rather than the homozygous-looking variants.
As for the other tools, it appears that despite performing the worst at identifying
shared homozygous-looking variants GATK HaplotypeCaller performs the best with
heterozygous variants. This is useful as it proves that using GATK HaplotypeCaller was
a good choice as the supplemental variant caller for Red Panda when it cannot use its
unique bimodal distribution model. Lastly, it’s interesting to note that it is rare for any
tool to have more than 100 heterozygous variants shared between cells. This is likely due
to the stochastic nature of allele-specific expression.

Comparing variant callers using simulated data
To accurately assess the sensitivity of each variant calling tool in a controlled
environment, simulated data was generated against which we can compare the results
from the five different variant callers. This simulation consists of ~1,000 variants
generated per cell. They are created by programmatically inserting variants into the
alignments generated from the normal MEFs. The list of simulated variants consists of
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650 homozygous variants and 350 heterozygous variants, roughly 70 of which are
bimodally-distributed. These numbers are used because they are close to the proportions
seen in the variants corroborated by the exome sequencing in the articular chondrocyte
data, and while these proportions do not match those expected based on bulk
sequencing experiments86–88, they do match what is expected from scRNA-seq data31.
Once this simulated list is created, the variants are inserted into the original
alignment files for each cell. These new alignment files are used as input for the variant
calling pipelines described above for the MEF sequencing data. Once a new list of
variants has been generated by each of the five tools, the results will exclusively be
compared against the list of simulated variants. For this analysis, all other locations
identified in the standard variant calling process are not considered as they are due to
normal variation in that cell and not part of the simulated set.
To generate the new alignment files containing the simulated variants, a number
of important steps have to performed, as illustrated in Figure 30. To ensure variants
could be identified by each tool, a read depth cutoff of 20 was used for locations where
variants could be inserted. This was achieved using the coverage module from the
bamtools package89. This list of potential insertion locations was then used as the source
of the locations of the ~1,000 simulated random variants. For the 650 homozygous and
280 heterozygous variants, the locations were not restricted except that they must
originate from this list.
The bimodally-distributed heterozygous variants had a number of extra
parameters that determined their placement. It was required that they originate from
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Figure 30. Workflow for inserting simulated variants. To assess each tool, ~1,000 simulated
variants (650 homozygous, 280 heterozygous, and ~70 bimodally-distributed heterozygous) were
inserted into the alignments for each cell. Standard variant calling was then performed using
each tool, and these results were compared to the list of known variants to assess their
performance.
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genes that were considered to be expressed ( TPM > 1) and that they have a minimum of
two of variants placed in the expressed gene. From the MEF sequence data, an average
of ~3 (a range of about 2–5) variants per gene was observed; this results in roughly 23
genes containing bimodally-distributed variants: 70/3 = 23.33. Thus, to simulate this class
of variation, 23 expressed genes were randomly chosen wherein 2, 3, 4, or 5 variants
were randomly inserted into the gene, but only if there were more than 250bp of viable
locations where a variant could be inserted. That is, a gene was only in consideration to
have bimodally-distributed variants added to it if more than 250bp of its sequence had
sequencing depth of at least 20 reads.
After ~1,000 locations had been chosen, a new alignment file was created
containing the simulated variants. Additionally, a VCF file containing all of the variants
was generated for ease of comparison in the downstream analysis.
This type of custom simulation was necessary because, while there are a number
of methods available to imitate read counts and expression profiles90–96, there currently
exist no tools to generate scRNA-seq reads in silico. Were such a tool available, raw reads
with built-in variation would have been generated, from which accuracy metrics for the
variant calling tools could have been calculated. However, since this was not possible,
random variants were inserted into the alignments already generated in the MEF
analysis. This has the benefit of recreating a more realistic simulation environment
because all of the artefacts and flaws inherent to scRNA-seq are maintained. One
downside however, is that it disallows us from calculating any accuracy statistics
requiring False Positive numbers. Since real scRNA-seq data is being used, it already
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contains variation inherent to the MEFs. It follows that the variant callers will pick up
this possibly-real variation that would then be classified as a False Positive because it is
not contained in our list of ~1,000 simulated variants for that cell.
Due to this limitation, sensitivity is the main metric by which each tool is
measured, and it was calculated for each tool across every cell. These numbers were
then plotted using a violin plot to assess the distribution of True Positives identified by
each variant caller. Figure 31 (boxplots for the raw number of True Positives) and Figure
32 (the aforementioned violin plots for sensitivity) show that for homozygous variants
and bimodally-distributed heterozygous variants, Red Panda consistently performs
better than the other four tools, and its results are statistically significantly different than
the results from every other tool when compared using T-tests. For heterozygous
variants taken as a whole, FreeBayes performs the best of the tools. It is unsurprising
then that Red Panda does not perform as well in this category because it uses GATK
HaplotypeCaller (shown to accurately identify few heterozygous variants in this
simulation) to validate heterozygous variants that do not follow a bimodal distribution.
In this instance, GATK HaplotypeCaller and GATK UnifiedGenotyper perform poorly
because they both utilize a feature where all samples are considered simultaneously.
This results in poorer performance on samples that are more genetically diverse, or put
another way, single cells that have private mutations. And for our simulation, the
mutations being tested are unique to each cell. Red Panda does not suffer from this
limitation as it explicitly directs GATK-HC to call variants at specific locations one at a
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Figure 31. Raw counts of True Positives for each tool. The box plots of the raw number of True
Positives show how well each tool is at identifying variants in the simulation for: all variants, all
homozygous-looking variants, all heterozygous variants, and all bimodally-distributed
heterozygous variants. Due to advantages gained in identifying homozygous and bimodallydistributed variants, Red Panda identifies the highest number of True Positives. Comparisons
were performed using T-tests: ns = not significant, * is p < 0.05, ** is p < 0.01, *** is p < 0.001, and
**** is p < 0.0001.
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Figure 32. Sensitivity for identifying simulated variants for each tool. The violin plots of the
sensitivity, calculated for each cell using each class of simulated variants are shown: (a) all
variants, (b) homozygous variants, (c) all heterozygous variants, and (d) bimodally-distributed
variants. Comparisons were performed using T-tests: ns = not significant, * is p < 0.05, ** is p <
0.01, *** is p < 0.001, and **** is p < 0.0001.
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time rather than jointly. However, as seen in the results in Figure 29f, this can result in
lowered sensitivity for samples that are genetically similar.

Evaluation of Red Panda by Sanger confirmation on MEFs
To complement the simulated data, Sanger sequencing was performed on 40
variants: 20 that were identified by all five software and 20 that were only identified by
Red Panda. These variants were pulled from the VCF files generated for cell C14 as seen
in Figure 33, and cross-referenced with the other 54 cells to make sure that at least one
other cell contained the variant. This low number—a minimum of two cells sharing the
same variant—was necessary because it was rare for variants to be present in more than
two cells when pulling from the list that were identified by all five variant callers as seen
in Table 15. This table shows a breakdown of the number of variants identified by each
tool that were common to: at least 2, 5, 10, 22 (50%), and 41 (75%) of the cells. Ideally, a
minimum of 20 variants unique to each tool would have been chosen for Sanger
sequencing, but it was outside the scope of this project to do so.

Primer Design
Primers (see Appendix A) were designed to amplify specific target regions
containing 39 SNVs and one indel. To generate sequence fragments for primer design,
900bp sequences upstream and downstream of the variant were obtained from the
mouse genome mm10 using samtools faidx. This resulted in an 1800bp fragment that
was searched for primers using Primer3Plus. The parameters in Table 16 were used to
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Intersection of variants for each tool in cell C14

Figure 33. The overlap in the number of variants identified in the cell C14. Here we can see
that there is a sizeable (69 variants) overlap between all the tools that identified variants in this
cell. Red Panda identifies the most variants unique to a specific variant caller (295). It is from
these two populations that variants are chosen for confirmation via Sanger sequencing.
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Intersection of
Present in:

FreeBayes

GATK-HC

GATK-UG

Platypus

Red Panda

all tools

>= 2/55 cells

2922

2463

1991

2947

3159†

96*

>= 5/55 cells

970

894

693

324

1051

18

>= 10/55 cells

416

398

309

161

565

0

>= 23/55 of cells

129

122

84

66

257

0

>= 42/55 of cells

38

24

27

22

98

0

Table 15. Breakdown by tool of variants present in more than one cell. The number of cells in
which a variant was found was broken down into five groups: presence in at least 2, 5, 10, 23, or
42 of cells. Additionally, the variants identified by all tools were checked for their presence in the
five groups listed above. The variants submitted for Sanger sequencing were drawn from the two
groups labeled with a cross (†) and an asterisk (*).
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Parameters used to design primers on Primer3Plus
Product Size Range

401-700*

Min primer

18

Opt primer*

20

Max primer

27

Primer Tm Min

57

Primer Tm Opt

60*

Primer Tm Max

63

Max Tm difference

100

Primer GC% Min

20

Primer GC% Opt

50*

Primer GC% Max

80

Concentration of monovalent cations

50

Concentration of divalent cations

0

Annealing Oligo Concentration

50

Concentration of dNTPs

0

Max Self Complementarity

4*

Max #Ns

0

Max Poly-X

5

CG Clamp

1*

Max 3' Self Complementarity

3

Max 3' Stability

9

Pair Max Repeat Mispriming

24

Pair Max Template Mispriming

24

Table 16. Parameters used to design the primers used for PCR and Sanger. Parameters with a *
were changed from their defaults to ensure good sequencing.
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design the primers. In total, 38 primer pairs were created as seen in Appendix A and
were named based on the range of sequence that was searched by Primer3Plus. Only 38
pairs were needed as two variants could be validated by the primer pair for
‚chr8:85260471-85262071‛ and two variants can be validated by the primer pair for
‚chr19:60770223-60771823‛.

PCR Amplification
Shrabasti Roychoudhury and Suravi Pramanik performed the PCR amplification.
For the first round of sequencing, the PCR reaction was performed using GoTaq Hot
start polymerase following the manufacturer’s protocol with an annealing temperature
(Tm) of 50°C. After amplification, PCR products were run on 1.5% agarose gel and
visualized in Kodak gel doc and specific DNA bands were recovered using QIAquick
Gel Extraction Kit. Purified DNA products paired with their forward primer in 0.2 mL
PCR 8 tube-strips were then submitted to Genewiz for Sanger sequencing.
Additional amplification and second sequencing pass was performed on the 18
fragments containing variants specific to Red Panda due to the poor quality as seen in
Table 17. To attempt to increase the quality of the PCR reactions, a Tm 55°C was used,
followed by running the PCR products on 2% agarose gel. Each fragment was added to
two 0.2 mL PCR 8 tube-strips wherein one tube contained the forward primer and one
tube contained the reverse primer resulting in 36 total products to be submitted to
Genewiz for Sanger sequencing. This increased the likelihood of obtaining usable
sequence.
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Number Hom/Het

Variant Location

Variant Validated by Sanger Cells supported by

1

Het

chr1 43954701

T→G

N

2

2

Hom

chr1 181176175

C→T

N

2

3

Het

chr2 3328501

G→T

N

2

4

Het

chr2 22940605

G→C

5

Het

chr2 33246775

A→G

N

2

6

Het

chr2 39195366

A→G

N

2

7

Het

chr3 19133919

A→G

N

2

8

Het

chr4 43977653

A→G

N

2

9

Het

chr8 36567823

T→C

N

2

10

Het

chr8 71359979

A→G

N

2

11

Het

chr6 83802489

G→T

N

2

12

Het

chr9 44742670

C→A

N

2

13

Het

chr10 112926193

T→C

N

2

14

Hom

chr11 73175960

A→G

N

2

15

Het

chr13 75771943

G→T

16

Het

chr13 90105223

T→C

N

2

17

Het

chr16 49868008

C→T

N

2

18

Hom

chr16 58466497

G→A

N

2

19

Het

chr17 12683939

A→G

N

2

20

Het

chr18 43321798

T→C

N

2

2

2

Table 17. Validation of variants identified by all five variant callers. Blue indicates that the
sequence was of good quality at the position of the variant. Yellow indicates mediocre quality at
the position of the variant. Red indicates bad quality at the position of the variant. Dark grey
indicates that there was no sequence available at the location of the variant.
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Number Hom/Het

Variant Location

Variant Validated by Sanger Cells supported by

1

Het

chr2 120515974

T→C

N

2

2

Het

chr3 19133919

A→G

N

2

3

Hom

chr3 95734876

T→C

4

Het

chr4 130165817

T→C

5

Hom

chr4 132833055

C→G

9

6

Hom

chr5 104435120

C→G

2

7

Hom

chr7 27205154

TA→T

2

8

Hom

chr7 27205568

A→G

4

9

Het

chr8 85261271

A→C

2

10

Het

chr8 85261288

G→A

2

11

Hom

chr10 40251185

G→A

12

Hom

chr11 72777865

C→A

2

13

Hom

chr12 54783425

T→C

2

14

Het

chr13 31630905

A→G

15

Het

chr14 54542219

T→C

16

Het

chr16 52270742

C→A

N

2

17

Hom

chr16 94468834

C→T

Y

34

18

Het

chr19 60771023

C→A

2

19

Het

chr19 60771042

G→T

2

20

Hom

chrX 101404519

C→A

38
N

N

N

2

2

2
2

N

2

Table 18. First sequencing pass: Validation of variants only identified by Red Panda. Blue
indicates that the sequence was of good quality at the position of the variant. Yellow indicates
mediocre quality at the position of the variant. Red indicates bad quality at the position of the
variant. Dark grey indicates that there was no sequence available at the location of the variant.
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Results for first sequencing pass
As seen in Table 17 and Table 18, good quality sequence was only produced in
12 out of 38 samples, but enough valid sequence was generated by 26 (all those except
dark grey color) to validate the presence of their corresponding variant. Out of 26, only
one variant, which was exclusively identified by Red Panda, was validated by Sanger
sequencing. The most likely reason for this is that the variants being validated are part of
a small fraction of the total number of cells (frequently the variant was supported by
only 2/55 cells). The only variant confirmed by Sanger was supported by 34 cells.

Results for second sequencing pass
Sequence was obtained for 15 of the 20 variants being validated. Table 19 shows
that three out of the 15 variants identified by Red Panda were confirmed to exist
including the one confirmed in the first pass. In all three instances, the variants were
found in nine or more cells and were homozygous. It is possible that these confirmed
variants were identified because they were homozygous, but a likelier explanation is
variants identified in more cells are confirmed to be representative of the entire cellular
population and thus are able to be seen in the Sanger sequencing. It is unclear then
whether the variants identified by each tool in a low number of cells are in fact False
Positives because they may be private mutations to a very small subset of cells.
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Number Hom/Het Variant Location

Variant

Validated by Sanger Cells supported by

1

Het

chr2 120515974

T→C

N

2

2

Het

chr3 19133919

A→G

N

2

3

Hom

chr3 95734876

T→C

Y

38

4

Het

chr4 130165817

T→C

N

2

5

Hom

chr4 132833055

C→G

Y

9

6

Hom

chr5 104435120

C→G

N

2

7

Hom

chr7 27205154

TA→T

8

Hom

chr7 27205568

A→G

N

4

9

Het

chr8 85261271

A→C

N

2

10

Het

chr8 85261288

G→A

11

Hom

chr10 40251185

G→A

12

Hom

chr11 72777865

C→A

2

13

Hom

chr12 54783425

T→C

2

14

Het

chr13 31630905

A→G

15

Het

chr14 54542219

T→C

16

Het

chr16 52270742

C→A

N

2

17

Hom

chr16 94468834

C→T

Y

34

18

Het

chr19 60771023

C→A

N

2

19

Het

chr19 60771042

G→T

N

2

20

Hom

chrX 101404519

C→A

N

2

2

2
N

N

2

2
2

Table 19. Second sequencing pass: Validation of variants only identified by Red Panda. Blue
indicates that the sequence was of good quality at the position of the variant. Yellow indicates
mediocre quality at the position of the variant. Red indicates bad quality at the position of the
variant. Dark grey indicates that there was no sequence available at the location of the variant.
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CHAPTER 3: DISTRIBUTION OF RED PANDA

Introduction
Adoption, distribution, and ease-of-use is necessary for any bioinformatic
application. Given that, the popular source code repository GitHub97 is used to
distribute Red Panda. This is done under the MIT License98, one of the most permissive
Free Use licenses available, to ensure easy adoption by any end-user. It states that:
‚Permission is hereby granted, free of charge, to any person obtaining a copy of this
software and associated documentation files (the "Software"), to deal in the Software
without restriction, including without limitation the rights to use, copy, modify, merge,
publish, distribute, sublicense, and/or sell copies of the Software, and to permit persons
to whom the Software is furnished to do so‛. Additionally, Read the Docs99 is used to
create documentation on how to run Red Panda.

Distribution and function
Red Panda, written almost entirely in the Perl programming language, relies on a
number of different tools to function. The ‘Statistics::Basic’ Perl package is needed to
perform basic statistics within the main Red Panda Perl script. The tool mpileup found
in the samtools package41 is required to generate a list of every variant in a sample.
GATK HaplotypeCaller25 is necessary to check variants that do not fit the expected
bimodal distribution; however it is possible to use any standard variant caller for this
step. Based on the above results, we recommend GATK HaplotypeCaller or FreeBayes.
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Bedtools100, vcf-sort found in the vcftools package101, and Picard Tools102 are all necessary
to manipulate the different types of files used during the variant calling process.
As these tools are all supported by different institutions under different licenses,
Red Panda does not come prepackaged with them. Instead a script is provided that
assists the user in acquiring each tool, with the only exception being the Statistics::Basic
package. As this is a Perl package the user will need to install this independently via
CPAN103.
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DISCUSSION

Variant calling on human articular chondrocytes
Red Panda performs better than software designed for bulk NGS data and
proves that scRNA-seq offers unique information on a small number of variants which
Red Panda takes advantage of.
Using the exome data as a reference for comparisons, Red Panda’s superior
performance is well evidenced. There is consistent overlap in the results between the
tools. Furthermore, while Red Panda shares a significant number of variants with those
identified by other tools, it also identifies the most unique variants. Because of this, Red
Panda provides both the highest PPV (45%) of any of the tools as well as the highest
number of variants in concordance with the exome (913 on average). In comparison, on
average FreeBayes identifies 65 variants, GATK HaplotypeCaller 705, GATK
UnifiedGenotyper 222, and Platypus 386.
Unexpectedly, this superiority is not entirely from the heterozygous variants
found in each sample. Instead, it appears that Red Panda gains an advantage against
other tools by intentionally separating homozygous-looking variants from those variants
that are heterozygous and then processing them differently. From the heterozygous
data, on average Red Panda identifies 154 variants in agreement with the exome as
compared to 31 for FreeBayes, 136 for GATK HaplotypeCaller, 118 for GATK
UnifiedGenotyper, and 36 for Platypus.

117

PPV was used as the main metric to determine how well each tool performed
because calculating sensitivity provides results that are difficult to interpret due to the
extremely high number of True Negatives identified in variant analysis. Red Panda’s
average PPV was the highest at 45% followed by GATK-HC with 32%. The rest of the
tools all had a PPV of <10%. Despite having the highest PPV of any of the tools, 45% is
still far lower than what we would expect in a variant calling experiment using bulk
sequencing32. This is likely due to much higher quality sequencing that is acquired in
traditional NGS.

Variant calling on mouse embryonic fibroblasts
As with the articular chondrocyte results, Red Panda performs better than the
four bulk variant callers assessed with the MEF results. After VCF files were generated
for each cell by all five tools, the files were compared by looking at the total number of
variants identified by each tool as well as the percentage shared in every pairwise
comparison of each cell.
Red Panda identifies, on average, the highest number of variants per cell,
surpassing all of the other tools: 1,071 on average by Red Panda, 865 by FreeBayes, 611
by GATK HaplotypeCaller, 574 by GATK UnifiedGenotyper, and 315 by Platypus.
Assuming we can extrapolate from the PPV results from the articular chondrocyte data,
this also means that Red Panda is identifying the highest number of True Positives as
well. Surprisingly, FreeBayes identifies the second highest number of variants of the
four tools. This is unexpected due to the results from the human articular chondrocyte
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data where FreeBayes had the fewest number of variants shared between the scRNA-seq
results and the exome. One explanation from this is that while FreeBayes identifies a
high number of variants, the majority of those are False Positives. This idea is supported
by the PPV numbers seen in Figure 20 for FreeBayes.
Since a paired exome to which we could compare our scRNA-seq results was not
generated for MEFs, every possible pairwise comparison between each cell for every
tool was performed instead to attempt to assess the quality of the variant calls. The
MEFs sequenced are presumed isogenic, so the variants identified in each cell should
theoretically exist in every other cell. Given this, these pairwise comparisons helped
assess whether each variant caller performed well based on the consistency of their calls
or if they performed poorly, randomly identifying variants in each cell. Comparisons
were split up into three groups: total variants, exclusively homozygous-looking variants,
and exclusively heterozygous variants.
These comparisons showed that each tool, especially Red Panda and FreeBayes,
performs reasonably well when only the homozygous-looking variants are being
compared, but they all suffer when assessing purely heterozygous variants. However it
is important to note that, while GATK HaplotypeCaller and GATK UnifiedGenotyper
both have a good fraction of overlap among homozygous-looking variants, it does not
appear to affect the overall fraction of variants identified by these tools. This is because,
for these two tools, homozygous-looking variants do not contribute much to the total list
of variants shared. Also important is that Red Panda performs extremely well for
homozygous-looking variants, but is average for heterozygous variants when compared
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to the other tools. This is due to the fact that, while Red Panda, in principle, confers an
algorithmic advantage to identifying heterozygous variants, the monoallelic nature of
gene expression and uneven sequencing coverage depth may preclude the tool from
realizing its full potential. Due to this caveat, the majority of the heterozygous variants
identified are actually picked up by GATK HaplotypeCaller since most of these are
unsupported by a bimodal distribution as seen in Figure 19.
When looking at both the raw number of variants overlapping and the fraction of
variants overlapping in these pairwise comparisons, Red Panda performs the best at
both. This is important because, as is the case with FreeBayes, it is possible to have a
large number of variants shared, but also have a small fraction of the total variants
possible be shared. This indicates that there are potentially a lot of potential False
Positives in the data generated by FreeBayes which fits with what was seen in the
articular chondrocyte data.
It is clear that the tools with the highest fraction of variants shared pairwise
between two cells comes from the homozygous-looking class. This makes sense as it is
less likely that allelic dropout will occur in this class as a result of allele-specific
expression making for a more stable population of variants in the scRNA-seq data.
Tying into this is the fact that it is rare for any tool to have more than 100 heterozygous
variants shared between two cells. This is likely due to the stochastic nature of allelespecific expression.
Lastly, due to the results from the Sanger sequencing, it is difficult to say with
certainty whether these tools were ineffective at identifying variation in scRNA-seq data
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or if there was simply not enough DNA from the cells containing the variant to be
picked up in the Sanger sequencing. Out of forty variants tested, only three were
confirmed to exist, all of which were exclusively identified by Red Panda. However, this
is likely due to these variants having been found in a larger proportion of cells than
those variants being tested from the group that were identified by all five variant callers.
Ideally Sanger validation would have been performed for locations supported by all five
tools and found in more than 10 cells, but no such variants existed to be tested.
It is clearly possible to detect significant variation at the single-cell level, but due
to the challenges in proving its existence with corroborative orthogonal sequencing it is
difficult to know with certainty what software performs the best. Instead, we must rely
on paired genomic sequencing as done with the human articular chondrocytes and
simulated data to assess quality.

Evaluation using simulated data
Ideally, orthogonal sequencing would be able to validate variants that only
appear in a small population of cells, but in the absence of such data, simulations can
provide valuable insight. For our purposes, this involves inserting random variation
distributed throughout the transcriptome and then using that as a master list of True
Positives against which each tool can be measured. After adding ~1,000 simulated
variants to the alignments from the MEFs, we were able to evaluate how well FreeBayes,
GATK-HC, GATK-UG, Platypus, and Red Panda performed. Based on these results, Red
Panda proves its advantage in identifying bimodally-distributed variants as well as
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homozygous variants, a class of variant that saw other tools struggle in comparison.
When assessing total heterozygous variants, FreeBayes is superior to the other tools.
This is counterintuitive to what was seen in the results from the human articular
chondrocyte experiment where FreeBayes identified very few variants in concordance
with the list obtained from exome sequencing.
Both GATK-HC and GATK-UG perform similarly in the simulation with the
latter consistently performing slightly better than the former. However, it is because of
this similarity in results that might offer an explanation for why FreeBayes seemingly
performs so poorly in the chondrocyte data. When variants were called in the exome to
generate a master list against which the variants from the scRNA-seq data could be
compared, variants were only retained if they were identified by at least two of the
following three tools: FreeBayes, GATK-HC, and Platypus. However, if the variants in
this master list were consistently only supported by the latter two, then it follows that
variants identified by FreeBayes in the scRNA-seq experiment would be filtered out and
make it appear as though FreeBayes identified a low number of True Positives as seen in
Figures 17-20.
The simulated data seems to indicate that FreeBayes has good sensitivity, but
identifies a large set of variants different from both GATK-HC and Platypus. This is
corroborated by data in Figure 33. Given this, in order to improve the accuracy of Red
Panda, it might be wise to switch to only using FreeBayes or using a combination of both
FreeBayes and GATK-HC to evaluate heterozygous variants that do not follow a
bimodal distribution. For example, when searching for variants that are assumed to be
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private to a small number of cells—e.g., tumor cells—Red Panda could switch to using
FreeBayes under the hood and then switch to using GATK-HC in situations where
variants are expected to be shared across the majority of cells.

When to use Red Panda
Red Panda consistently performs better than other variant callers based on a
number of metrics. Whenever it is necessary to analyze variation specific to a single
cell—for example, looking at clonal tumor cell populations—, Red Panda will likely
provide the best results. However, there are instances where using a different variant
caller makes sense. Specifically, one should use GATK HaplotypeCaller for variant
calling when it is preferred to pool together the reads from all of the cells. As seen in
Figure 29e-f, this allows for greater sensitivity in identifying heterozygous variants.
After identifying this specific class of variant, results can be pooled with those generated
by Red Panda.
Lastly, it is important to note that the advantages conferred by Red Panda are
currently limited to scRNA-seq generated by library-preparation methods that generate
cDNA from full length transcripts such as Smart-seq2 and Holo-seq104, although the
latter has not been tested.

Final remarks
Based on the human articular chondrocyte and MEF data, Red Panda can
provide a distinct advantage over other available software. However, this improvement
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is not entirely from the heterozygous variants as expected. Instead, Red Panda gains its
major advantage in predicting homozygous-looking variants over other tools by
intentionally separating heterozygous variants from variants that are homozygouslooking and then processing them differently. Due to the unique nature of scRNA-seq
data, one must treat heterozygous variants with special consideration. Red Panda does
provide a custom approach to this class of variant, but the number of variants that are
specific to its method of dealing with bimodally-distributed heterozygous variants is, as
seen in Figure 19, limited.
From these results it is clear that due to the inherent nature of RNA expression
patterns in single cells, it is difficult to assess what variants exist in the genome with the
same accuracy that we can with standard exome or WGS. Despite this, Red Panda
provides a novel method of identifying variants in scRNA-seq and performs this
function better than variant callers designed for bulk NGS datasets in certain categories.
Future work includes creating a select dataset of genes that show consistent biallelic
expression and testing the performance of Red Panda on this dataset.
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APPENDIX A: SANGER SEQUENCING
Sequencing primers
#
1
2
3
4
5
6
7
8
9

Primer name

Forward primer

Reverse primer

chr1:43954201-

TGGATTCACTAT GGTCACAATGGA

43955201

GGCAGCAA

chr1:181175375-

TGCTGACTCCGA CATTCAAACTGG

181176975

TCTGTCAC

chr2:3327701-

CAGCAAGTGGA TCTAGCAAGGTG

3329301

ACAAAGTGG

chr2:22939805-

TGCTTCATGTGC GATTCAAGGGA

22941405

AGAAAACC

chr2:33245975-

TGCTCAGTTCTC CCTATTGGCAGC

33247575

AGGTGCTG

chr2:39194566-

TAGCAGATTCCC TGGTGTGGTTTTT

39196166

TCGCCTAC

GAACAGC

chr3:19133119-

TGAGGCTGGAG

AGAATGAGGAT

19134719

GAGAAAATG

GTGGCTTGG

chr4:43976853-

TTTCCCACAGGG CAGAATCCTCAA

43978453

CACTTTAC

chr6:83801689-

AGCAGGCACAG TATAACCAGAGC

83803289

AACTCCTTC

chr8:36567023-

AAGCAAGGATG ACTCACCCACCA

10 36568623
chr8:7135917911 71360779_7
chr9:4474187012 44743470
chr10:11292539313 112926993
chr11:7317516014 73176760
chr13:7577114315 75772743
chr13:9010442316 90106023
chr16:4986720817 49868808
chr16:5846569718 58467297

GAAACGATG

GAGCAGGT
TGCTGTGG
GGTGAAGC
GGGTGTGAG
GACTTCTC

AGCCCAAG
CGGGTGAG
ACAGGAAG

Variant location Expected length
chr1:43954701

510*

chr1:181176175

484

chr2:3328501

606

chr2:22940605

690

chr2:33246775

585

chr2:39195366

495

chr3:19133919

619

chr4:43977653

676

chr6:83802489

691

chr8:36567823

520

chr8:71359979

549

chr9:44742670

461

chr10:112926193

607

chr11:73175960

690

chr13:75771943

515

chr13:90105223

473

chr16:49868008

455

chr16:58466497

407

AGGAGGCTGTTG GCCCATGTCCAG
TTCCAGTG

GTTACAAG

CTATCCCAGTCC CACCTCCCTCTC
CCTTCCTC

TGTCCTTG

TCCCTTTCATGTT ATCTCTCATGGC
TCCCAAG

TCCCTCTG

TTACCCAATCCA CTCATTCTCAAA
GCAAAAGc

GCGGGAAG

GTTGGTGTGTGT ATGCTTCCCTTTT
TTGCTTGG

CAACTGG

CCCAAAGGTGGT TTCAAGCACGAT
ATTTGTGG

GTCAAAGC

AAACTGTGGTCA AACACGAGTGC
TCCCTTGC

CAGACTCAC

GGTCTCAGCTCT ACTTGGGTCAGT
GCTCATCC

TGGGATTG

137

chr17:1268313919 12684739
chr18:4332099820 43322598

AGGCACCACGG CAGCAAGGAGG
AGTTAGATG

AGGAGACAG

chr17:12683939

428

chr18:43321798

506

AGCAATAACTTG CTGTAATTCTGC
GCGTTTGG

GCCTCCTC

Table. Primers for variants identified by all five variant callers
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#
1
2
3
4
5
6
7
8
9

Primer name

Forward primer

Reverse primer

chr2:120515174-

GAAAGAGAAATG TCAGAACAACAA

120516774

GCGCAGTC

chr3:19133119-

TCTGTCTTGTGCG CCACGGATGTGTT

19134719

GAAAATG

chr3:95734076-

CTTCCTTTCCACA TGCCTATCCACAA

95735676

GCAGGAC

chr4:130165017-

TAGGAGGGTGATG TGCGATCCAGAT

130166617

AGGTTGG

chr4:132832255-

GGCAATGTCTGAG TCAGGAAGATGA

132833855

GCTTCTC

chr5:104434320-

GAAAGTTCTGCCG TGAAAATACCGG

104435920

AGACAGC

chr7:27204354-

TATGTGGTTGCTG GGTGTGGAATAT

27205954

GGAATTG

chr7:27204354-

GGACAGCCCATAT AGCACAGCGGTC

27205954_2

TCCACAC

chr8:85260471-

TTCATAGATTGGC TTTCCAGAAGAC

85262071

CCCTCAG

chr10:40250385-

AGCTCACTCTGGC CTTCATTTGGGCG

10 40251985
chr11:7277706511 72778665
chr12:5478262512 54784225
chr13:3163010513 31631705
chr14:5454141914 54543019
chr16:5226994215 52271542
chr16:9446803416 94469634
chr19:6077022317 60771823
chrX:10140371918 101405319

CTTGAAC

GCGACAGG
CAAAGTG
CCTCCTC
GTTGAGAC
GGCAGGAG
GAAACCTG
GGGCTGTC
AGGTAGAC
CTGGGTTC
ATAGGAC

Variant location Expected length
chr2:120515974

602

chr3:19133919

598

chr3:95734876

611

chr4:130165817

658

chr4:132833055

523

chr5:104435120

688

chr7:27205154

485

chr7:27205568

689

chr8:85261271

559

chr10:40251185

628

chr11:72777865

540

chr12:54783425

525

chr13:31630905

429

chr14:54542219

428

chr16:52270742

465

chr16:94468834

680

chr19:60771023

662

chrX:101404519

600

GGCAGGTGGATTT GCTGGTACTTGGA
CTGTGAG

GCAGGAC

GTCTCGCTGGTCC TGGACTGCTGGG
TTGAGAG

ATTAAAGG

ACTGCAACGGACT GGCACCTGTATCC
CACACTG

GAAGAAG

GTTCTGCCTCCAC GCTGGCCCCTAA
TCAGCTC

ACTCTTTC

TTCCTCTCCTGGG TGCCCTGTGTCAT
AAAAGTG

CTACCAC

GCTCTCAGCCTCC CAGGGACACCAC
TCAGTTC

AGACAATG

CTCCCGAATGTCC CTGCAAAATACA
TGAGTTC

GGGGAAGG

CTACATCTCCAGC TCCCCATCTTACC
CCCTGTC

TTTGTGG

Table. Primers for variants only identified by Red Panda
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Summary of the quality for the first round of sequencing
Primer Name

QS

CRL

Failure Reason

1-SR_chr1_43954201-43955201

50

458

Poor Quality

2-SR_chr1_181175375-181176975

54

427

3-SR_chr2_3327701-3329301

56

555

4-SR_chr2_22939805-22941405

38

385

5-SR_chr2_33245975-33247575

57

532

6-SR_chr2_39194566-39196166

53

446

Poor Quality

7-SR_chr3_19133119-19134719

32

244

Poor Quality

8-SR_chr4_43976853-43978453

37

529

Poor Quality

9-SR_chr6_83801689-83803289

54

643

10-SR_chr8_36567023-36568623

40

439

11-SR_chr8_71359179-71360779_7

56

495

12-SR_chr9_44741870-44743470

41

402

13-SR_chr10_112925393-112926993

54

527

14-SR_chr11_73175160-73176760

57

637

15-SR_chr13_75771143-75772743

11

1

No Priming

16-SR_chr13_90104423-90106023

51

422

Early Termination

17-SR_chr16_49867208-49868808

52

395

18-SR_chr16_58465697-58467297

56

356

19-SR_chr17_12683139-12684739

53

377

20-SR_chr18_43320998-43322598

57

453

21-SR_chr2_120515174-120516774_1_F

44

528

Poor Quality

22-SR_chr3_19133119-19134719_1_F

43

528

Poor Quality

23-SR_chr3_95734076-95735676_7_F

23

215

Poor Quality

24-SR_chr4_130165017-130166617_2_F

49

482

Poor Quality

25-SR_chr4_132832255-132833855_7_F

18

14

Poor Quality

26-SR_chr5_104434320-104435920_F

34

220

Poor Quality

27-SR_chr7_27204354-27205954_7_F

13

11

No Priming

28-SR_chr7_27204354-27205954_F

25

99

Poor Quality

30-SR_chr8_85260471-85262071_F

20

17

Early Termination

Poor Quality

Early Termination

Non-specific
Homopolymeric or Repetitive
Region
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31-SR_chr10_40250385-40251985_8_F

55

567

32-SR_chr11_72777065-72778665_5_F

44

269

High Background

33-SR_chr12_54782625-54784225_1_F

24

235

Poor Quality

34-SR_chr13_31630105-31631705_F

43

303

Early Termination

35-SR_chr14_54541419-54543019_1_F

41

374

Poor Quality

36-SR_chr16_52269942-52271542_F

55

422

Poor Quality

37-SR_chr16_94468034-94469634_3_F

26

507

38-SR_chr19_60770223-60771823_F

33

366

40-SR_chrX_101403719-101405319_6_F

57

551

Homopolymeric or Repetitive
Region
Homopolymeric or Repetitive

Table. Sequencing results from first round of Sanger sequencing
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Summary of the quality for the second round of sequencing
Primer Name

QS

CRL

Failure Reason

SR-21-F_chr2_120515174-120516774_1_F

45

532

Non-specific

SR-21-R_chr2_120515174-120516774_1_R

44

538

Non-specific

SR-22-F_chr3_19133119-19134719_1_F

56

545

SR-22-R_chr3_19133119-19134719_1_R

54

545

Poor Quality

SR-23-F_chr3_95734076-95735676_7_F

18

70

Non-specific

SR-23-R_chr3_95734076-95735676_7_R

31

330

Non-specific

SR-24-F_chr4_130165017-130166617_2_F

14

11

Poor Quality

SR-24-R_chr4_130165017-130166617_2_R

50

600

SR-25-F_chr4_132832255-132833855_7_F

38

338

Non-specific

SR-25-R_chr4_132832255-132833855_7_R

39

420

Poor Quality

SR-26-F_chr5_104434320-104435920_F

19

43

Non-specific

SR-26-R_chr5_104434320-104435920_R

31

220

Poor Quality

SR-27-F_chr7_27204354-27205954_7_F

12

24

No Priming

SR-27-R_chr7_27204354-27205954_7_R

13

1

Poor Quality

SR-28-F_chr7_27204354-27205954_F

51

631

SR-28-R_chr7_27204354-27205954_R

50

627

SR-30-F_chr8_85260471-85262071_F

22

77

Non-specific

SR-30-R_chr8_85260471-85262071_R

15

28

Poor Quality

SR-31-F_chr10_40250385-40251985_8_F

52

554

SR-31-R_chr10_40250385-40251985_8_R

21

82

Non-specific

SR-32-F_chr11_72777065-72778665_5_F

28

197

Non-specific

SR-32-R_chr11_72777065-72778665_5_R

23

84

Non-specific

SR-33-F_chr12_54782625-54784225_1_F

11

1

No Priming

SR-33-R_chr12_54782625-54784225_1_R

17

72

Poor Quality

SR-34-F_chr13_31630105-31631705_F

38

259

Early Termination

SR-34-R_chr13_31630105-31631705_R

24

132

Non-specific

SR-35-F_chr14_54541419-54543019_1_F

15

32

Poor Quality

SR-35-R_chr14_54541419-54543019_1_R

13

1

Poor Quality
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SR-36-F_chr16_52269942-52271542_F

55

404

SR-36-R_chr16_52269942-52271542_R

53

412

Poor Quality

SR-37-F_chr16_94468034-94469634_3_F

21

221

Poor Quality

SR-37-R_chr16_94468034-94469634_3_R

39

434

Non-specific

SR-38-F_chr19_60770223-60771823_F

23

320

Poor Quality

SR-38-R_chr19_60770223-60771823_R

30

321

Non-specific

SR-40-F_chrX_101403719-101405319_6_F

56

545

SR-40-R_chrX_101403719-101405319_6_R

56

544

Table. Sequencing results from second round of Sanger sequencing
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Sequence from the first round of Sanger sequencing
Sanger sequence for sample 1-SR_chr1_43954201-43955201:
NNNNNNNNNGNNTAGANCCTTCNTGTGGAACCATCCTAAAACTAGTCTACACTCCAAGCTAA
GCTTTAGTATATACTTTTCACTTGCCCTGATGGTTCTCTGTATCATCTCTGACCATCCATGTCCT
TGTGTGTGGGTTAGCATTGACTTCTGGGGAACTTCTGACCTAAGCCTAACTGCTTACTCTGTGA
AACAAAGGAATGTAGTCATTGGATTTGAGTGGTGGGAGAGGAAAGCAATGAGAAGGTGACTG
AGAAACTGTATTGTGTGATCTTTAAAAAGGAGTGGGAGGATAAATTTTAATGCCTATTTCTCC
TTCCCAACAGAGCCTGTGTTGATTCAAATGAGAATGGGGACTTGAGTAAATGTGCCGTATTGA
GAAACTACAAAGAGGCCCAAGAGTACAGTTCTTTTGGCACAGCTGAGATGCTGAATTACTCTG
TGAACATTTATGACGATGGGAACCTGCTCTCCATTGTGACCA

Sanger sequence for sample 2-SR_chr1_181175375-181176975:
NNNNNNNNNNNNNNNTGGGANANGACCACTGCCTTCCTGGCTTTTCCCTCCCTGCGACCCCCA
CAATGGGAAGACCCCTCAGTACAAGCCTCTCTCTTCTCTCAGGATCCCGAGGGGCATATGATC
ATGGTGAATGCTATGGACTTGGCTTGGCCTCAAGGGCAAGTTGTACCAGATTTTTGTTGTTGTT
GTTCATCAGGATACATTGGAGTTAATTCCACTTTTCCTTCCAAGAGCTGTGGTCACCCTGGTTA
TCTCCTATTGGAAAACATGGATTTCAAGGGAGACTGGTTAGACCCAGCAATTATGGAGTTGAA
AACACCATGAACATCAATCAGGCTTATGTTAGATATAGGGTCTTCAAAATGACAAGTCACTTT
TTTTCCATAAAGGAAACATTCCCGTAAACTAAAAGGGGAGGGAGAGGGAAAGACTGTCCACA
GCANNNNTTTGAATGA

Sanger sequence for sample 3-SR_chr2_3327701-3329301:
NNNNNNNNNNNNNNNTCNAANCTTGGGANGAAAAGTTTTGCTATCCCACTCACCTCCTAAAT
TCCACAATGACTTCCAGACAGAGTGGATTAGTAAAGTCCTGACAGCTCCACTCCCAGCCAGAA
AGACCCATCACTGTCTTGTCTGTCCTCGTGCCACATGTCAGCTAAGTACTGCTGTAATAAGTTC
TGGCTTAGGTTTTGTTTTTAGAGTTGTTAGCTTTGATTTTTGTTTGTTTTTGGTGCTGGGGATCA
AGCCAGGGATAGTATGTGCTGGTAAGCACATATTCTGCCATAGAGCTCTGCCCCTAATGTACT
CTTGATAGATGTTATATATTACAAGGAAACTGATGATGCGCAGGGAGAGAATTCTTATGAAAC
AACCTTATCAGGCTTTTGTTCTGTATCAATTAAGCCTTTCTCCCAAGCCTGCCTTGATGCTTAC
CTACAAAGAAAGCCAAATTACCACAAAGTAAAAATGACATGCCGCTCTGAAGGCAGTGTACT
GCTTAACATTTAGTGTCTCTCTCTCTCTCCGTTGCAACTGAGGACTTTCTTCAGTTGCTTCACCC
ACCTTTGCTAGAA

Sanger sequence for sample 4-SR_chr2_22939805-22941405:
NNNNNNNNNNNNNATTTCANCTTATTGATGGGCAATTTTTATTGGCAAAGTTTTTCGGAAAAC
TTTTTAAATGTAATTAAACCAGTGTCATTATAGTCCTATAAATTCTAATCGAGGTATCCTGATG
GTTATATGTGGTATTGTTTACACTGTTAATGCCCACATGTAAAGCCATTACACAAATAAATAA
TCAACGTTAAAATTCAAGTGGTTTGTCTTTGTTTCACCATAGGATTAAAGGTCAGAGAATTTTG
AAGTCTGTACTATTTAAATCCACATTAGTTATACTTTAACAATATCCAAATTTTTCATATAGGA
GCATAGTTTATTATAAAAGACTAGATAAAATTTAGACAACAGGTTATTTACAAATGAAGAAA
ACATTTTGCTTCAAAAAGGAAATGCATAATAAAGAGCTATCNGATTGCTAATGNCATAGTACT
TCGAAAGTAGGANAAGATAANGGNTATCTGGAGTCNGTGTTNTTGGNGAACNNNGGTCTTNN
GTTTTTGNGAT

Sanger sequence for sample 5-SR_chr2_33245975-33247575:
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NNNNNNNNCTNGCGCTNNNANATGTATGTCTCATTGTCTAAGGACAGAACAGGCATTGTAGC
CCTGATTTCAAAAACAGTCCTTGGCACTGCCTGGATTTTCCCAGAATGTCCTCAAGCTCATCTC
TCACATAGGGGCTCCTGGCCTTCTCTCCTTGAGCCCCACCTCCCCTCAGACTGTTGCACTTCCC
CTCTCAGGACGGCTCAGCATCCCTCCGTACAGTTACCCCTCAGCCTGCACCTCCTGTGCCTTAG
TCTCTGGCTGCTCACTGGAAGTCAAGTCCTCTTCTCCCTGCTCCCCTGGCCTCTCCTTTTCTGCC
ACACAGAGCTTTATTTCTGGCACAATTCGTTGGCCTCTGGGCAGGAAACAGTCTGGGCTCAGG
TCCTGGCTGAGAAGGGAAGGCCAGGCCAGAAGCCACAGAGGCAGCGGCATAGACCTGTATTC
AGTTCTGCACCTTCCATTCATACTTTAGCCTCCACAGAATTTTAACCTCTACACAAACAGTACC
CTGCTTTGCCAGAGACACCCCACTGGAGAGAAGTCGCTGCCCAATAGGANN

Sanger sequence for sample 6-SR_chr2_39194566-39196166:
NNNNNNNNNCNGNNNNNTCTCCCACAAGATTACTCTGTATAATACATAGCCCTTGTTTAGTAG
AGGGATCCAAATATTCTTTTTCAGGCTTACAAAGTCCAATACATTCATTCACTCTCTCTTTCCT
TCACAAGTCTAATAGCAAAAACTACTTTTTCCATGCCCCAAAGCCATTATCAGTGGAAGAATA
GTCAGGCAAAACAGAGATGGCAGTTAAGGAATGGACAGAATATTATTGGCACATGCCCAGCT
AGTGACAAACAAATGCAGTACACCATGACTTGAAAATAAGTCACATTACAAGGAGAATGAAA
ACAACTACATCAACTAAGCTAAGGAGTGTGAAGTGGAAAGGGGATTGAGAGTTACTGGTTTA
ACTGGTACAACTTAAAAGCAGGAGGGCAAGCACTTAAATACAATTCATGGTAACATGATCAA
GAAAATACTGCAGAGCTGTTCAAAAACCACACCAAGTNANNN

Sanger sequence for sample 7-SR_chr3_19133119-19134719:
NNNNNNNNNNNNNNNTGTNNACAGAATAAAGCTACACATACATTCGGTTTTAACAGTGGACC
CATGTTTTTCANAACAAAATGTGAGGCAATTAAGCAAAGGAAAACAATACCAAAATACCTTC
ATAAACAAACTTGACCTGTAGCCTCTGTCTTGTGCGGAAAATGTCCAATAAGATGTAAAATGC
AGCATACATAGTCATGTAATCTAGAAACTTTCCATGATAATTAATTGCAAATTGCACTTGACA
GTTCACCACAACAATGGAAAGCTGGNCCCCTGTTGGTTTGCACAGTCCTTGAACCCCTAACTG
AANTTAAAGNCNCCAGNNAAATGATCTGGAAGTGTGTATGN

Sanger sequence for sample 8-SR_chr4_43976853-43978453:
NNNNNNNNNNNANNNNNNGANNNAGGCGTGGGGAAGGCATCTGCGAGTGACGGGTCCTCCT
TTGTGGTGGCTAGATACTTCCCAGCAGGGAATATTGTCAACCAGGGCTTCTTCGAAGAGAATG
TCCCACCTCCAAAGAAGTAGCTCTCGCCAGCAAGTGTAACGAGATGGAGATGCATATATGAA
GTGCCTATAGAACCACAAAAGCACCAGCGAGTGTCTGTCCCCGTGGGTGTGTGTATTTATGTG
TTTACCTGTGAGCATCTCTCGTGACAGCTACACCTGAGTACCTTCTGATTGAAGGATGGCCATC
TGAAACATTTGTCCAGAGGGCTAGCTAACCACAATTGGGTAAGATTAGTTCTGAAATCTTTTT
TCTGTTTTTGTTTGGTTGGGGTATTGTTTGTTTGTTTTGCTTTTATTTTTGTTTTGTTTTGTTTTTT
CAAGGCAGGGATTCTCGGTGTAGCCTTGGCTGTCCTAAAATTTGCTCTGCANACCAGGCTGGC
AGAGATGCACCTGCCTGTGCCTCCCAAGTGTGGGANTAAAGGCATGATCCACCACTGCCTGGN
TTTTGNTTTTGCTTTTTAAAACAAACTTNTTTTGAAACNGTCGTCCNTCTANTATCCNTCCNTG
G

Sanger sequence for sample 9-SR_chr6_83801689-83803289:
NNNNNNNNNNNNANNGCGGCATTCTTCTGCATTGGGGGGTGCCAGCCTGGGGGCCAGGCACA
TTGGATACCACCTTCCCATGGACTACAGTATCAATGCCATTGCCTTCTATTCCTATACCTTCTA
GAGTCTGTCCCCCTGCCCAACCAGCCAACACCGAGAGCTGGGAGACTTTCCTTTTTAAAAAAC
ACATATGGAAGAAAATAAATGCACTTTACTCCTTCCCTAGCAGGGTGTCATCTTCCATACATT

145

GCTGTGCATGTCCTTGGCACCTCCAGCAGGTTCACCTAGCAAGCTCTCAGTTTAAAGACCCAC
CAGGCTCTTAGGCATATAAGAGCCCAGACCTTCCCATTTCCACACTATATGCTTTGGCTGCCA
GAAGCTGGGACCCAAGTTTCCTCTTAGCAGTTATGATTCCTCATGACAGAACTAAGTGTGTCT
AAGCCTACCTCCTGGGGAATGACCCAAGGTCTATTGTCTCCCAAGCTCTGGGAGACAGTACAA
TCCTAGTCTCAATTTTGACTTAATTTTATTTGGTAGCTGTAGGTACACAGGGCAGTTTTTCTTTC
TCATGTGTGCATGAATCCCCTGAGGGCCAAGTAGGCATTGCTTAACTCAGTGGCCTGCCTGCT
TTCTGACTGCTGCTCACNCGGCTCTGGTTTNANAANN

Sanger sequence for sample 10-SR_chr8_36567023-36568623:
CGNNNNNNNNNTAGGGTCATGCTAAGCTACCTTTTTGTCTCTTAAAAAATAAGAGAAGCAAA
TTCAATCAGTGTTCTTTAGCAAATGATCAATTTATTAGGTGTCTACAAGTACAAAACACTGAC
AGCTGCTGTAGAGAAGTAGAAAGATGTGCAGGAGATGAGCCTGCCCTTGAAGAACTCACAAT
CTAGACCCAAGAATCATCACGGGGACAAATCGTGGCCACAGTACAAGATGTTAACACCAGTT
CTTGGAAAGTTCCGTGCTCTGAATTCTCTCCTCTGGCCAGACGTAGGTAATCTCTTCAACAGGA
AAGTCAAAAGTGGGAAAGAGACCTCTTGCGGACTCATCAGTGACCTTTCCTTTGCTTCTAAGC
ATCGTTCCGTTGCTGTTGCTCTGTTCTNGGAACCTCTGGGCATCCTTTCTGACCTTGGTCTGGG
GAGACTCTCCGACTTCCTGAACCTTCACCANGNCTTCCTGNTGGTGNNNNNANTANTCAANNC
CCTTGAANTG

Sanger sequence for sample 11-SR_chr8_71359179-71360779_7:
NNNNNNNNNNNNCGCAGANAGGACCAGGTACATTCCGTATACATCGCCCCTGGGGCTGACCT
GCCATCACAGAGTACACTGATAGCCCTGGACCATGATACCATACTTCCTGGGACCAAGCGCAG
GTATTCGGACCCCCCTACCTACTGCCTGCCCCCCAGCTCCGGCCAGGCCAATGGCTGAGGACC
ATGACTGGCAGTCTGCATCTCCTAACATCCCCGAACTGGCATCCCAGCTGTGGAGCTGGCCTT
CACTTTCTGAGAAGGATCTAGAATGAAAAGCTCCCAAAGGGATGCAGTGGCCAGCTCTGTGT
GTTGTGGAGACTGGGAGCTGCTGGCCAGGAGCCATCAGAGCCCCAACCTGCACAGCAGTGGC
TCCTTTGTCCTTTCAGTAACTGTTTCTCTTTTTGTGGTTTACATAACTTTTAAGTTCATAACAGC
CTTAATGGAGGACCAAACTTTTGTATTTGTATGTCTGAACTTTTATATTAACTCTGCACCCTTG
TAANTGNNNNNGGGGCAAN

Sanger sequence for sample 12-SR_chr9_44741870-44743470:
NNNNNNNNNNNANCTAGAGATANGGATTCTTCCCTGATGCANNNTAGGGAAAAAGGAAAGG
CTAGAAATTTCTTTGGCAAGCCATCCCAGCCACAGTCTTCTGTGGGACTGCCCTGCTTCATGGA
TAGTATACTCTTGCCAGGGAAGGCAGGTGTTCAGAGGGAGATCTCTGCTCTGCTCTGCTCTGC
AGCCACCTGAGAGAATGGAGGTCATCTACTGCTTCCCATTGCTACTGCTTGCAGCCTTCAGCA
ACTGATCTTCCGCCCCACCCAGTTCAGTGCTTGGCGGGTGGGATTGGCTGATTCAGCCTCTATT
GAAAAGGTAATAGATCAAAATGAGCTGAGAAACTCCTACAATTATTACATGATGACACCAAA
AAGCCAGAGGAGGANAAAAAAGGTTTTCANAAACAAGGACANANAGGNNNNNGTGNNNNN

Sanger sequence for sample 13-SR_chr10_112925393-112926993:
CNNNNNNNGNNCTCNCACTGCTTTTTTGNTTTTCCACAATTCACTGAAGGTTTTTAAAGAACTC
ATGTAGCAAGGTATCTTTTAAGTATTTTTTAGCTCCTGCCAAGGTTTTACTCACGTTCTCAAAA
TTCTTGGACTAAGGATCCAAACTGTAACTAGGCCCCAACCCTGAGCTGCAAAACTCTGAGAAG
GCAACAACAGACAGTCTCAAGGCTCAAGCACTATAATTGCCTCAACTCTTTGAGTATAATCCA
AATTAGTCCACACACTTCAAATAGCTCCTGGGAGAAGGAAGATACATACACAATAGGATTAG
AAATGTGGAGCAGAACCAACTCCTTCCTTGTGTATGCCAGCATTCCTGGCTCTGCAGTAAGTC
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CTAAGAGGCCGTATCCAAGTAGCAATGGGAAGAAAGAACTCATGACAGGCAGGGAGATATAC
TAGCAAGGCAGCCTTATATAAGAGAAACACTTAGACATGACACTGCCTTGTAAATTTAAAAA
AAGGTTGTTTTTTTTTTTTTTTTTTTTTTTNNNNTTTTCCCCNTCCCNNCCCAAANNNGGGGNNC
NNNNNNAAAAAAAN

Sanger sequence for sample 14-SR_chr11_73175160-73176760:
NNNNNNNNNNNNGNCTCGNNNNGCCCCCTTCCAGACGAGCCACTTCTGGCAGAGACAACTAA
CTTCTCTGTGCTTCAGGTTTTTCATTAACAGAAAGTTAGCAGTAACATCTCCATTGCTATGGCG
AGAATGAAAACACACAATGCCGGTACACAGTGAAAGCTTAGTAACACGAACTGTTACCAGTT
CTTAAGATGTTAACGTTAAATTCTCTCATGTATACTCTAGAGGTCCCTTTGGACTTACTAGGCG
TTAAATCCAAAAAAATATACAGGCTGTGGCCTCGTACTTGCTCTCCAGGGAGCAAATCTTGGC
GACTTCAAAGCTTGGCTAAGCAAGGAACGACAAGGTGTCACACTTCATTTAATCTGAAGAATA
ATATTACAGGCTCTGTCTTCAGATATAAATTATAACAGTACAGAACAAGCAGCGAATTCCAAC
AATTTAAAATCTAAGTAAGTCTACCCGGTGTTAATTCTGGCAAGAGCCTTGCCGATCTGTTTTA
AAGTCACCCCTGCCCTCATTTCAGTAGACGTGCACCATGCCATAGAGGAAGGTCCAAAAGAG
GACGTAGGTGAAGAGGCCTCCAATGAGGCCTCCCGTAAAGAGAGGTCTTCGTGACTTAAAAT
ATTTGTTCCACCTCCTTCCCGCTTGAANNAATGAGNA

Sanger sequence for sample 15-SR_chr13_75771143-75772743:
NNNNNNNNNNNNNNNNNNNNNNNACANNNNANNNNNNTNNNNNNNNNNNNCCCTGGNNTT
CTCNGCGNACNNNNNNNNAGNNNNNNCGTGAAAACNACAACAAGGGANACGACACCTCTCG
AACCTCCCCACTNCNAGCCCCCCGGATNNNNTCACNTGTGGCGNNTTCNACNATNNTGNTGGT
TTCGTNTTTCTCTTNNCCACTATANNGATNCTGNTTNTTTTNCNCNATTNTCGTTTCTGTTGCTG
TTTATGAATATCNTGNCTTCCTTNAAANN

Sanger sequence for sample 16-SR_chr13_90104423-90106023:
NNNNNNNNNNNCTTNAGTCTAGTGTATGTTCTGTCAGCTTGAACTGGAATCTCTCTTGTAACT
TTGTAGGTTATAAACATATCTCATATCTGCTTTAGTCTGGGTACTATGCTCTAAGTACATTTCA
GCTTTGACACAGAATGTGAATAGACGAATATCAAAGGATACTTACAAGTTTGTATCCAACATT
TCTTCAGGTTCAGCTGAAAATCAGTTACTGTTTCAAAACAAAGAGGAATTAAATCCTAGCTGA
AAACTATACATAGCATTTATTAATTAATTACTGGGTTTAACTGCTCTTTTTAAAAGTTTGAAAA
AGAAAAAAAAAATTTTTTTCTTAAAAGTGAAGTTTCTATAAAAACAAAGCCCTGAACTTGCAG
TCTTCACTGTGTAGCCCAAATGGCCACCAGAGCTAGCTAGACCATCAGCTTTGACATCGTGCT
TGAAANGN

Sanger sequence for sample 17-SR_chr16_49867208-49868808:
NNNNNNNNNNNNNNGCNCNNNCACCGAAGANNGTTTGTGAAGTGGAAGTTGAACAAATCGT
ATATTTTCATCTATGATGGAAATAAAAATAGCACTACTACAGATCAAAACTTTACCAGTGCAA
AAATCTCAGTCTCAGACTTAATCAATGGCATTGCCTCTTTGAAAATGGATAAGCGCGATGCCA
TGGTGGGAAACTACACTTGCGAAGTGACAGAGTTATCCAGAGAAGGCAAAACAGTTATAGAG
CTGAAAAACCGCACGGGTAAGTGACACAGTTTGCCTGTTTTGAAACGTGTGTTGAGATATGGT
TGCCACTGTGGGAGTGCTGTAAGGTGGAACCTTGCAGAAGTCACTAGGAGGAATTAAGGCTC
TTCTTGGGCAAGTGGGCTAGCCATCTGGATAGAAAGTGAGTCTGGCACTCGTGTTA

Sanger sequence for sample 18-SR_chr16_58465697-58467297:
NNNNNNNNNNNTGCTCACCTGTGTTCATAAACCCTGGCAGCTCCTATCCAGCAGCAGTCACGG
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GAAGCCAGCCCTTCCCATCTTTAAGTATACTTCTCCACAGGGAACTGGGAGAGAAGCAACTTA
CGATGTAGAAAAGCTATAAAGGGAGTCCTCTGCGTCACTAAAGTAATCTGTAAATTACTTTAG
GGACAAAGTTAAGGGGGAACTAAAATTTAACCTTCTTTGCTTTCTTTACACACAAGCCCAAAA
ATTTGCAAAATTTTTTTTAAATTTCAATTAAATTTTTAAATTTAATTTTAAACCATTGTAAGAA
AAAGAAAGCCAACATGAGCCAGGTCTGATGGCTCAAGCCAGCAATCCCAACTGACCCAAGAA
N

Sanger sequence for sample 19-SR_chr17_12683139-12684739:
NNNNNNNNNNNNCNCTGTCNTCATGGANGGACACCAGCTTGGCAGGGGCTGTTGGCTTGCGC
TGTCCGGGTCTGAACTTCCCTTTTCTGGCCTTCTCACCTCGGACCAGCCCCAGCCTCTCACCCT
CCCTTTCCTTCAGGACCTTGCGCTGTGGGTTTCTCAGGGGCTGTGAGCTTTCCACCTCCGCTCC
TCGGCCTGAGTGAACTTTCACCTCTGGAACGGTCAGGACCTCATCCTCACTGTCCTGGTCGTCC
CCATGCAGGGACGAGAGAGCTTCTGCTTTCACCGCCTTGGTGGTGATATGGCCATTTTCTTGCC
CGTCCTTGCCTAGTCTTGGGGCTGGCACCTGGATCTCTTCCATCAGCCATTCTGTCTCATTCTC
ATCTGTCTCCTCCTCCNCNNANGNNN

Sanger sequence for sample 20-SR_chr18_43320998-43322598:
NNNNNNNNNNNNTAGANNNNANTTGGTGGAAGCCCCGATGACAGAGCTACTTGAGAGAAGA
TGGTACCAGCACGCTCTCCCACCCTGGAATGCGGCTGTCTGCCTGTGAAGCAGAAGCAATTTG
CATTTTGATTTGTAGCTCAAGTAACATGTTGCTTAGAAAAATTCTCATGTTAAGAAAACAGTT
GGGGAGTTGCCAAGGGATTCTCAGGATTTACGAGGCTTGGGCACTACTCATAGTGAATGAAG
AAAGAGACGCATCCTGAGATGGCGCCTGCCCACCTTGAGGACTTCAAGAAGCTGTTCCTTGCA
CAGGAAAGGAACACTTGAGTGGAACATAAGGTTTCGGCACAGTGGTACACTTTGGAAATGCC
AAGTGCAGTGCAAATGACCCAAAGGAGTTTATTTTTCATGATCAGAGAGACCCTGGAAGGGC
TCAGGCATGGGGAACCACACAGTTGAGGAGGCGCAGAATTACAGA

Sanger sequence for sample 21-SR_chr2_120515174-120516774_1_F:
NNNNNNNNNNNNNNTGTCTCNCTGNNNTTGAAAGCACACTGGTAAATGTGAATTTCCTTCCTA
TTTTGAGATGAATGCAAACTGCATGAGATAATGTTTCCCAGACAATTTTCTAACTGAAAATAC
ATGCCTTACCACTCACCAGACACTGATGAACTTGCCAGGGCATTGCTGAGTTCATGGCCTATG
CAGGACAACTATGAACTATCCTAGAAGGGCACAGAGTGCGGCCACAATAAAATACATTTGCT
TCTTGCTAGCTTTGTGCTTTAACCCAGGCACAAAGGACTATGATCTCCCTGACTGTGCTCTTTA
CAGGATGCCTGTTCTAAGCCTCACCGCACAGCAGCAGAAACGCCATCAATCCCATCCGTTCCC
TCACCTTCATGCACAGAACAGTCTNGCTGTGGCCCTCCAGGGTTCGGAGCAGCAGTCCGTTCC
GTGCATCACGAACACTAATGGTGCAGTCGTAAGATCCTACAACCAGCAGTTTTCGGGCACCTT
CCTGAGCTGTTGCGAGGCANCTGACTGCCCNAGGGCCATGGCATTCAAANATCTCCTGTCNCT
TGTTTGTTNNNNAANNNANNNN

Sanger sequence for sample 22-SR_chr3_19133119-19134719_1_F:
NNNNNNNNNNNATGCAGCATACATAGTCATGTAATCTAGAAACTTTCCATGATAATTTATTGC
AAATTGCACTTGACAGTTCACCACAACAATGGAAAGCTGGCCCCCTGTTGGTTTGCACAGTCC
TTGAGCCCCAAACTGAAGTTGAAGTCACCAGTAAAATGATCTGGATAAAAAGTTTGCTGCTGT
GCTCAACCAGCTGGCTCCACCTTCAGGGTGCGATCCAACCCGGGACACTGCCTTGTCCTGCTC
CTTTGTGGGACTCTCATCCTCAGGCAGGTAGTCAGGTAGCTCTGTGTTCTCTTCCACTTCCACA
GGGGCATCCTGAAAAGGGACCAGCATCTGACACGGAGAAGCCGGAAGAGCCATTACAACCA
ACCTAACACGACACGTACATCCCCACAGCCACATCCTCATTCTATGCATCATCTTCATTCCCAA
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GAGTCGCAAGGGCTCGCAATCTAACGCTTTCTTCTTTCATGCAGTCAGTCTGTCTGGGTTCTAG
GACAGGAGTAACCTATCNGTGTAGAAATGGGTTAAACGGGTGCAGGGCANCTTTGA

Sanger sequence for sample 23-SR_chr3_95734076-95735676_7_F:
NNNNNNNNNNNNNNNNNNTGCNNNNNANGGGGCCTTCNNNGTCCACACCTCTCACCCCCAAC
TCCCCCCACACACACACACCTTGTACTCTTTTCCCCTACAGACCCTGCTTTTACTCCGAGGCAT
CTGGAGGCTGGAGGCTCTGCCATCATCCGATGCTGGCTGGCTCATCAGCTGTTGCCATGGAGA
CCAGCCAGCAATCAGATCCATGCCCTCCTGCTGCTGGGCACAGTGGAGGTAAAGCCACAGAG
AACCTTGACAAATGAGGGAAAGNGCATACCTCCACGCCCACAGAAGACNATGNCTGNTTANC
TCCTCTTTCCTGCGGGAGGTGACCTCTGGAAGTCATTTCACCCCCCAAGGTCACTNCACTGGA
ATGNGGATGGGGCTGNCAACCCCTGCTGTTATATAGAGGTGAAATANNCCCCNGNNGTGTGT
GGGCCTGACAACACTTTTTGACGGNNTATGACTTCTGATTGA

Sanger sequence for sample 24-SR_chr4_130165017-130166617_2_F:
NNNNNNNNNNNNNGTCTTGGNTGGCTGACCAGGGACCTGGAATCTGTCTATACTCCCTGCAG
TTTCCAAACAGGGCCCTTCCCAGTTCCGGCTGTGATATCTGGGGGCTTCCGCCAGCCTGGTGC
ATCTTTGTCTCCTAGGTGGGATTCTGCCTTAGCGCGCACGCGCGGATCTGAGTCTGTAGAGATT
AGCACCTGGTCCCGAAGTGCACACAAGGCTTCATCGGGCATGGCCCCCAAGGCCTCTTCTGTG
GCTGTGGATCCCACCTCGCCTAGTGGCTGAGACTCAGTGGTGCCCCATGTCCTCCATTCCCAC
GCGACCCCAGACGCCCAGCACGAAGGTCTCGATGTCGCACTCGTTGGTGCCACGCACGATCCG
GAAGTGGCCCCTTTCACCCCACCATGGGCCCCACGAGTTGGCAGCAGTCTGGGAGTGAAAAG
GGGAGAGACATGAGGCAAAAGACAGATGATGGAGGGCTCAGAAGGGCAGGAACTTGGGACT
CGNCCTCGCACCAGANACTCACCCANTACTTAATGGTNCTTCCGTCTGGCAGCTTCTN

Sanger sequence for sample 25-SR_chr4_132832255-132833855_7_F:
NNNNNNNNNNNNNNNNNNNNNGCGCCNATGAGACCGTAGAATCGATGGG

Sanger sequence for sample 26-SR_chr5_104434320-104435920_F:
NNNNNNNNNNNANNAGTCTGANAGATCAAATTGTGTATCCATGTGGCCTTTATCTGTAACTTA
GATAGGAGAATCCATACCTTTCATCCCCATTGATGTTTTTCTACTAATTCAGTAACTATAAACA
AAGTCTCTGTGAGGGTGATCTACTCTTCCTTTCCTTATGGATCCCTGATGCTCTTCCGGGATTC
TAAATGCAGTCTATAAATGAAAAGGGTAGTTAATGACATCGTTCATCAGNAATGCTTTGTGTG
TGTTTCCTTTTCTTCCTTTTTTTTTTTTTTACCCACAAAACCAAAGGAGGAAGGTTAGGCNCTCT
NCCGCTTCCTCGCGCNCTAACTCNCTGCNCTCNACCNTTCNCCTGCGGCTGGCNNNATCNNCT
CNCTCAAANGCNCNNNATTCGGTTATCCNCNGAATCTNGNGATNACNCAGGAAANA

Sanger sequence for sample 27-SR_chr7_27204354-27205954_7_F:
NNNNNNNNNNNNANNNNCAGTGCTCTTANCTGCTGAGCCATCTNTCCANCCCCCCNANNTNA
TTCCANCNCNNANNGGTGNCGGGTTGCTNTTNNNNNNTACTGTTTGGGCGGTTTAAAANCGNC
CATGGGANTATGAAANCCCTGGGNCCCCCNGANNCATNNNNNCANACCCGNTTNNNTCCTTT
ACAGAAATTTTCCTCCNNTTCTNNTTCTTTACCTTNAANCTNNCTGAC

Sanger sequence for sample 28-SR_chr7_27204354-27205954_F:
NNNNNNANNNCTCNCNTNNATTTCTATGTTTTTCAAAGAAACCAAAATTTTTGCTACAGAGTC
ATGACCCCTTTGGGTGTCAAAAGACCCTTTCACAGGGATTGCCTAAGACCATCAGAAANAATA
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TATATTTANTTTATGATTCNTANTANNANAGNATATTGTAGTNATAGCNTANGGATCTNNTGA
ANTATATTT

Sanger sequence for sample 30-SR_chr8_85260471-85262071_F:
NNNNNNNNNNNNNNNNNNGNNNNNGCCAGTATCTCAGCATTGTTTGAAGGAAAAA

Sanger sequence for sample 31-SR_chr10_40250385-40251985_8_F:
NNNNNNNNNNNNNNNNNNNNCTGCNNNNTCACTGGGANTTCAAGCATGTGCTATCACATCCC
TCTAGTACTAGGCACCGATCCCAGGGCCCCACACATGCTAGGCAAGTGCTCTTGACCACTTAT
CTACACTCACAGCCCAAGAGTGCCCCTCTCCAGAGAAGGAAGTGAACGAACCTATGTTTTCTT
CTCCTTCCTTCTTTTCTGTCAGAAGCGTCCTTGTCATGCTCAGCTTCTTCATCGTGTGGCACTTG
TACTTCAGCACCGTCTTATCAGTCCCCTCTGGATCCACTAGGACATGAAATGATCTTATTATAC
CGCTTCATGCCATCAGATGTTGAGGGAGTTAGTCTCAACTACTTCCTATGGGAACAGCACAGG
AAGTTCCCACTGCAATTGATCACTCCTGTCCCACGTGCAAAGAAATGACAGATAACACTGACA
TTTGAAGGCACAATAGGTCTCACACACAAAAAACTCTAAGGACAGAGACACGTAAACACAGA
GACTAACGCAACAAGGTAGGGTTCCTAACATGGGAAATGGGGCTTAGGAGTTGGCCCGCAGA
GCACTGTGTCTACAGTCCTATCGCCCAAATGAAGA

Sanger sequence for sample 32-SR_chr11_72777065-72778665_5_F:
NNNNNNNNNNANNNNANANTNNGCATGGTTGCTGTGCTCNGTAATTTCTGTAACTGATGACA
CAAACAATCAAGTTCTTTTAATGTGGGAAAGCTAATGTGGTAATTATCATGCAAGTAACATAG
CAAATCTTAAGACTAATGGTGGGAACTCAAAGATATGTGGGGATGAAACCTGCTTCAAGTTTC
TAGAGCTTCACAGAGGATTTTTAGTGGGTGAGCTTGAACATGTGAGGGCAAACATGTTTAATT
TCGATGAAACAGCTCAGTGTCCTGCTCAAACATTTTGGTGTCCTGCTCCAAGTACCAGCAN

Sanger sequence for sample 33-SR_chr12_54782625-54784225_1_F:
NNNNNNNNNNNNNNNNNNNNCACNNNNATTTCANTCAGACCCTTCCNGGTTCCAAATTAGGC
TTCACTATGAGCAANTCGTTGGTTCTCTGAGCTTCCACACTCTCAACTCTAAAGTGAANACAG
TGAAGTTAGGCTGGGCTGTGGGAAGCTATGAGGGATGCACAAGTCACGTGCTTAATACAGTG
GATGGCTAACCAAGTAAAACCACTGCTATATGGTACAAAGTCCTGANAAGGAAAAATGAACT
TANAATTATTTTTTTTAATTCATAAACCTGACCAGGCAGTGGTGGTGTATGCCTTTAATCCCAG
CAGTCCAANNCCC

Sanger sequence for sample 34-SR_chr13_31630105-31631705_F:
NNNNNNNNNNCNNANNGCAGNNNNAGCACACCCATCACTTAGACAAATACCCAAGGGAGTT
CTGCTCACCGATATTTGCCCGGCCCCTGGAAGAGGAAACCTTTCGAAAGCTAATATCCCAGAA
GAGCGACAGACAGAGGAGGTGACTACATGTAAGACATATGTTACTGTGTGGAGGACATAAAA
CTTTTCAGTTCTGGGGTGGCCATTGCATTCACTAATCAGGGTCTGAAAAGGGAGGTGTGTGTG
TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGCTTTTCAAAATTGCAGTGCTAAAAACACACTATT
TCAAGAAAGCCTTCTCTATCTCCCTGGCTCAGTAAGATTTTTCTTCCACCCACTCCCACTCCCC
CCACTCTCCTTTCTTCATATACGGGNGACA

Sanger sequence for sample 35-SR_chr14_54541419-54543019_1_F:
NNNNNNNNNNANGGNNNNNNCTTAGGTCTCTGGGCCTCACAGAGGCCCGAGATAACAGGTTC
GAAGTCTTGGACATCCCNGACACAGCTGGACACCGAGGAAAACATAAGAACAAAATGGGAG
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CCCCAGGAACAGCTCAGTCAGCTCAGGGACCAAAGGGAGGAGAGGGCAGGAAGAGAGAGGG
CACTGGGTGGTTCCCATGCGGATGAGAGTCCTTGGTCCAGTCCTTGGCTGGAGCACAGGAAGG
CCTTCTGGCAGGAGGTTAGATGCTGCTCTTTAGGGGAAAGCCTATCCCACCGTTCAAGCATGG
TGGGTCTTGATGAGCAGAGACAGTTTATAATTTTAGAACTTTATTGTAGAAAGGCAAGGAGAA
AGAGAGAAGGNAGAAAGAGTTTANGGGCCAGCA

Sanger sequence for sample 36-SR_chr16_52269942-52271542_F:
NNNNNNNNNNNNGANTGACTTAACTGTGAAGACAAGGGTAGTAGAAGAATGGAAACCAGGT
AAAAAAGAAAACNNNAACCTCATGGCGATGATATCAAAATGCCAAACAAAAGCGTGAAACTT
ACCATGATGCAGTACAGGGAGATGGAACTGAAGATGTTAAGCTAATGAAGAATAACTTCAAA
TTTTCTTACGGTTTTAATGCCAGAAATGAAATACTCACTCGCAGAGACATTCAGGGAGTTTAC
TGTTCTCTCCAGTTGGTTTTCTGCTGTGCAAGTTAATGTTACATTCTCCTCAGGGGAAATGATA
ATTTTACTATAATACCTGCCATTAATATAAGGAGACTCCTCTGTCTGGAAGAAGAAGGAAGAA
GAGTTTAGAGATGGAGGTGCACTTTACAAGTCTGGGAAAGCATAGTGGTAGATGACACAGGG
CAANACNANN

Sanger sequence for sample 37-SR_chr16_94468034-94469634_3_F:
NNNNNNNNNNNANCNNNTCNTAATTTTTAAGTGCTTATGATTCAATTAATCTACATTTTGGTA
ATCAATTATAAAATACTTTTTAAATTAGTATTGGCTATTTTTTTTTTTTACCCTGGGAAAATGCT
GTCTGCTCCCAGGAGTCCCACCCTTGGCACTTACACTAAGGTTACCATGTAAGTCTCATGATTC
AGCAGTGCTTGGAAGTGCACAGCTGGCTAGGGCTGAAAACAGGACATATGGCCCAGCGCAGG
GCAACCACCCTCACCCTCCTTCCTTATCCTTCCACCAAAAAAAAAATGTACCACAGCCCTGAT
GTGTTGGTGTTAACATTGTTCTGTTTGACTTTTGTGTAAAGTAATGCATGCAATCTTGTAATGG
GGCCTGAAAACAAGCTAACTGTATTAAAAACTATTCAAAAACTAGGTATTTTTAGTGACCTGT
AGGGAGTGGCAAATACAGACATGGGAACCTTGAATACATTACATTTCTCTCAAACACAAAAA
AAAAAACAAAAAACTTTTCCACCGTGTTCTCTGGTGCCCTGGAAATGCCNTCACCTTCCACCC
GTGTCTGTGTAANTTGTGGTGCCTTAGNGACTTANNATGNGACTCACTCCTTATTTNGAAANG
NTGTCTGTGGNGTCCCNGN

Sanger sequence for sample 38-SR_chr19_60770223-60771823_F:
NNNNNNNNNNNNNNNNCTCNCAACCATCTGTAATGATATTTAACCACCTCTTCTGGTGTGTCT
GAAGACAGTTACAATGCACTTACATATAATAATAAATAAATCTTTAAAAAAGAAAAAAAACT
TAGGGAAAAAAAAAAGACTCTAGAGGTAGCTATCTGGTAGGCCTGAAATTCCATCCTGCACT
GCCCCCAAAATCCCACACTTCAAAAAGATCAAAAAAAATAAACTTTCTTCTTTGAAACACTTG
AAAAGATTAAAATATCTCCCAACTCATCTATACAAATACTGAGTAATTACCTGTTAACCTTTA
ACCTGTGTTAAGGGAAAATCCTCAAAAAAAAACTAAAATTTCACAAATTAAACTTTTCCCTAA
ACAAAACAAACAAAAANNANCNCATTANTGAGCTTACCTCNTNNGCATATGGCAGGGCATNT
T

Sanger sequence for sample 40-SR_chrX_101403719-101405319_6_F:
NNNNNNNNNNGTCTGTCNNAGGGAGCACCCAGTTCTTTCCCTGTTGGCTTTGCTGTTCCCCAG
CCTTCTTTTTGTGTTTTTATAACTGTCCTCAGTTTAGCCACTGTTAAAATGTATATATTGTACTG
AGGTGCCTGGCCTGTTCCTTCAGTGAGCCATGCCCACCCTTGTGTTGTAGTGAGAAACTGTTGT
CACAACTAACTTGTCTCTGGAATTGTTTCAAATAAAGAGTTAAAATTGTTCTTTGCTTTCTCTG
GGGGAGGTAGAGCTGGCGTTGAAGAGTGGAAGAGAAGAGAAAGAGCACCCACTGTGGGTCC
CTGAAGATTAGTCTTCCCTCAGTCAATGAATATCACAACGTTGGTCCTCTTCTCATACATTTTC
AGATACATCAGAAAAAAATATTTTTCAATAGCCATTTATTGAGCTAGAGTTGCTTATGTCTAT
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AATCCCAGTAGTTGGGAGGTGGAGGCAGGAAGTTAGGAATTCAGTCATCCTTGGCTACATGTG
GAGTTCAGAGCCAACCTAGGTTATGTGAAACCCTGTCACAAAATGGGGACAGGGGCTGGAGA
TGTAGAA
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Sequence from the second round of Sanger sequencing
Sanger sequence for sample 21-F-chr2_120515174-120516774_1_F:
NNNNNNNNANTCTGNNTNTCTGTNACTTNNNNNCNCACTGAATAAATGTGAATTTCCTTCCTA
TTTTGAGATGAATGCAAACTGCATGAGATAATGTTTCCCAGACAATTTTCTAACTGAAAATAC
ATGCCTTACCACTCACCAGACACTGATGAACTTGCCAGGGCATTGCTGAATTCATGGCCTATG
CAGGACAACTATGAACTATCCTAGAAGGGCACAGAGTGCGGCCACAATAAAATACATTTGCT
TCTTGCTAGCTTTGTGCTTTAACCCAGGCACAAAGGACTATGATCTCCCTGACTGTGCTCTTTA
CAGGATGCCTGTTCTAAGCCTCACCGCACAGCAGCAGAAACGCCATCAATCCCATCCGTTCCC
TCACCTTCATGCACAGAACAGTCTTGCTGTGGCCCTCCAGGGTTCGGAGCAGCAGTCCGTTCC
GTGCATCACGAACACTAATGGTGCAGTCGTAAGATCCTACAACCAGCAGTTTTCGGGCACCTT
CCTGAGCTGTTGCGAGGCAGCTGACTGCCCGAGGGCCATGGCATTCAAAGATCTCCTGTCGCT
TGNNNNNTCTNAAA

Sanger sequence for sample 21-R-chr2_120515174-120516774_1_R:
NNNNNNNNNNNNNNNCTCNGGCNGTCNGCTGCCTCNCTCANCTCAGGAAGGTGCCCGAAAAC
TGCTGGTTGTAGGATCTTACGACTGCACCATTAGTGTTCGTGATGCACGGAACGGACTGCTGC
TCCGAACCCTGGAGGGCCACAGCAAGACTGTTCTGTGCATGAAGGTGAGGGAACGGATGGGA
TTGATGGCGTTTCTGCTGCTGTGCGGTGAGGCTTAGAACAGGCATCCTGTAAAGAGCACAGTC
AGGGAGATCATAGTCCTTTGTGCCTGGGTTAAAGCACAAAGCTAGCAAGAAGCAAATGTATTT
TATTGTGGCCGCACTCTGTGCCCTTCTAGGATAGTTCATAGTTGTCCTGCATAGGCCATGAACT
CAGCAATGCCCTGGCAAGTTCATCAGTGTCTGGTGAGTGGTAAGGCATGTATTTTCAGTTAGA
AAATTGTCTGGGAAACATTATCTCATGCAGTTTGCATTCATCTCAAAATAGGAAGGAAATTCA
CATTTACCAGTGTGCTTTTCAAGTTACAGAGGAGACAGAACTTCCGCAGAAGTGACTGCNCNT
NNTTCTCTTTTCN

Sanger sequence for sample 22-F-chr3_19133119-19134719_1_F:
NNNNNNNNNNNATACNTAGTCATGTAATCTAGAAACTTTCCATGATAATTTATTGCAAATTGC
ACTTGACAGTTCACCACAACAATGGAAAGCTGGCCCCCTGTTGGTTTGCACAGTCCTTGAGCC
CCAAACTGAAGTTGAAGTCACCAGTAAAATGATCTGGATAAAAAGTTTGCTGCTGTGCTCAAC
CAGCTGGCTCCACCTTCAGGGTGCGATCCAACCCGGGACACTGCCTTGTCCTGCTCCTTTGTGG
GACTCTCATCCTCAGGCAGGTAGTCAGGTAGCTCTGTGTTCTCTTCCACTTCCACAGGGGCATC
CTGAAAAGGGACCAGCATCTGACACGGAGAAGCCGGAAGAGCCATTACAACCAACCTAACAC
GACACGTACATCCCCCAAGCCACATCCTCATTCTATGCATCATCTTCATTCCCAAGAGTCGCA
AGGGCTCGCAATCTAACGCTTTCTTCTTTCATGCAGTCAGTCTGTCTGGGTTCTAGGACAGGAG
TAACCTATCAGTGTAGAAATGGGTTAAACGGGTGCAGGGCCACTTTNANNNNNTCCGTGGGA

Sanger sequence for sample 22-R-chr3_19133119-19134719_1_R:
NNNNNNNNNNNNNTTCTACNCTGATAGGTTACTCCTGTCCTAGAACCCAGACAGACTGACTG
CATGAAAGAAGAAAGCGTTAGATTGCGAGCCCTTGCGACTCTTGGGAATGAAGATGATGCAT
AGAATGAGGATGTGGCTTGGGGGATGTACGTGTCGTGTTAGGTTGGTTGTAATGGCTCTTCCG
GCTTCTCCGTGTCAGATGCTGGTCCCTTTTCAGGATGCCCCTGTGGAAGTGGAAGAGAACACA
GAGCTACCTGACTACCTGCCTGAGGATGAGAGTCCCACAAAGGAGCAGGACAAGGCAGTGTC
CCGGGTTGGATCGCACCCTGAAGGTGGAGCCAGCTGGTTGAGCACAGCAGCAAACTTTTTATC
CAGATCATTTTACTGGTGACTTCAACTTCAGTTTGGGGCTCAAGGACTGTGCAAACCAACAGG
GGGCCAGCTTTCCATTGTTGTGGTGAACTGTCAAGTGCAATTTGCAATAAATTATCATGGAAA
GTTTCTAGATTACATGACTATGTATGCTGCATTTTACATCTTATTGGACATTTTCCGCACAAAG
ACAGAA

Sanger sequence for sample 23-F-chr3_95734076-95735676_7_F:
NNNNNNNCNNNNNNNGNGTNNTCTGNNANNGCTNNAGGCTTCTCGGGACGGCNGNACTGAG
GTTCTCCAAGAAGGATTNNCCTTCTTTAACTCCCANAAATGGTCTATTCTCCTCNACCTGACTT
CTGCGAACAGGCTTGAGGTACTAAAAAGAGGGGTAACCTCTACATCTANCCTTCTGATTCCCT
GGAGCCTTGGAATCCCAGGTCACACGCACTCACCTCCTCTTCACCGCAACACGCCTGTTCTGG
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ATATGGAAGCTCGAAACAGCGGACGTCCATATTCTGGATCAGCCCCGGAATCTGTTTACTGTG
GTTGGTATGAAANAGGNNCNNTCNNGNTTTCTGTCCCTTCCGCANCATCCANGGNCTGCTGGG
GGCGGTGGCTTATGCCGGTAATCTCTTTACTTGAAGTACNNGGGANAGAAGATTGGTCCNGTT
NNAAACNNCCTTGACNACNNANTGAAACTTTCANNATATNTNANNNTCTCNTNNNNNCANCA
ACTCAAATGGAACTGGGAAGTCATGATTTTGACCTCCCCAAGGGAACCCCCGGGGAGGAGGA
GGTTGGGGGATNAGGCAA

Sanger sequence for sample 23-R-chr3_95734076-95735676_7_R:
NNNNNNNNNNNGNNGGNNNNCNNNNNATGACTTCNNNNTTCCGTTTGANGCTGGTGGGGTG
AGTGAGATGTTTATTTATTGTGAAAGTTTCACTCCGTGGTCAAGGCTGTTTTGAACTGGACCAA
TCTTCTTTCCCCTGTACTCCAAGTAATGAGATTACAGGCATAAGCCACCGACCCCAGCAGGCT
TTGGGTGCTGTGGAAGGGACAGATACCCTGAGCTCTTCCTCTTTCATACCGACCACAGTAAAC
AGATTCCGGGGCTGATCCAGAATATGACCGTCCGCTGCTGCGAGCTTCCATATCCAGAACAGG
CCTGCTGCGGCGAAGAGGAGGTGAGTGTGTGTGACCTGTGATTCCAAGGCTCCAGGGAATCA
NAAGGCTAGATGTAAAGGTTACCCCTCTTTTTAGTACCTCAAGCCTGTTCGCAGAAGTCAGGT
TGAGTGGAATAGATCATTTCTCGGAGTTCTAGAAGGCTTCTTCCTTCCCGAGAACCTCTTGTCC
CTGCCCTGGGCCTCAAGCTTCTAGCATTTCCAGATGTACACATCTGTCAGGGACAAGCAGGCA
GTCCTGCTGTGGAAAAGGAAGA

Sanger sequence for sample 24-F-chr4_130165017-130166617_2_F:
NNNNNNNNNNNNNNNNNTNNNNNNNNNCTGANCNGGNACCTGGNATCTGTCTATACTCCCTG
CAG

Sanger sequence for sample 24-R-chr4_130165017-130166617_2_R:
NNNNNNNNNNNNTCNNNNNTTGCTTTGCCGCTAGGTGGGGAGAAGAGACGCTGCCAGACGG
AAGGACCATTAAGTACTGGGTGAGTCTCTGGTGCGAGGCTGAGTCCCAAGTTCCTGCCCTTCT
GAGCCCTCCATCATCTGTCTTTTGCCTCATGTCTCTCCCCTTTTCACTCCCAGACTGCTGCCAAC
TCGTGGGGCCCATGGTGGGGTGAAAGGGGCCACTTCCGGATCGTGCGTGGCACCAACGAGTG
CGACATCGAGACCTTCGTGCTGGGCGTCTGGGGTCGCGTGGGAATGGAGGACATGGGGCACC
ACTGAGTCTCAGCCACTAGGCGAGGTGGGATCCACAGCCACAGAAGAGGCCTTGGGGGCCAT
GCCCGATGAAGCCTTGTGTGCACTTCGGGACCAGGTGCTAATCTCTACAGACTCAGATCCGCG
CGTGCGCGCTAAGGCAGAATCCCACCTAGGAGACAAAGATGCACCAGGCTGGCGGAAGCCCC
CAGATATCACAGCCGGAACTGGGAAGGGCCCTGTTTGGAAACTGCAGGGAGTATAGACAGAT
TCCAGGTCCCTGGTCAGCCAGGCCAAGACCACAGGAGCTAAGACACCCCAACCTCNNNNCCC
CTCCTAAAN

Sanger sequence for sample 25-F-chr4_132832255-132833855_7_F:
NNNNNNNNNNNNNNNGGACNCGCCANTGANACNNNGTAATCAATGACCAATCCGTTGAGGC
TTGATGAGGTTCCNNTTTAAATGGGACCCTCTAGTTTGCCATGTGCTGCAAAGGCGAGTCTTA
AGTGTAAAGGGAGATACCAGCGCATAGGTAGCCAGTGCTCCCTTGCAGGATGTCAGGCAGCT
CCCACAGTTCATCAAGTTAGCCANCCTAACTGTTAGTGTTTAATGATAATAAGTGTCATATTCA
GGATCACTGACACAAAAGCACCTTTTTTGTTTCTTTTTTCTTTTACAGTACTAGGGTCAACCTT
AGGGTTTTGCCCATCCTAGGCAAGCACCCTACCATTGAGGTACAACCCAGCCCTTGGTTTCTG
AGTCAGAGTCTCACTATATAGTTAGGGCTGGCTTCCAACTTACTATGTAGCCAGTTTGGAGTC
AAACAAACTATGTCAACCAGACTGACTGAACTCATAATTCTCCTGCCTCATCTTCCTGAA

Sanger sequence for sample 25-R-chr4_132832255-132833855_7_R:
NNNNNNNNNNGNNNCGGNNGNATATTNTGATTGACTCCCACTGGTTACATATCAAGTTGGAC
ACCTTCCCTAACTATATAGTGAGACTCTGACTCNAAACCAAGGGCTGGGTTGTACCTCAATGG
CANGGTGCTTGCCTAGGATGGGCAAAACCCTAAGGTTGACCCTAGTACTGTAAAAGAAAAAA
GAAACAAAAAAGGTACTTTTGTGTCAGTGATCCTGAATATGACACTTATTATCATTAAACACT
AACAGTTAGGGAGGCTAACTTGATGAACTGTGGGAGCTGCCTGACATCCTGCAAGGGAGCAC
TGGCTGCCTCTGCGCTGGTCTCTCCCCTTACACTTAAGACTTGCCTTTGCAGCACATGGCACTT
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TCTTGGGTCACATTCGGCTGGAACCTCACAAGCCTCAACAGATTCCCATCGATTCTACGGTCTC
ATTTGGCGCGTCCACGAGGGCATACACTCTGCGAGAGAAGCCTCAGACATTGCCA

Sanger sequence for sample 26-F-chr5_104434320-104435920_F:
NNNNNNNNNNNNNANTNATANAGGTCACTGCCCTGTGGAAAGGTGTGCTCTCTTCTGGGCTA
GCCACCCTTGGCTATCACTCCACACAGCTGGGATGGGGGCTGGTCACTCTGCTGTGCCTCCCA
ATTTCCCCCAGGTTTCCCGGTATTTTCAAN

Sanger sequence for sample 26-R-chr5_104434320-104435920_R:
GNNNNGNANNNANNNNANTGACCAGACCNNNTCCCAGCTGTGTGGAGTGCTAGNNNAGGGT
GGCTAGCCCACAANAGAGCACACCTTTCACCACGGCAGTGACCTTTATGAGTCTTACTTGTTG
GTTTAGGCTCCNGGGCTGTCTCGNCANAACTTTCANCTGCCGCAGAAGACTGCAAACCCAAGC
AAGGATGCTTCTTCAGTGTGAGCTGCTGGTGGCTCAGACCTCCCAGAATTTAAATGCTGGTCC
AGACAGTCTCCACCAATCAGGAGGTGGAGTGATGTGTCATGAGGTTTTTGCCACTACCCGGCC
CACCTGCTCCTACACTTCCTCCTCTGGTTTTGTGGTTAAAAAAAAAAAAAAGGAAAAAAAGGA
AACCCCCCCAANNCTTTACTGATGAACNATGTCTTTANCTACCCTTTTCTTTTATAAACTGNNT
TTAAAATCCCGNAAAANCATCNGGGNTCCNTAAGGAAAGGAAAAGTAAATCNCCCCCACANA
AACTTTGTTTATANTTACTGANTTANTANAAAAACATCNNTGGGGATNAAAGGTATGGATTCT
CCTATCTAAGTTACANATAAAGGCCACATGGATACACAATTTGATTCTCTCNNACTTACTTAA
ATCTANAAAACTGCTGTCTCGNNAAAAATTTTANN

Sanger sequence for sample 27-F-chr7_27204354-27205954_7_F:
NNNNNNNNNANNNNNGTCNGTGCTCTTNNNGNTGAGCCATCTCTNCAGCCCNTATTCTNCAC
CATATTNTCANTGNTCAGTGNTGCGNNTNNNNNGGAATCGTTTGTTGATATTTNGGCANNGCA
NNTGNNANNNNATAACGTNNCTNNGGNNANAANAAANGAATNNNCANAAGGNCNNGANCCN
GGNAGNGGNGANTAGTGCACTAAGGGTGTAGGGTATTAAAGCTCAAAATTTNATTCATTTTGC
TTCATTGATANGCCTTACTNAANNCCCCNAATCCACAACACTCCNNNCNCGANGACTGGGGN
ACTTTTTTTTTTTAACATCAGAAAACCCCCNAAATTACNNAGGCTCCANCCTGGNAAAGCTTTT
TGAAAATGGANAANNCACCCCTTNCTAATNAAGAAACTTTCCCTCGGGGGGGGGNANNCCAT
TTTNCNCNCAAANTNGTATCTNCCTTTTNCCNCGNANNAGACGGCCTGGNGCTNCNTGCCTCC
GNCNGGACGTNTTCCTANGAGTNGANGGATCNNTGNGANTTGTCTGTCCNTCGGNGANTGTG
CCNTCGNTTATTNNTTCATANGGGNAGTGGTCGGNGTTACTGNNGNTTTNCANANCGTTCGGT
TCTNCTNNATCNTNGCCNTGTGGGAGTGANACGAGCGGNTNTACTGNAGTTGNNGAGTAGAG
NNGNGAGNGGCNNACGNNANGTNNAGTNNCNNNTGNTNNGNAGNNACNNAGNNGTNNNNG
NNGNNAANNNNNNNNNNGNNTNNNNTNAGNNGTNNTAGANNGNAGNAATNGNNNNNTNGA

Sanger sequence for sample 27-R-chr7_27204354-27205954_7_R:
NNNNNNNNNNNNNNANNNNNNCTGCTCTTCTGANNTCCTGAGTTCTNTTCCCANCNACCACA
TAAAAGGAACCTTTGGGGCTGGAGNNATTCCNGGTCTGCTAACTGTGGTTAGTGGANNCCGG
AACAGACATANGGNNTCCTACGAGGTTAAGNTGGGNNAGCGGTNNCGTGCTTGGGGAGGATC
CCCGTTAACTTCCAAGAAGCTGCCTAANTGGCTGCANGGNGNNAAGCCCTGNCTGCTCTTTGT
GAGGTCCTGAGTTCCNTTCCCGCTGACTTCATAANGNNACANAACTAACCCTTGTCTCGAGAT
CTATTCCNAGCGACGACNTAAAANCACANGNNACGCACAAACAAANCAATGGNTTGNGGTGN
CCGTAAAAANAGCATTNCNTTGCAACCACCGTGCTGGTCTGNCGGATCACCGGAATTCACTTC
CCACGGTCCTTACAAAGTNCCGAGTACCTTGCAACGATCATGATACATNNNTTNANATTTATT
TTTTNGTGATGNNCTTTAGGCGGTCCCTGNNATNNGNNCNGNNNNNNNCNTAAGGNGTCTGN
NCCCTNNANNAAAATTTTNGNTGTGC

Sanger sequence for sample 28-F-chr7_27204354-27205954_F:
NNNNNNNNNANCTNCTNNNNTAATATTTCTATGTTTTTCAAAGAAACCAAAATTTTTGCTACA
GAGTCATGACCCCTTTGGGTGTCAAAAGACCCTTTCACAGGGATTGCCTAAGACCATCAGAAA
AAATATATATTTACTTTATGATTCATAATAGTAGCAAGATTATAGTTATAAAGTAATGATGAA
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AATAACTTTATGGTTTGGGGTCACCACAACATGAGGTTATTATTCAAGGGTTGCAGCATTACA
AAGGTTGAGAACCACTGAGATAGAGGTAGCTGATCTGTGAGTTTGGAACCAGCCTGGTCTAC
ATAGCAACATCTAAGCCAGCCAGGGCTACATAGTGAGAACCTGCCTCAAAAGCAAAACAGCA
GTCTTACTATGTAGCCCTAGATGGCCTAGAACTCCCTATGCAGTAGGCCAGGTTGGCCTTTGCT
TCCTGTGTCCTGGGATTAAAGGCCTGTTCCTACATGCCTAGCCTAGAAGGCTCTTGGTAGTAA
CTCAGACCCTAGTCGTGGCCCTCCCACCTGAATGTGACATCCACTGGTCTTTCTTTGGGGGAAT
TGTTAAAGACACTGTCAGTTCACAGAGCAGGACTTAGCCCAGCTTCCTTCTCCTTGGCACACT
CAGACTACCCCGTCTNNNNNNNNCNNNNNNGNNNNNNN

Sanger sequence for sample 28-R-chr7_27204354-27205954_R:
NNNNNNNNNNNNNNNNANGAGCTGGGCTAAGTCCTGCTCTGTGAACTGACAGTGTCTTTAAC
AATTCCCCCAAAGAAAGACCAGTGGATGTCACATTCAGGTGGGAGGGCCACGACTAGGGTCT
GAGTTACTACCAAGAGCCTTCTAGGCTAGGCATGTAGGAACAGGCCTTTAATCCCAGGACACA
GGAAGCAAAGGCCAACCTGGCCTACTGCATAGGGAGTTCTAGGCCATCTAGGGCTACATAGT
AAGACTGCTGTTTTGCTTTTGAGGCAGGTTCTCACTATGTAGCCCTGGCTGGCTTAGATGTTGC
TATGTAGACCAGGCTGGTTCCAAACTCACAGATCAGCTACCTCTATCTCAGTGGTTCTCAACCT
TTGTAATGCTGCAACCCTTGAATAATAACCTCATGTTGTGGTGACCCCAAACCATAAAGTTAT
TTTCATCATTACTTTATAACTATAATCTTGCTACTATTATNAATCATAAAGTAAATATATATTTT
TTCTGATGGTCTTAGGCAATCCCTGTGAAAGGGTCTTTTGACACCCAAAGGGGTCATGACTCT
GTAGCAAAAATTTTGGTTTCNNNNAAAAACATAGAAATATTATGGGAGTATGTTTTCATTTTA
ATCCCAGGTGTNNNNNNGGGNNNNNNNCNAN

Sanger sequence for sample 30-F-chr8_85260471-85262071_F:
NNNNNNNNNNNNNANCNCNNTGCTCTNTGTAGTTGTGCAATGCTTGGTGCTATGCCCCCCCTG
NTCNCTGGTCTCGTGAAACCCNGATCCTTCTCATNTCTTTTGAATAGGTTGGTTCGAGACTTGA
ATGGTTACCTACAAAAAGAATAATTGTGTAGANGGCNTGTATCACCAAACAACATTTATCAGC
ACTGTTTTAAGGAACTTGCGTTACTTTCATCCCTACTTGAGTAATTATGAAAAAGAGATGAGA
ATATGATTCTGAGTTTAAGCAACGTCTATTACCTATTCATTAAGGAAAAAACAATTGTAAAAA
CTCAAAATATANAGCAACATAAACCAGCAAAAGAACAAAAAAACAAAACTGCCTTTAACTTA
AAAATCTTTTAAAAATGTATTTACTTCTATTTTATGTGCATTGGTATCTTGTCTGAATGTATGCC
TGGGTGAGGGGGTTGGATCCCGGAGTTACAGACAGTTGTGAGCCGCCATGTGGGTGCTGGGT
ATTGAACCCAGGTCTTCTGGAAAA

Sanger sequence for sample 30-R-chr8_85260471-85262071_R:
NNNNNNNNNNNNNNNNTNGNNNNTTTTGACCCGGGAGAATCCCCATCAGGGGGGGGAGACA
GAGATTTGGGGCGNGCGAAGAGCCTTACTATAAAAAGCTTTCTCNGATTGTTGNGTTGNNCAG
CGCTCGTTTCCTNCCTCTTTAGTTGGTTNACGTTGATCTATATTTTGAGTTTGCCGGTTCTTTTT
TCCNNAATGAAAAGCTATGACANGTTGCTTGAAATCGGAANCATATACTCATCTCATTTTCNT
AGTTACTTCGTATTTGATGANNGTCNTGCCNTTCCTTAAANAGNGCTGCTAAATTTTCTTTTGG
GATCCATGCCTGCTACCCAATTATTCTTGTTGCCTTTAACCTTTCCTTTCTTGAAGCTGCTTATT
CNAAAAATTCGAGAANATCTCCCAAATCNNGANTCCAGNGAANAANCNNAAAANATAAACA
AGCATTTTCNCAACNCATNGNAGCACTTGCGCTCAANANNNNAATCACCAGAGTCTGAGGGG
CCAATCTATGAAA

Sanger sequence for sample 31-F-chr10_40250385-40251985_8_F:
NNNNNNNNNNTNNNNNNTGNNNNANCACTGGNAGTTCAAGCATGTGCTATCACATCCCTCTA
GTACTAGGCACCGATCCCAGGGCCCCACACATGCTAGGCAAGTGCTCTTGACCACTTATCTAC
ACTCACAGCCCAAGAGTGCCCCTCTCCAGAGAAGGAAGTGAACGAACCTATGTTTTCTTCTCC
TTCCTTCTTTTCTGTCAGAAGCGTCCTTGTCATGCTCAGCTTCTTCATCGTGTGGCACTTGTACT
TCAGCACCGTCTTATCAGTCCCCTCTGGATCCACTAGGACATGAAATGATCTTATTATACCGCT
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TCATGCCATCAGATGTTGAGGGAGTTAGTCTCAACTACTTCCTATGGGAACAGCACAGGAAGT
TCCCACTGCAATTGATCACTCCTGTCCCACGTGCAAAGAAATGACAGATAACACTGACATTTG
AAGGCACAATAGGTCTCACACACAAAAAACTCTAAGGACAGAGACACGTAAACACAGAGACT
AACGCAACAAGGTAGGGTTCCTAACATGGGAAATGGGGCTTAGGAGTTGGCCCGCAGAGCAC
TGTGTCTACAGTCCTATCCNNNNAAANNNAANGAA

Sanger sequence for sample 31-R-chr10_40250385-40251985_8_R:
NNNNNNNTCNNNNNNNNNNTNNTNNGCNCCATTTNCCATGTTANGAACCCTACCTTGTTGCGT
TAGTCTCTGTGTTTACGTGTCGCTGTCCTTANAGTTTTTTGTGTGTGAGACCTATTGTGCCTTCA
AATGTGNNTGTTTTCTGTCATTTCTTTGGACGTGGGACAGGAGTGATCAATTGCATTGGGAAC
TTCCTGTGCTGTTCCCTTGAGTGNTAGTTGAGACTAACTCCCTCATCATCTGATGGNGTGAAGC
GGTATAATAATATCGTTTCATGTCCTANTGGATCCANAGGGGACTGATAANAANGTGCTGAAG
TACAAGTGCCACACGATGAAGAAGCTGAGCATGACTAGGACGCTTCTGACACAAAAGAAGGA
AGGANAATAAAACCTACGTTCTTTCACTTCCTTCTCTGGATAGGGGAACTCTTGGGCTGTGAG
TGTANATAANNGGTCAANAGCACTTGCCTANNATGTGTGGGGNCCTGNGATCGGTGNNNNNN
ACTNNNNANNTGTGATAGCACATGCTTGAAATCCCAGTGATTTGGGCAGTTGGGGAAGGCAG
CTGAAGATCATGAGTTCAAGGCCNGANNTGAGCTA

Sanger sequence for sample 32-F-chr11_72777065-72778665_5_F:
NNNNNNNNNNNNNNNNNNNTNNGANNCTGNNCCNCNTTTTGGTACCCGNTCTGGAAAAAAA
NNAATATTTTAATGGAGANGAGCTNATGTGGTAGTGTGCATCAAAGAACGGNATTCTGTCTTG
GGAGTGNTGNNGCAGCNTCGAAGACTCGTGGNGANGTGGCTGCTTAAAGGGATNCTTTTNCT
AAGGAATGAGTAAGGAAGAGTGTTTGATGGACACGNCGGAAGGGGGATTATGGTGTGATCCA
TCTGTGTGTCCTGCTCCCCCAAATCGGCGACTCGATCTTATTATCTCCACTCACTGGACCATCC
CAGTTCTCATGGAGTCAGTTTGCCCTGGAGTAGAGGTTTTAGAAATGTCACAAATGTCAGAAG
TTAAGAGCTCAGTCAATTACCCTGTGACTTAGAACAGTTACCTTCATTTTACTAAGGTGCAAA
ATCTTCTTGGGAAATGTCTGATTTTCCACTGAGAACCACAGTCCTGCTCCNANNTACCANN

Sanger sequence for sample 32-R-chr11_72777065-72778665_5_R:
NNNNNNNCNGACNCNNNNTNCNNNNNCCATTTCCCATGTTAGGAACCCTACCTTGTTGCGTTA
GTCTCTGTGTTTACGTGTCTCTGTCCTTANAGTTTTTTGTGTGTGAGACCTATTGTGCCTTCAAA
TGTGNNTGTTTTCTGTCATTTCTTTGGACGTGGGACAGGAGTGATCAATTGCATTGGGAACTTC
CTGTGCTGTTCCCTTGAGTGNTAGTTGAGACTAACTCCCTCATCATCTGATGGNGTGAAGCGG
TATAATAATATCATTTCATGTCCTANTGGATCCAGAGGGGACTGATAANAAGGTGCTGAAGTA
CNAGTGCCACACGATGAAGAAGCTGAGCATGACAAGGACGCTTCTGACACAAAAGAAGGAA
GGAGAATAAAACATACGTTCTTTCACTTCCTTCTCTGGAGAGGGGAACTCTTGGGCTGTGAGT
GTANATAANTGGTCAANAGCACTTGCCTANCATGTGTGGGGCCCTGGNATCGGTGNNNNNNA
CTANNNNNNTGTGATAGCACATGCTTGAAATCCCAGTGATTTGGGCAGTTGGGGAAGGCAGC
TGAAGATCATGAGTTCAANGNNNAAAGTGAGCCNN

Sanger sequence for sample 33-F-chr12_54782625-54784225_1_F:
NNNNNNNNNNTNNNNNNNNNNTCGNNNNGTCTTTCNNNNNNNCATGCCTTTNATCCCNGCNN
TCCAANNNNNNNNNNNNGNNNGNTNNCNGCTTCTCCAAGNNCCGTTTTTTCTTCTGGNCTCTG
TGGNCNCTGCNGNNGGCTCATGCCTNTATTNCNNNCTGTCCNNGNAGNNANGCAGGANATGG
TGAANGAAGGAAAGCCAAAGCTANNCNNGCACCNNACTTNNAAAGGAACCTGNATAGTCNN
CTTATCNTTTTAAAGAATTATGACNGNACATGAATTGATGNNGTNTGCNAACNATCGCAAATT
CTCATTTCTTANNATTTGGCAATGATTNCTGTCTANACNNATCTTTCTTGANNNNAGCANCCN
NNTCCTCANATCTTNGNNTNNNNANNNANNNNNNNNTTATATATTGNANNGNNNNNCNTNNN
NNNNNNNNTNCTTTNNNNNNNNNTCNTNNNNNNNNNCCTTNNATCNTNNNNNNCCANNNNTN
NTNTGNNNNNNNNNN

Sanger sequence for sample 33-R-chr12_54782625-54784225_1_R:
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NNNNNNNNNNNNNNNTAGCTGNTTTTNACCCAGGAGAATCCTCCTCAGGTGGCGTANAANAG
ATTTGATGTTGNGAGAAGAGACTAAATATAAAAAGNTNTCTCNGATTTTTANGTTGCCCCACG
CTCGTTTTTTTGCTCTTTTGTTGGTTNACGTTGATCTATATTTTGAGTTTTTACGATTCTTTTTTC
CTTAATGAATAGCTAATACATGTTGCTTAAAATCNGAAGCATATACACATCTCATTTTCATAGT
TACTCNNGTATTTGATGAAAGTAATGCAAGTTCCTTANAANNGTGCTGCTAAATTTTCTTTTGN
GATCCATGCCTGCTACCCAATTATTCTTTTTGTNTTTAACCTTTCNNGTCTTGAACCNACTTATT
CAAANGATTCGAGAANATCTCCCAAATCTTGANTCCAGTGAANAAACATAAAAAATAAACAA
GCATTTTCACAACACATTGGAGCACTTGCGCTCAAGACNNNAATCACCAGAGTCTGAGGGGC
CNATTCTATGAAA

Sanger sequence for sample 34-F-chr13_31630105-31631705_F:
NNNNNNNNNATANCNGTAAGTANCACACCCATCACTTATACAAATACCCAAGGGAGTTCTGC
TCACCGATATTTGCCCGGCCCCTGGAAGAGGAAACCTTTCGAAAGCTAATATCCCAGAAGAGC
GACAGACAGAGGAGGTGACTACATGTAAGACATATGTTACTGTGTGGAGGACATAAAACTTT
TCAGTTCTGGGGTGGCCATTGCATTCACTAATCAGGGTCTGAAAAGGGAGGTGTGTGTGTGTG
TGTGTGTGTGTGTGTGTGTGTGTGTGTTTTTCAAAATTGGAGTGAAAAAANCACACTATTNAN
ANANNNCTNTCTCTATCNCNNTGNCTCANNNAGATTTTTCNTNCNCNCTCTCCCACCCCCCCC
ACTCTCNNTTNTTCANATANGGGANANAN

Sanger sequence for sample 34-R-chr13_31630105-31631705_R:
NNNNNNNNNNGNNANNNTGNNNAATGTCCTACTGAGCCAAGGAACTAAGAAGGCTTTCTTGA
AATTGTGTGCTTTTAGCACTGCAATTTTGAAAAGCACACACACACACACACACACACACACAC
ACACACACACCTCCCTTTTCACACCCTGATTAGTGAATGCAATGCCCCCCCCAAAACTGAAAA
TTTTTATGCCCTCCACACAAAAACATATGTCTTACATGTACTCACCTCCTCTGTCTGTCTCTCTT
CTGGGATATTATCTTTCNAAAGGTTTCCTCTTCCGGGGGCCGGGCAAATATCGGAGAACAAAA
CTCCCTTGTGTATTTGTCTAAGTGATGGGTGTGCTACTTACTGCTATTCTCTATCCAGCGTGCA
CAGTGAGANTCNNTTTGAAATANA

Sanger sequence for sample 35-F-chr14_54541419-54543019_1_F:
NNNNNNNNNNNNNNNNNNNACTCTCNNNNNCTNCNGTGTGCTCGNGACTGGCTGGTACTGNA
ATCATTCCCCGGGCCCCCATGTAGCCACTCCTCCTGGANATTGTAGTCCCACCNACTGAACTC
AATGNNCCTANNCCCTCTGGGNAGGTCGATTTCATTTTCACAGGAGAGGCTAGGTGGGGGAG
GGATCAGCAGAAAAAGTTTAGGGGCCAANAATGGNTGGAGCACGGGAANGCATTCTGGCAA
GAGGAAAGATGCCGCTCTTTANGGGAAAGCCTCTCCCACCGTTCTCTCATGGTGGGTCTTGAG
GAGCAGAGACAGTTTATAATTTTAAAACTTTATTGNAGAAAGGCAAGGAGAATCTNNGAAGG
NTGAAAGAGTTTAGGGGCCNANNNNNGATATGCCGAAGGAGTTTAGGGGCCANNGNTAGTTA
CAACCTACCGCTAACAGANCTTNNATCCTCTANAACATCTACTCGCCTNNAANNTTTNCCNNC
GCCNTCACAACTACTNNTTANAAGCAGANNNCGTAACAGCATTAAGGGAGGACTCTTAGTTA
CTTTTCTATTGCTGTNNAAGGNTGATCATGNCCNGGCATCTTATAGNNNAAAGAATTTAGGGG
CCCANCANANAGNAGTANGGGGGGNGNNNNNTTNNNNNTGGNNACCANNNTCTGCAATNNA
NGNNNNATNGGNNATNNCCGTTTCNGTNNNNNTNNNNNGANNNNNN

Sanger sequence for sample 35-R-chr14_54541419-54543019_1_R:
NNNNNNNNCNNNNNTCCNNATNNTNTNNGTATACACTTCTGACGGTGTTGTAAGACACCGCT
GATNGAGGCTAAACAGATCCTTTAAGCGTGGCTAAAGTGCTCCCGGGGGCCAGATACNCTGN
CTGNGATCNNCTATCAGACTGGACNNNGTNTCTCTTCCTGTGATAACGNCCATGAACCTATCN
CTTCCTGCCCTAGGCTCNNNNNGGTCCCTGANCTGACTGANNTGTNCCTGGGGCTCCCATTTT
GTTCTTATGTTTTCCTCGGTGTCANNNTGTGTCTGTNATGTCCATTACTTCGAACCTGTTATCTC
GGNCCTCTGTGAGGCCCNNNNCCTAANACTGCCCCTTGCCCACCCCCTTGANCTGANNGNNNG
NNNANNNNNNGT
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Sanger sequence for sample 36-F-chr16_52269942-52271542_F:
NNNNNNNNNNNANTGACTTANNTGNNNNACAAGGGTAGTAGAAGAATGGAAACCAGGTAAA
AAAGAAAACGGTAACCTCATGGCGATGATATCAAAATGCCAAACAAAAGCGTGAAACTTACC
ATGATGCAGTACAGGGAGATGGAACTGAAGATGTTAAGCTAATGAAGAATAACTTCAAATTT
TCTTACGGTTTTAATGCCAGAAATGAAATACTCACTCGCAGAGACATTCAGGGAGTTTACTGT
TCTCTCCAGTTGGTTTTCTGCTGTGCAAGTTAATGTTACATTCTCCTCAGGGGAAATGATAATT
TTACTATAATACCTGCCATTAATATAAGGAGACTCCTCTGTCTGGAAGAAGAAGGAAGAAGA
GTTTAGAGATGGAGGTGCACTTTACAAGTCTGGGAAAGCATAGTGGTAGNNNNNNCAGGGCA
A

Sanger sequence for sample 36-R-chr16_52269942-52271542_R:
NNNNNNNNNNNNNAAAGTGCNCCTCCNTCTCTNNNCTCTTCTTCCTTCTTCTTCCAGACAGAG
GAGTCTCCTTATATTAATGGCAGGTATTATAGTAAAATTATCATTTCCCCTGAGGAGAATGTA
ACATTAACTTGCACAGCAGAAAACCAACTGGAGAGAACAGTAAACTCCCTGAATGTCTCTGC
GAGTGAGTATTTCATTTCTGGCATTAAAACCGTAAGAAAATTTGAAGTTATTCTTCATTAGCTT
AACATCTTCAGTTCCATCTCCCTGTACTGCATCATGGTAAGTTTCACGCTTTTGTTTGGCATTTT
GATATCATCGCCATGAGGTTCCGTTTTCTTTTTTACCTGGTTTCCATTCTTCTACTACCCTTGTC
TTCACAGTTTAAGTCACTTCATATATTAGCACTCAGACACTTTTCCCAGGAGAGGAAAN

Sanger sequence for sample 37-F-chr16_94468034-94469634_3_F:
NNNNNNNNNANNNNNNNCTAATTTTTAAGTGCTTATGATTCGTTATTCTACATTTTGGTAATC
AATTATAATATACTTTTTAAATTATTATTGGCTATTTTTTTTTTTTACCCGGGGAAAATGCTGTG
TGATCACGAGGATCCCNCACTTGNNCCTTACCCTAAGGTTACCATGCTGCNCTCATGAGTNNT
CCTAGCTTGGAAGTGCACGTNNCTGNTAGGGCTGAAAACAGGACATAGGGCCCAGCGCAGGG
CACCCACCCTCACCCTCCTTCCTTATCCTTCCACCAAAAAAAAAATGTACCACAGCCCTGATGT
GTTGGGGTTAACATTGTTCTGTTTGACTTTTGTGTAAAGTAATGCATGCAATCTTGTAATGGGG
CCTGAAAACAAGCTAACTGTATTAAAAACTATTCAAAAACTAGGTATTTTTAGTGACCTGTAG
GGAGTGNCAAATACAAACATGTGAACCTTGAATACATTACATTTCTCTCAAACACAAAAAAA
CAAACAAAAAACTTTTCCAGCGTGTTCTCTGCTGCCCTGGANATGCCGTCACCTTCCACCCGT
GTCTGTGTGAGTTGTGGTGTCTTAGTGACTTAGTATGTANCTCACTCNTTATTCTGAAACATTG
TCTGNGGGTGNNCNNNGN

Sanger sequence for sample 37-R-chr16_94468034-94469634_3_R:
NNNNNNNNNNNNNNNNNNNCTNNNTCACTANNACNCCNCAACTCACACAGACACGGGTGGA
AGGTGACGGCATCTCCAGGGCAGCANAGAACACGCTGGAAAAGTTTTTAGTTTGTTTCTTTGT
GTTTGAGAGAAATGTAATGTATTCAAGGTTCACATGTCTGTATTTGCCACTCCCTACAGGTCAC
TAAAAATACCTANTTTTTGAATAGTTTCTAATACAATTAGCTTGTTTTCAGGCCACATTACAAG
ATTGCATGCATTACTTTACACAAAAGTCAAACAGAACAATGTTAACACCAACACATCAGGACT
GTGGTACATTTCTCTTCTGGTGGAAGGATAAGGAAGGAGGGTGAGGGTGGCTGCCCTGCGCTG
GGCACTATGTCCTGTTTTCAGCACTAGCCAGCTGTGCACTTCCAAGCACTGCTGACTCATGAG
ACTTACATGGTAACCTTAGTGTAAGTGCCAAGTGTGGGACTCCTGTGAGCAGACAGCATCTTC
CCAGGGTAAAAAAAAAAAATANCCAATACTAATTTAAAAAGTATTTTATAATTGATTACCAA
AATGTANATTAATTGAATCATAAGCACTTTAAAAATTTATGACGGGGATGCTACAGTGCCACA
TGAGGAACTGAGANGGNNNNNNNNNNNNN

Sanger sequence for sample 38-F-chr19_60770223-60771823_F:
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NNNNNNNNNNNNGNNNNNNNNCTNCNCNNGNGTNNGTAANGATCTCTCCGGGTGTCCCTGA
AGGTTGNCTCCTGCACTTGAATTTTGCAGTAAATAAATCTTTAACACACAAAAAAAACTTAGG
GAAAAAAAAAAGACCCTANAGGATTATATCTGGTATGCCTGAAATTGCACCCTGCATTGCCCC
CAAAANCCCNCNCTTNAAAAGGATCGAAAGGAAGANCTTTNATCTTTGAAANNCTTGAAAAG
ATTAAAATATCTCCAAACTCTTCGACACTACCTTCGANTGNTTACCTGTGAACCTTTAACCTGT
GTTAAGGGAAAATCCTCAAAAAAAAACTAAAAGTTCACAAATTAAACTTTTCCCTAAACAAA
ACAAACAAAAAAAAACCCCATAGTGAGCTTACCTCGTAAACAAACTGCCGGGCAGCTTTGAG
GCGCATCACAAATAAATCTCTGTCTTCCAACATTCNTGACATCCTATTCTTATGCTCCAAAGCT
TTTTCTCGTTCTANCTGCATTGTANTGATCTGAAAGTACACAGCACTAGGTAATCTCCAAAGC
ATCACTCCAGGAAAATGCTCACCTTCCTTACACTGANAAGCTTCTCCTTCNNGNNTTTTTTNNA
GN

Sanger sequence for sample 38-R-chr19_60770223-60771823_R:
NNNNNNNNNNNNCTGANGNNAGCANCTTNCATGNCACTGGTGNANGACACNGTTCNCAGAG
GCTGTGTCTGGGAAAGGANGACNAGACATTCNGAAGAAGAAATGCTCGGGAACATCTTAATA
GGATGTCACAAATGTTGTAAGACAAAAATCTATTGGAGAGGCGCCTCAAAGCTGCCCGGCAG
TCTGTCTCNNTTCCTGCTCACTATGGGGTCTTTTTTTGTTTGTTTTGTTTAGGGAAAAGTTTAAT
TTGTGAACTTCTANTTTTCTTTTGAGGATTTTCCCTTAACACNGGTTAAAAGTTAACAGGTAAT
TACTCAGTATTTGTATAGATGAGTTGGGAGATATTTTAATCTTTTCAAGTGTTTCAAAGATGAA
AGTTTATTCTTTTTGATCTTTTTGAAGTGTGGGATTTTGGGGGCAGTGCAGGATGGAATTTCAG
GCCTACCAGATAGCTACCTCTAGAGTCTTTTTTTTTTCCCTAAGTTTTTTTTCTTTTTTAAAGAT
TTATTTATTATTATATGTAAGTGCATTGTAACTGTCTTCAAACACACCAAAAAAGGTGGTTAA
ATATCATTACANATGGTTGTGAGCCACCGTGTGNTTGCTGGGATTTGAACTCNNNNNTTTCGG
GAGN

Sanger sequence for sample 40-F-chrX_101403719-101405319_6_F:
NNNNNNNNNNNNNNNAGGGAGCACCCNGTTCTTTCCCTGTTGGCTTTGCTGTTCCCCAGCCTT
CTTTTTGTGTTTTTATAACTGTCCTCAGTTTAGCCACTGTTAAAATGTATATATTGTACTGAGGT
GCCTGGCCTGTTCCTTCAGTGAGCCATGCCCACCCTTGTGTTGTAGTGAGAAACTGTTGTCACA
ACTAACTTGTCTCTGGAATTGTTTCAAATAAAGAGTTAAAATTGTTCTTTGCTTTCTCTGGGGG
AGGTAGAGCTGGCGTTGAAGAGTGGAAGAGAAGAGAAAGAGCACCCACTGTGGGTCCCTGA
AGATTAGTCTTCCCTCAGTCAATGAATATCACAACGTTGGTCCTCTTCTCATACATTTTCAGAT
ACATCAGAAAAAAATATTTTTCAATAGCCATTTATTGAGCTAGAGTTGCTTATGTCTATAATCC
CAGTAGTTGGGAGGTGGAGGCAGGAAGTTAGGAATTCAGTCATCCTTGGCTACATGTGGAGTT
CAGAGCCAACCTAGGTTATGTGAAACCCTGTCACAAAATGGGGACAGGNNNGNAANAAATGT
AAGAA

Sanger sequence for sample 40-R-chrX_101403719-101405319_6_R:
NNNNNNGNNNNNNNNNNCTAGGTTGGCTCTGAACTCCACATGTAGCCAAGGATGACTGAATT
CCTAACTTCCTGCCTCCACCTCCCAACTACTGGGATTATAGACATAAGCAACTCTAGCTCAAT
AAATGGCTATTGAAAAATATTTTTTTCTGATGTATCTGAAAATGTATGAGAAGAGGACCAACG
TTGTGATATTCATTGACTGAGGGAAGACTAATCTTCAGGGACCCACAGTGGGTGCTCTTTCTCT
TCTCTTCCACTCTTCAACGCCAGCTCTACCTCCCCCAGAGAAAGCAAAGAACAATTTTAACTCT
TTATTTGAAACAATTCCAGAGACAAGTTAGTTGTGACAACAGTTTCTCACTACAACACAAGGG
TGGGCATGGCTCACTGAAGGAACAGGCCAGGCACCTCAGTACAATATATACATTTTAACAGTG
GCTAAACTGAGGACAGTTATAAAAACACAAAAAGAAGGCTGGGGAACAGCAAAGCCAACAG
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GGAAAGAACTGGGTGCTCCCTCTGACAGACACTAACCTTTCTGGGCCCACAANNGNNNNNTG
GGGGAA

